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Abstract 
 
High-grade gliomas, including the astrocytoma glioblastoma multiforme (GBM), are the 
most common adult primary malignant brain tumor. The mean post-diagnosis survival time of 
patients with GBM is approximately 14 months and has improved only minimally over the last 
several decades given a lack of novel and effective therapeutic strategies or interventions. 
Similar issues persist for other forms of brain cancer, notably medulloblastomas (MB) in the 
pediatric patient population. Given our inability to extend survival and enhance quality of life 
adequately in these brain tumor patients, there is a critical need for novel chemotherapeutic 
agents in the treatment of GBM and MB that may work as monotherapy agents or in synergistic 
combinations with current interventions.  
In this work, the role of the natural product withaferin A (WA), a steroidal lactone with 
intriguing cytotoxic properties, was studied alone or in combination with currently approved 
anti-cancer agents (temozolomide, radiation therapy, and proteosome inhibitors) against GBM 
and MB brain tumors. It was shown that WA could produce G2/M cell cycle arrest and apoptosis 
with inhibitory modulation of the Akt/mammalian target of rapamycin (mTOR) pathway in 
GBM. Similarly, WA inhibited Wnt/β-catenin signaling through degradation of transcription 
factor (TCF)/lymphoid enhancer-binding factor (LEF) family members in MB. Overall, exposure 
to WA was associated with generalized N-acetyl-L-cysteine-repressible cellular oxidation, thiol 
reactivity, and alterations in the heat shock protein (HSP) 90 chaperone axis. WA failed to alter 
intrinsic HSP90 activity but reduced the association between HSP90 and co-chaperone Cdc37. 
These findings were expanded to demonstrate WA-mediated potentiation of cytotoxicity with 
concurrent proteasomal inhibition through an accumulation of aberrant proteins. WA also 
increased tumor cell radiosensitivity through disruption of normal DNA damage recognition and 
iv 
 
repair. While WA failed to significantly enhance the cytotoxicity of temozolomide (TMZ), it 
demonstrated the ability to re-sensitize TMZ-resistant GBM through reduction in O
6
-
methylguanine-DNA methyltransferase (MGMT). 
This study identifies novel utility for the cytotoxic steroid lactone WA in the treatment of 
the malignant brain tumors GBM and MB through its alterations of oncogenic cellular signaling 
pathways, protein homeostasis, and the DNA-damage response mechanism. As such, WA 
represents a promising experimental therapeutic that warrants further translational exploration. 
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1.1 Brain tumors 
 
1.1.1 Glioblastoma mutiforme 
 
According to the National Cancer Institute, there were an estimated 22,070 new cases of 
primary brain tumors with 12,920 deaths from such tumors in 2009 in the United States. High 
grade gliomas, such as anaplastic astrocytoma and glioblastoma (GBM), account for 
approximately 38% of primary brain tumors, and, unfortunately, few definitive observations 
have been reported for potential environmental, occupational, or genetic causes of these tumors. 
The cell of origin for GBMs remains poorly defined, but studies have shown the most likely 
target cells to be astrocytes, neural stem cells, and/or oligodendrocyte precursor cells (Jiang and 
Uhrbom, 2012). Given the fact that these tumors occur in the central nervous system (CNS), 
treatment options have remained limited. Following optimal surgical debulking, radiation 
therapy (RT) is able to increase mean survival time from approximately six months to only one 
year (Gillingham and Yamashita, 1975; Onoyama et al., 1976; Sheline, 1977). Even ideal 
utilization of stereotactic radiosurgery known as Gamma Knife has only been shown to improve 
survival by approximately 2.3 months (Pouratian et al., 2009). Of the few treatment options 
available and approved for high grade malignant gliomas, surgical debulking followed by 
radiation therapy and concurrent chemotherapy with the methylating agent temozolomide (TMZ) 
represents the most effective option but still only yields a two-year survival rate in GBM patients 
of 26.5% (compared to 10.4% for radiation-only patients, the previous standard) (Stupp et al., 
2002; DeAngelis, 2005; Stupp et al., 2005; Taphoorn et al., 2005; Chamberlain et al., 2007). 
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While TMZ confers survival benefit to the glioma patient population as a whole and was 
approved for use in 2005 by the U.S. Food and Drug Administration (FDA), its extent of efficacy 
is largely influenced by the methylation state and expression status of the MGMT (O
6
-
methylguanine-DNA methyltransferase) gene promoter, which occurs in 35-45% of these tumors 
(Paz et al., 2004; Hegi et al., 2005). In patients whose tumors have an unmethylated promoter, 
the MGMT protein is expressed and repairs the initial DNA lesions caused by TMZ, essentially 
eliminating any anti-cancer effects of the drug (Hansen et al., 2007; Kitange et al., 2009). These 
statistics suggest that well over 55-65% of glioma patients do not display tumor phenotypes 
favorable for treatment with TMZ, and given the lack of adequate preliminary screening 
techniques for MGMT status, many of these patients end up receiving a therapy that will 
ultimately have no or minimally significant impact on disease progression. This clinical reality 
exposes the critical need for improved diagnostic and therapeutic approaches for patients with 
gliomas. 
Although not typically considered first-line standard of care, the Gliadel wafer represents 
an FDA-approved localized therapy that combines a biodegradable polymer backbone with the 
alkylating agent carmustine (BCNU) (Buonerba et al., 2011). Following surgical debulking, the 
wafer is set into the resection cavity to allow for a maintained release of drug to residual cancer 
cells at the margin of the resection. Average post-diagnosis survival was shown to be increased 
by two months with the Gliadel wafer, which, while significant, remains a poor outcome for 
these patients (Westphal et al., 2003). Lastly, in 2009, the anti-angiogenic agent bevacizumab, a 
monoclonal antibody against vascular endothelial growth factor (VEGF)-A to prevent the 
recruitment of additional vasculature to the site of the tumor, was approved by the FDA for use 
in patients with malignant gliomas (Serwer and James, 2012). This option is typically reserved 
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for patients with recurrent lesions who have failed or otherwise become resistant to TMZ and RT 
and has demonstrated the ability to extend progression-free survival in Phase II trials (Desjardins 
et al., 2008; Friedman et al., 2009; Zhang et al., 2012a); Phase III studies are ongoing (Serwer 
and James, 2012). 
 
1.1.2 Blood-brain-barrier 
 
Currently, the mean post-diagnosis survival time of patients with GBM and other 
aggressive high grade brain malignancies is approximately 14 months and has improved only 
minimally over the last several decades. This low survival duration following treatment is partly 
due to the lack of long-term efficacy of current treatment and partly a result of the highly 
infiltrative nature of these tumors, resulting in residual invasive tumor cells after surgical 
resection, high rates of recurrence, and poor clinical outcomes (Giese et al., 2003). Various 
groups are attempting to identify novel treatment modalities that better target these infiltrative 
lesions, including identification of chemotherapeutic agents possessing structures more likely to 
pass through the blood-brain-barrier (BBB), novel delivery mechanisms that circumvent current 
limitations, and enhancement of the anti-cancer properties of the immune system through 
immunotherapy (Alam et al., 2010; Serwer and James, 2012; Hamilton and Sibson, 2013). The 
brain displays a unique perivascular environment as a result of this selectively permeable BBB 
that limits the movement of chemicals and endogenous molecules from the blood into the brain 
parenchyma and thereby acts in a protective nature. However, this same protective mechanism 
under normal conditions establishes a therapeutic challenge in the case of a primary or metastatic 
brain lesion. In fact, while many inhibitors of pathways known to be important in the progression 
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of brain tumor growth already exist, the unimpressive results of their use in clinical trials can 
almost always be attributed, at least in part, to pharmacokinetic and biodistribution shortcomings 
(Serwer and James, 2012). While the architecture of the BBB is largely disrupted in advanced 
cases, such a finding becomes largely irrelevant in the context of the poor prognosis 
subsequently observed at that point (Zhang et al., 1992). Additionally, treatment of such lesions 
where the BBB has been compromised, while sometimes locally successful due to disruption of 
the barrier in this location, often fails due to recurrence from peripheral and/or infiltrative 
portions of the tumor where the BBB is still intact (Agarwal et al., 2011). A large portion of the 
success achieved with TMZ in brain tumors is due to its ability to cross the BBB (Patel et al., 
2003). 
 
1.1.3 Medulloblastoma 
 
One major challenge faced in the treatment of cancer, particularly brain tumors with 
CNS-directed chemotherapy and radiotherapy, is the damage known to be caused to normal brain 
and peripheral tissue, resulting in acute and chronic cognitive impairment known as post-
chemotherapy cognitive impairment or “chemobrain” (Butler et al., 2006; Nokia et al., 2012). 
Consideration of long-term complications is particularly important in the treatment of children 
who are affected by these diseases. The most common brain tumor in children is 
medulloblastoma (MB), a high grade lesion that typically arises in the posterior fossa and 
represents 25-30% of primary brain tumors in children but can arise in individuals of all ages 
(Khatua et al., 2012). MBs are categorized in several unique molecular subgroups based on 
tumor genetics, cell histology, growth, and clinical outcome including sonic hedgehog (SHH), 
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Wingless (Wnt), group 3, and group 4 (Northcott et al., 2012). As with glioma, the cell of origin 
for MB has remained elusive, but studies have suggested that different subgroups may develop 
from different cancer stem cell precursors including granule neuronal precursor cells in the SHH 
subgroup and dorsal brainstem precursor cells in the Wnt subgroup (Gilbertson and Ellison, 
2008; McCarthy, 2011). Although the overall 5-year survival rate for MBs in both children and 
adolescents is around 70%, differing somewhat between subgroups, therapeutic challenges 
remain to simultaneously address both treating the tumor and ensuring a high long-term quality 
of life in the pediatric patient population (Smoll, 2012). Current standards of care includes 
surgical resection followed by craniospinal radiation and DNA-damaging chemotherapeutic 
agents such as vincristine, lomustine, cyclophosphamide, carboplatin, and cisplatin (Khatua et 
al., 2012). However, because of significant morbidities associated with these agents, it has been 
reported that long-term survivors of childhood MB suffer from endocrine, cognitive, and 
neurological complications with significant deficits in daily psychosocial functioning including 
driving, employment, independent living, and personal relationships when compared to their age-
matched peers (Boman et al., 2009; Frange et al., 2009; Robinson et al., 2012). 
 
1.2 Proposed targets of withaferin A 
 
1.2.1 Oncogenic pathway signaling inhibition 
 
A recent screening of over 200 compounds derived from natural sources with promising 
anti-cancer potential at the University of Kansas Lawrence identified a 28-carbon steroidal 
lactone, withaferin A (WA), with intriguing cytotoxic properties (Figure 1-1). Interest in WA has  
7 
 
Figure 1-1.
  
 
 
 H
3
C 
CH
3
 
O 
OH 
O 
CH
3
 
OH 
CH
3
 
O O 
8 
 
Figure 1-1. Structure of withaferin A.  
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increased within the last ten years as demonstrated by increased publication on its anti-cancer 
and anti-inflammatory properties (Vanden Berghe et al., 2012; Vyas and Singh, 2014). In these 
publications, WA is reported to target or otherwise modulate a plethora of different proteins and 
signaling pathways including Akt, Notch-1, heat shock protein (HSP) 90, nuclear factor kappa-
light-chain-enhancer of activated B cells (NFκB), activator protein 1 (AP-1), estrogen receptor 
(ER), RET, and p38 among others (Mohan et al., 2004; Singh et al., 2007; Mandal et al., 2008; 
Oh et al., 2008; Stan et al., 2008; Oh and Kwon, 2009; Shah et al., 2009; Koduru et al., 2010; 
Samadi et al., 2010a; Yu et al., 2010). Recently, our group and others have demonstrated a pro-
oxidant potential of WA in non-brain tumor cells (Malik et al., 2007; Widodo et al., 2010; Hahm 
et al., 2011; Mayola et al., 2011; Grogan et al., 2013) and its ability to bind to certain thiol 
residues (Yu et al., 2010; Thaiparambil et al., 2011; Santagata et al., 2012). Despite these 
findings, the specific mechanism of WA’s diverse and widespread effects remained elusive, 
especially in brain tumors where work has been largely absent. Regardless of the ultimate 
mechanism, development of WA as an anti-cancer agent has been suggested to provide a 
potentially unique approach compared to most standard therapies because, in contrast to 
disrupting a single molecular pathway or interaction like the integrity of DNA as with TMZ, WA 
demonstrates the ability to modulate several oncogenic pathways simultaneously (Vanden 
Berghe et al., 2012; Vyas and Singh, 2014). Many cancers, including GBM and MB, often 
display overactivation and/or dysregulation of multiple oncogenic signaling cascades, including 
the mitogen-activated protein kinase (MAPK) and PI3 kinase (PI3K)/Akt/mammalian target of 
rapamycin (mTOR) pathways, establishing therapeutic challenges given the heterogeneity of the 
activation and the great level of proliferative signaling (Gilbertson et al., 2006; Wen and Kesari, 
2008; Mohan et al., 2012). 
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1.2.1a Mitogen-activated protein kinase pathway 
 
The MAPK/ERK signaling pathway involves a chain of proteins in the cell that 
communicates a signal from a receptor on the cell surface to the nucleus where promotion of 
growth and proliferation occurs through selective transcription (Figure 1-2A and 1-2B) (Chang 
and Karin, 2001). The generation of an activated membrane receptor complex activates rat 
sarcoma protein (Ras), which subsequently promotes the protein kinase activity of 
rapidly accelerated fibrosarcoma protein (Raf). Raf kinase phosphorylates and activates MEK 
(MAPKK), which subsequently activates a MAPK, frequently extracellular signal-regulated 
kinase (ERK1/2) (Avruch et al., 2001). c-Jun N-terminal kinase (JNK) and p38 MAPKs are more 
responsive to stress signals. Disruption of this pathway at any point can lead to a failure of signal 
transduction and a slowing of cell growth. Inversely, various cancers often demonstrate 
activating mutations of proteins in the cascade like Ras and Raf or elevated activation of a 
surface receptor that promotes pathway signal transduction (Dhillon et al., 2007; Krakstad and 
Chekenya, 2010). GBMs predominately favor the latter, with 40-60% of cases demonstrating 
amplification of the tyrosine kinase epidermal growth factor receptor (EGFR) and 40% of those 
displaying activating EGFR mutations (Krakstad and Chekenya, 2010). Indeed, targeted 
therapeutics against EGFR are currently in clinical trials for GBM, but, despite some promise, 
they have not been approved as standard therapeutic agents (Krakstad and Chekenya, 2010). 
Trials in pediatric CNS tumors patients have also been ongoing but little has been published to 
date (MacDonald et al., 2014). These studies suggest that inhibition of MAPK signaling in brain 
tumors may yield improved therapeutic benefits. WA has been shown to affect this signaling  
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Figure 1-2.
  
12 
 
Figure 1-2. A) Simplified schematic of the MAPK/ERK signaling pathway. Activation of a cell 
surface receptor through ligand binding induces the downstream activation of a Ras GTPase. Ras 
recruits Raf  to the membrane and promotes its protein kinase activity. Raf kinase phosphorylates 
and activates MEK, which subsequently activates a MAPK, frequently ERK1/2, the main 
effector protein of the pathway with over 70 identified substrates. Ultimately, this pathway 
promotes cellular growth and proliferation occurs often through selective transcription of target 
genes. B) Detailed schematic demonstrating the complexities of the MAPK/ERF signaling 
pathway including the involvement of numerous adaptor, scaffolding, and regulator proteins. 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell 
Biology (http://www.nature.com/nrm/index.html). Kolch W. Coordinating ERK/MAPK 
signalling through scaffolds and inhibitors, 2005. 
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pathway in non-brain tumor models. In leukemic cells and squamous cell carcinoma, WA was 
shown to deplete total levels of Raf-1 but induce phosphorylation of ERK1/2 and the isoforms 
p38 and JNK (Mandal et al., 2008; Samadi et al., 2010b), with activation of p38 associated with 
induction of apoptosis (Mandal et al., 2008). 
 
1.2.1b PI3 kinase/Akt/mammalian target of rapamycin (mTOR) pathway 
 
Similar to the MAPK pathway, the PI3K/Akt/mTOR pathway can be activated by 
external signaling through tyrosine kinase receptors like EGFR. This leads to a signal cascade 
through PI3K, Akt, and finally mTOR, with numerous additional proteins playing supporting 
roles (Figure 1-3) (Krakstad and Chekenya, 2010). Because the tumor suppressor phosphatase 
and tensin homolog (PTEN), which counteracts PI3K, is inactivated by genetic alterations in 
approximately 60% of GBMs and mutations have been noted in MBs (Hartmann et al., 2006; 
Lee et al., 2011) that lead to constitutive activation of Akt and mTOR, this pathway is likely to 
be highly clinically relevant in the treatment of malignant brain tumors (Koul, 2008; Lino and 
Merlo, 2011). Hyperactivated Akt has been shown to result in uncontrolled cell cycle 
progression and protection from apoptosis (Nogueira et al., 2008). Inhibition of Akt, mTOR, and 
downstream p70 S6 kinase (S6K) represent potential targets for prevention of the pathway’s 
proliferative effects. In the presence of cellular stress, 5' AMP-activated protein kinase (AMPK) 
suppresses mTOR through phosphorylation of the tumor suppressor tuberin/TSC2 or the mTOR 
subunit Raptor (Mihaylova and Shaw, 2011). It has previously been shown that AMPK 
activation contributes to apoptosis in GBM cells (Zhang et al., 2010). Therapeutic activation of 
either the AMPK complex or tuberin/TSC2 represents a more indirect route to inhibit this  
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Figure 1-3. 
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Figure 1-3. Schematic of the PI3K/Akt/mTOR signaling pathway. PI3K is primarily activated by 
extracellular signaling through tyrosine kinase receptors at the cell surface but can also 
associated with Ras. PI3K activity is negatively regulated by PTEN. PI3K ultimately activates a 
signaling cascade including Akt and mTOR with signaling through phosphorylation. mTOR 
increases protein synthesis and cell proliferation through inhibitory phosphorylation of 
translational repressor 4E-BP1 and activating phosphorylation of p70 S6K. Reduction of 
pathway activity is mediated by stress indicator AMPK and tumor suppressors TSC1/2. 
 
Reprinted and adapted by permission from Macmillan Publishers Ltd: Nature Reviews Drug 
Discovery (http://www.nature.com/nrd/index.html). Faivre S, et al. Current development of 
mTOR inhibitors as anticancer agents, 2006. 
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pathway. Current early phase clinical trials in GBM are utilizing agents to inhibit the function of 
EGFR, Akt, PI3K, and mTOR in this pathway (Krakstad and Chekenya, 2010). Although  
multiple groups have demonstrated decreased levels of total and phosphorylated Akt in response 
to WA treatment in several non-brain tumor cancer models (Oh et al., 2008; Oh and Kwon, 
2009; Samadi et al., 2010a; Samadi et al., 2010b), no previous reports described its effects on 
other proteins in the PI3K/Akt/mTOR signaling pathway despite this early promise. 
 
1.2.1c Wnt/β-catenin signaling pathway 
 
MBs are categorized in several unique molecular subgroups including SHH, Wnt, group 
3, and group 4 based on a number of unique tumor traits (Northcott et al., 2012). The Wnt 
subgroup of MB patients is defined by overactivation of the canonical Wnt/β-catenin signaling 
pathway, often through overexpression of β-catenin or inactivating mutations of adenomatous 
polyposis coli protein (APC) and Axin1/2 thereby acting independently of extracellular signaling 
of Wnt through the frizzled surface receptor and downstream disheveled protein (Figure 1-4) 
(Kim et al., 2011). This leads to excessive nuclear accumulation of β-catenin, which associates 
with transcription factors of the transcription factor (TCF)/lymphoid enhancer-binding factor 
(LEF) family to promote cell migratory and proliferative activity of the pathway at the 
transcriptional level (Taylor et al., 2012). As a result, this pathway has been suggested as a 
potential therapeutic target in MB. Only poly(ADP-ribose) polymerase (PARP) inhibition, 
described to destabilize β-catenin through Axin, is under trial for MB (Waaler et al., 2012). 
The Akt/mTOR pathway establishes cross-talk with the Wnt/β-catenin pathway through 
glycogen synthase kinase-3β (GSK-3β) such that activation of Akt produces inhibitory  
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Figure 1-4. Schematic representation of the Wnt signaling pathway in (a) the absence of Wnt 
ligand and (b) the presence of Wnt ligand. Without Wnt ligand, β-catenin is sequestered by a 
complex that includes GSK-3β, Axin, and APC which targets it for proteasomal degradation. 
TCF/LEF transcription factors in the nucleus remain associated with repressor proteins Groucho 
to prevent target protein transcription. In the presence of Wnt ligand binding a receptor complex 
that includes Frizzled and low-density lipoprotein receptor-related protein (LRP), the functions 
of dishevelled and CK1 ultimately lead to diminished GSK-3β and a failure to form the 
destruction complex. This leads to accumulation of β-catenin with its eventual translocation into 
the nucleus where it associates with TCF/LEF members to activate gene transcription. Activity 
of GSK-3β can also be reduced with cross-talk from the Akt/mTOR pathway in which Akt 
phosphorylates GSK-3β at Ser9 to inactivate it. 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery 
(http://www.nature.com/nrd/index.html). Barker N and Clevers H. Mining the Wnt pathway for 
cancer therapeutics, 2006. 
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phosphorylation of GSK-3β, a reduction in the phosphorylation of β-catenin, and enhanced 
stability of β-catenin. As such, inhibition of PI3K/Akt signaling has been shown to inhibit the 
Wnt/β-catenin pathway in MB (Baryawno et al., 2010). Given the previously described 
alterations in Akt induced by WA exposure, it was hypothesized that WA could act as a novel 
inhibitor of the Wnt pathway in MB by a similar mechanism. Until this study, WA had not 
previously been explored as a Wnt/β-catenin signaling inhibitor nor examined against MB. 
 
1.2.2 Proteotoxicity 
 
Malignant transformation to cancer often results in deregulation of normal homeostatic 
processes that is subsequently associated with increased cellular stress, including oxidative, 
replicative, metabolic, genomic, and proteotoxic stress (Luo et al., 2009). Cancer cell adaptation 
to these stressors is therefore necessary for survival, resulting in dependence on non-oncogene 
proteins and mechanisms that would otherwise play a less vital role in a non-malignant cell. 
Pharmacological induction of oxidative stress has emerged as an intriguing means by which to 
mount an anti-cancer effect. It is shown that pro-oxidant intervention can alter the redox 
homeostasis of cancer cells, already stressed by exposure to constitutively high levels of reactive 
oxygen species (ROS) not observed in normal cells, by shifting the balance to a state of 
cytotoxicity (Laurent et al., 2005; Cabello et al., 2007). In fact, several investigational 
chemotherapeutics with redox potential have recently been explored in preclinical and clinical 
settings (Wondrak, 2009; Tew and Townsend, 2011). Such an oxidative stress mechanism has 
also been demonstrated to effectively induce the proteotoxic stress of protein 
unfolding/misfolding, resulting in a downstream secondary cytotoxicity that likely preferentially 
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affects these already susceptible cancer cells (Xu et al., 2011; Qiao et al., 2012). Previous reports 
of others have demonstrated the pro-oxidant potential of WA in multiple cancer models (Malik et 
al., 2007; Widodo et al., 2010; Hahm et al., 2011; Mayola et al., 2011; Grogan et al., 2013). 
While this has largely remained a general finding, mechanistic evaluation demonstrated that 
overexpression of Cu,Zn-superoxide dismutase (SOD) resulted in a partial protective effect 
against WA treatment in breast cancer cells (Hahm et al., 2011). The same study suggested that 
WA-mediated ROS generation and toxicity was a result of mitochondrial respiration inhibition. 
While the WA exhibits both thiol reactivity and the ability to induce ROS, it has been 
suggested that the nature of such activity occurs with some protein specificity. It has been 
described that WA is capable of binding to the C-terminus of the chaperone protein HSP90 and 
altering its activity (Yu et al., 2010), although evidence of the latter is largely indirect and 
downstream. HSP90 is an well-conserved protein, making up ~1-3% of total cellular protein in 
any given cell, directly responsible for interacting with and maintaining the stability and function 
of over 400 key cellular proteins (Barrott and Haystead, 2013). Inhibition of HSP90 results in the 
depletion of client proteins critical to the proliferation and ultimate survival of cancer cells such 
as pro-growth signaling proteins, tyrosine kinases, cell cycle regulators, and steroid receptors 
(Zhang and Burrows, 2004; Powers and Workman, 2006; Sidera and Patsavoudi, 2014). 
Inhibition of this activity is cytotoxic. Cancer cells demonstrate enhanced responsiveness to 
HSP90 inhibition compared to normal tissue, and this has been suggested to be a result of 
enhanced reliance on HSP90 for stabilization of oncoproteins, localization in stressful 
microenvironments, and selective accumulation of inhibitors in cancer cells (Sidera and 
Patsavoudi, 2014). To date, 17 HSP90 inhibitors, all N-terminal inhibitors of ATPase activity 
such as 17-allylamino-17-demethoxygeldanamycin (17-AAG) (Workman, 2003), have been 
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brought to clinical trial, and while some have shown therapeutic promise despite formulation 
challenges, none have been approved for standard use against any cancer (Heath et al., 2005; 
Heath et al., 2008; Solit et al., 2008; Pacey et al., 2012). It has been noted that WA may function 
to indirectly modulate the HSP90 chaperone axis through disruption of the HSP90/ cell division 
cycle protein 37 (Cdc37) interaction (Yu et al., 2010; Grover et al., 2011; Gu et al., 2014). Cdc37 
functions as a co-chaperone to HSP90 and plays a vital role in localizing target kinases of the 
kinome with HSP90 for folding (Karnitz and Felts, 2007). 
It has been long-noted that oxidative and other stressor damage to proteins triggers their 
subsequent degradation (Stadtman, 1986). The major chaperones involved in protein quality 
control decisions are HSP70 and HSP90, which act together in a multi-chaperone complex to 
regulate the function, trafficking, and turnover of a wide variety of signaling proteins. However, 
despite being an oversimplification of the complexities of protein chaperoning, these two 
components of the machinery play opposite yet essential roles with HSP70 promoting 
ubiquitination followed by proteosomal degradation and HSP90 stabilizing proteins against 
degradation and instead promoting their refolding (Figure 1-5) (Pratt et al., 2010). This 
mechanism is supported by studies demonstrating that treatment with HSP90 inhibitors promotes 
the degradation of client proteins via the ubiquitin-proteasome pathway (Whitesell et al., 1994; 
Sepp-Lorenzino et al., 1995), and over-expression of HSP70 decreases the level of dysfunctional 
or misfolded proteins and improves viability in cellular models of certain neurodegenerative 
diseases characterized by the aberrant protein accumulation such as Parkinson’s disease, 
Huntington’s disease, and spinal and bulbar muscular atrophy (Jana et al., 2000; Bailey et al., 
2002; Klucken et al., 2004). Indeed, recent reports showed enhanced protein ubiquitination in the 
presence of WA (Bargagna-Mohan et al., 2006; Yang et al., 2012) and elevated total levels of  
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Figure 1-5. In general, chaperone HSP90 promotes protein refolding while HSP70 favors protein 
degradation to maintain protein homeostasis and prevent the accumulation of aberrant proteins. 
Various stressors, including oxidation, increases the frequency of protein misfolding. Inhibition 
of HSP90 shifts protein maintenance toward HSP70-mediated proteasomal degradation and vice 
versa. Simultaneous inhibition of the HSP90 and HSP70 axes, especially in the presence of a 
stressor, promotes cellular cytotoxicity through accumulation of many aberrant proteins, given 
an elimination of both homeostatic pathways. 
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HSP70 following treatment (Grogan et al., 2013). While several reports indicate that WA at least 
partially inhibits the proteasome itself, which can lead to an accumulation of ubiquitinated 
proteins (Yang et al., 2007; Yang et al., 2012), this finding remains unclear in the context of 
other data demonstrating that pretreatment with proteasome inhibitor MG132 completely 
reverses WA-mediated degradation of certain proteins (Zhang et al., 2011b) and that the doses 
used to achieve the effect were significantly above pharmacologically-relevant levels. 
Given reports of WA-mediated alterations in proteins and oncogenic signaling pathways 
potentially through oxidation and modulation of the HSP90 chaperone axis, ultimately resulting 
in protein depletion and proteotoxicity, it was hypothesized that combinational therapy with WA 
and an inhibitor of the proteasome would successfully synergize by eliminating the 
cytoprotective effect of homeostatic aberrant protein degradation and allowing the accumulation 
of these dysfunctional molecules. Indeed, inhibition of HSP70 or the proteasome in the presence 
of traditional N-terminal HSP90 inhibitors promotes a synergistic effect (Minnnaugh et al., 2004; 
Ma et al., 2014). In this work, we further define WA’s role in modulating the HSP90 axis and 
evaluate its efficacy in combination with a proteasome inhibitor. 
 
1.2.3 DNA-damage response modulation 
 
Maintenance of genomic integrity is an essential process for cell homeostasis. While 
cancer cells are transformed to malignant status through interruption and manipulation of this 
integrity, excessive disruption of the genome may lead to lethality. The DNA damage response 
(DDR) promotes accurate transmission of genomes in dividing cells by reversing the extrinsic 
and intrinsic DNA damage and is required for cell survival during replication (Harper and 
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Elledge, 2007). Radiation and genotoxic drugs represent a large proportion of anti-cancer agents 
used in the clinic for years, but DNA damage repair mechanisms are often associated with 
chemo- and radio-resistance. These agents promote DNA single- and double-strand breaks 
(SSBs; DSBs) that induce cellular cytotoxicity when unrepaired. DSBs are regarded as the 
primary lesion of ionizing radiation and require repair through homologous recombination (HR), 
which maintains fidelity of the sequence at the break site, or non-homologous end-joining 
(NHEJ), which simply anneals two broken ends together (Figure 1-6) (Mladenov et al., 2013). 
The overall response to DNA damage is regarded as an immensely complex coordination of 
damage recognition and repair with simultaneous signal transduction to halt cell cycling during 
the repair (Figures 1-7A and 1-7B). If such efforts fail, cells enter a sustained period of 
senescence or simply die (Lamarche et al., 2010; Baskar et al., 2012). 
To increase the efficacy of these DNA-damaging treatments and promote the failure of 
repair, inhibitors of the major components of the DDR such as ATM (ataxia telangiectasia 
mutated), ATR (ATM and Rad3-related), DNA-PKcs (DNA-dependent protein kinase, catalytic 
subunit), Chk1 (checkpoint protein 1), and Chk2 (checkpoint protein 2) among others have been 
used or have attracted interest in the drug development realm (Furgason and Bahassi, 2012). 
These inhibitors have demonstrated to sensitize cancer cells to the genotoxic standard therapies. 
Unfortunately, few of these therapeutic options have emerged in the treatment of brain tumors 
and limited compounds have been taken to clinical trials largely due to translational challenges 
including trial funding and poor drug pharmacokinetics. 
Given the observation that numerous pathways are altered in response to WA, perhaps in 
part due to wide-scale oxidation or inhibition of the HSP90 axis, WA’s mechanism would be 
expected to overlap with those involved in the response to other therapeutic agents. Disruption of  
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Figure 1-6. Double strand DNA breaks are repaired by either HR or NHEJ. In HR, lesions are 
detected by the MRN complex which subsequently recruits additional repair proteins that utilize 
the homologous templeate to copy and restore the original genetic code that was damaged. In 
NHEJ, lesions are identified by the Ku70/Ku80 heterodimer with a known role of the MRN 
complex as well which functions to recruit additional proteins to form the DNA-PK complex. 
This complex promotes the ligation of two broken ends independent of original DNA sequence 
and is therefore error-prone. 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell 
Biology (http://www.nature.com/nrm/index.html). Misteli T and Soutoglou E. The emerging role 
of nuclear architecture in DNA repair and genome maintenance, 2009. 
  
28 
 
Figure 1-7. 
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Figure 1-7. A) Simplified schematic of many of the proteins and interactions involved in HR and 
NHEJ repair responses to double strand DNA breaks induced by radiation or other cytotoxic 
therapies. Damage is identified by the MRN complex with subsequent recruitment of repair 
proteins, many of which demonstrate multiple functions. B) Simplified schematic demonstrating 
ATM phosphorylation-mediated signal transduction cascade in response to double strand DNA 
breaks. ATM phosphorylates p53, Chk1, and Chk2 in response to DNA damage which ultimately 
leads to checkpoint arrests of the cell cycle and ultimately cell death if the damage cannot be 
repaired. Transduction proteins such as p53 are frequently depleted or otherwise mutated in 
certain cancers. 
 
Reprinted and adapted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer 
(http://www.nature.com/nrc/index.html). Begg AC, et al. Strategies to improve radiotherapy with 
targeted drugs, 2011. 
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proteins important in the recognition and repair of DNA damage would be expected to sensitize 
glioma cells to the first-line standard therapy of TMZ and RT, both genotoxic agents. Indeed, 
direct inhibition of HSP90 to destabilize a number of client proteins has previously been shown 
to act as a radiosensitizer (Dote et al., 2006; Noguchi et al., 2006; Kabakov et al., 2010). Several 
preliminary studies have suggested that WA functions as a radiosensitizer in multiple cancer 
models. Utilizing a knockout model to alter the normal function of HR and NHEJ, one study 
reported that WA may inhibit NHEJ (Devi et al., 2008). Other studies have correlated 
combination of WA and radiation to enhanced cellular oxidation (Yang et al., 2011b; Yang et al., 
2011a), however, the underlying mechanism producing WA-induced sensitization to DNA 
damage has not been identified.  We hypothesized that WA would disrupt the normal DDR and 
have explored that in this work as a means of radiosensitization and also re-sensitization of GBM 
cells to TMZ through alterations in MGMT, a protein involved in the removal of TMZ-mediated 
DNA alkylation. 
 
1.3 Specific Aims 
 
The objective of this study was to evaluate the potential of WA either as a stand-alone 
chemotherapeutic in the treatment of chemo-sensitive and -resistant brain tumors including GBM 
and MB, or as an agent whose combination with current standard approaches could be 
synergized or potentiated. As a single agent therapy, the effects of WA were evaluated on several 
major proliferative pathways including the MAPK, PI3K/Akt/mTOR, and Wnt/β-catenin 
signaling pathways as well as its ability to generate intracellular stress through thiol reactivity 
and the creation of ROS. Further, given the induction of DNA DSBs in tumor cells treated with 
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TMZ or RT, interference with recognition and/or repair of this damage by the tumor cells 
indicated a potential broad mechanism through which WA could potentiate the cytotoxicity of 
DNA-damaging therapy. To this regard, proteins of the DNA damage response mechanism were 
evaluated in the context of WA treatment and functional manifestations of DNA damage 
recognition and repair were measured. Additionally, protein levels of repair mechanisms specific 
to TMZ including MGMT and mismatch repair were explored. 
It was hypothesized that WA would act as a potent cytotoxic agent against brain tumors 
and potentiate the activity of several standard therapies through disruption of homeostatic 
cellular processes necessary in the response to those agents. The specific aims designed to 
explore the underlying mechanisms and validate this hypothesis are as follows: 
 
1) Determination of the key anti-cancer mechanistic properties of WA in oncogenic 
signal transduction pathways in GBM and MB in vitro. 
a. Ability of WA to induce cell cycle arrest and apoptosis. 
b. Effects of WA on several major proliferative pathways including the MAPK, 
PI3K/Akt/mTOR, and Wnt/β-catenin signaling pathways. 
c. Ability of WA to generate intracellular stress through thiol reactivity and the 
production of ROS and the response of the cell to this stress. 
2) Evaluation of the proteotoxic mechanism of WA and its therapeutic implications in 
vitro. 
a. The effects of WA on cellular oxidation and the underlying implications. 
b. WA-mediated modulation of the HSP90/HSP70 protein chaperone. 
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c. Therapeutic implications of combination therapy with WA and proteasome 
inhibitors. 
3) Exploration of the effects of WA on the DDR mechanism in vitro. 
a. Exploration of WA’s effects on the DNA damage recognition and repair 
responses. 
b. Evaluation of the efficacy of WA in combination with radiation and TMZ. 
c. Determination the ability of WA to alter mechanisms of resistance to provide 
TMZ resensitization in resistant cell lines. 
 
This research demonstrates several means by which the novel natural compound WA was 
studied in the context brain tumors to further understand its properties so as to better evaluate its 
potential as a new treatment for this disease. Completion of these studies, as outlined in the 
subsequent chapters, provides excellent evidence for the benefit of WA as a novel 
chemotherapeutic strategy for brain tumors, including GBM and MB with great translational 
potential both as a monotherapy and in combination with standard agent. Ultimately, the goal of 
this proposal was to promote progression of novel pharmaceutical development to improve brain 
tumor patient survival and quality of life. 
 
1.4 Statement of Purpose 
 
The purpose of the conducted research was to identify, define, and utilize the cytotoxic 
anti-cancer properties and clinical utility of the steroidal lactone WA in high-grade brain tumors 
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through its alterations of oncogenic cellular signaling pathways, protein homeostasis, and the 
DNA-damage response mechanism. 
 Briefly, the following chapters identify and describe key cellular changes in brain tumor 
cells following exposure to WA. In Chapter 2 (Specific aims 1a-1c), WA was screened as a 
potential cytotoxic agent against GBM brain tumor cells and was identified to exhibit anti-
proliferative activity through induction of G2/M cell cycle arrest and ultimately apoptosis. These 
findings were associated with modulation of the Akt/mTOR and MAPK pathways and induction 
of thiol-mediated oxidation. In Chapter 3 (Specific aims 1a-1c and 3b-3c), TMZ-resistant GBM 
cells were shown to demonstrate enhanced responsiveness to WA as a monotherapy with a 
similar responsiveness to WA as sensitive cells. This study expanded on the inhibitory nature of 
the effect on the Akt/mTOR pathway but showed that alterations in the MAPK are a 
compensatory response to the compound. Additionally, WA pretreatment was shown to deplete 
MGMT and functionally re-sensitize these cells to TMZ. Chapter 4 (Specific aims 1a-1c) further 
demonstrates the cytotoxicity of WA in brain tumors with a model of MB. A comparable pattern 
of general efficacy was observed as in GBM. WA was demonstrated to inhibit Wnt/β-catenin 
signaling through proteasome-mediated degradation of the TCF/LEF transcription factors 
without significant alterations in the total levels nor localization of β-catenin. These findings 
were correlated with TCF/LEF depletion following HSP90 inhibition and WA-mediated 
alterations in HSP90 co-chaperone association. In Chapter 5 (Specific aims 2a-2c), mechanisms 
of action for the observed manifestations of WA treatment were explored. Specifically, WA 
induced reduction of many HSP90 client proteins and disrupted the interaction between HSP90 
and Cdc37 as well as Cdc37-dependent proteins without directly inhibiting intrinsic HSP90 
activity. Additionally, WA induced an NAC-repressible oxidation that was enhanced with 
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glutathione depletion. Overall, WA produced protein degradation through the proteasome and 
cytotoxicity that could be enhanced through the build-up of aberrant proteins with pretreatment 
of a proteasome inhibitor. Finally, Chapter 6 (Specific aims 3a-3b) demonstrates the 
radiosensitizing properties of WA through disruption of the DDR mechanisms and enhanced 
arrest of the cell cycle. WA depleted proteins involved in DNA damage recognition, signaling, 
and ultimately repair through HR and NHEJ. This was functionally associated with altered 
phosphorylation of H2A.X and enhanced DSB with combination of WA and RT. 
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Chapter 2 
 
Cytotoxicity of withaferin A in glioblastomas involves 
induction of an oxidative stress-mediated heat shock 
response while altering Akt/mTOR and MAPK signaling 
pathways  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted with permission from Springer Science + Business Media: 
 
Grogan, P.T., et al., Cytotoxicity of withaferin A in glioblastomas involves induction of an 
oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling 
pathways. Invest New Drugs, 2013. 31(3): p. 545-557. 
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2.1 Abstract 
 
Withaferin A (WA), a steroidal lactone derived from the plant Vassobia breviflora, has 
been reported to have anti-proliferative, pro-apoptotic, and anti-angiogenic properties against 
cancer growth. In this study, we identified several key underlying mechanisms of anticancer 
action of WA in glioblastoma cells. WA was found to inhibit proliferation by inducing a dose-
dependent G2/M cell cycle arrest and promoting cell death through both intrinsic and extrinsic 
apoptotic pathways. This was accompanied by an inhibitory shift in the Akt/mTOR signaling 
pathway which included diminished expression and/or phosphorylation of Akt, mTOR, p70 S6K, 
and p85 S6K with increased activation of AMPKα and the tumor suppressor tuberin/TSC2. 
Alterations in proteins of the MAPK pathway and cell surface receptors like EGFR, Her2/ErbB2, 
and c-Met were also observed. WA induced an N-acetyl-L-cysteine-repressible enhancement in 
cellular oxidative potential/stress with subsequent induction of a heat shock stress response 
primarily through HSP70, HSP32, and HSP27 upregulation and HSF1 downregulation. Taken 
together, we suggest that WA may represent a promising chemotherapeutic candidate in 
glioblastoma therapy warranting further translational evaluation. 
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2.2 Introduction 
 
Malignant gliomas, including the grade IV astrocytoma glioblastoma multiforme (GBM), 
accounting for 60-70% of such lesions, are the most common adult primary malignant brain 
tumors, representing approximately 14,000 new cancer cases yearly (Wen and Kesari, 2008). 
The mean post-diagnosis survival time of patients with GBM is approximately 14 months (Wen 
and Kesari, 2008; Stupp et al., 2009). Most high grade brain tumors are quite infiltrative, 
resulting in residual invasive tumor cells even after optimal surgical resection. This significantly 
contributes to the high rate of recurrence and poor clinical outcomes associated with this disease 
(Giese et al., 2003). Standard-of-care management typically involves surgical debulking 
followed by treatment with radiation and the methylating agent temozolomide. While this 
currently represents the most efficacious therapy for prolonging survival, tumors are often quick 
to develop resistance to this line of therapy (Chamberlain, 2010; Quick et al., 2010). Recent 
investigational therapies have yielded only modest response rates up to 15% at best without 
impact on 6-month progression-free survival (Wen and Kesari, 2008; Quick et al., 2010).  
Therefore, given a lack of current therapeutic strategies to extend survival in glioma 
patients, there is a critical need for novel therapeutic agents. We previously screened over 200 
natural plant extracts with promising anti-tumor potential and identified a 28-carbon steroidal 
lactone obtained from the Vassobia breviflora, withaferin A (WA), with intriguing cytotoxic 
properties (Samadi et al., 2010b). WA has been identified as a novel cancer therapy with anti-
proliferative, pro-apoptotic, and anti-angiogenic properties as well as a modulator of several key 
cell-survival and regulatory pathways including those involving Akt, Notch-1, heat shock protein 
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(HSP) 90, NFkappaB, AP-1, estrogen receptor, RET, and p38 among others (Mohan et al., 2004; 
Singh et al., 2007; Mandal et al., 2008; Oh et al., 2008; Stan et al., 2008; Oh and Kwon, 2009; 
Shah et al., 2009; Koduru et al., 2010; Samadi et al., 2010a; Yu et al., 2010). Additionally, WA 
has shown promising anti-tumor activity in several murine xenograft and/or orthograft models 
including prostate, breast, medullary thyroid, melanoma, uveal melanoma, ovarian, cervical, and 
brain cancers (Vyas and Singh, 2014). 
We have recently demonstrated the anti-proliferative effects of WA in malignant glioma 
(Grogan et al., 2010; Grogan et al., 2011), and this finding was subsequently confirmed 
demonstrating the thiol-reactivity of WA and its ability to induce a heat shock response via a 
reporter assay (Santagata et al., 2012). Several additional reports have identified the pro-oxidant 
potential of WA (Malik et al., 2007; Widodo et al., 2010; Hahm et al., 2011; Mayola et al., 
2011), however, the mechanism of WA’s diverse and widespread effects, especially in glioma 
cells, is largely unknown. Here, we expand on previous findings to further delineate the nature of 
WA’s anti-cancer effects in glioblastoma and examine the molecular response by the cell. 
 
2.3 Materials and methods 
 
2.3.1 Cell culture and general reagents 
 
Two human glioblastoma multiforme cell lines, U87 and U251, were generously 
provided by Dr. Jann Sarkaria (Mayo Clinic, Rochester, MN), and one murine GBM cell line, 
GL26, was graciously donated by Dr. John Ohlfest (University of Minnesota, Minneapolis, MN). 
All cell lines were grown in Dulbecco’s modified Eagle’s media (DMEM #6429; Sigma-Aldrich, 
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St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, 
MO) and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO) at a 37 °C humidified 
atmosphere of 5% CO2 in air. WA was extracted and isolated as previously described with a 
purity of 99% by HPLC and stored as a stock solution, adjusted for impurities, at 20 mM in 
DMSO at -80 °C (Samadi et al., 2010b). Propidium iodide (PI), RNase, and N-acetyl-L-cysteine 
(NAC) were acquired from Sigma-Aldrich (St. Louis, MO), and Annexin V-FITC was obtained 
from BD Biosciences (San Diego, CA). 
 
2.3.2 Cell proliferation and viability assays 
 
Cells were seeded in 96-well plates at 2,500 cells/well. Following a 6 h incubation 
period, WA-containing media in various concentrations was added to each well, and the cells 
were incubated for an additional 72 h. The number of viable cells was quantified by the 
colorometric CellTiter96 Aqueous MTS assay (Promega, Fitchburg, WI) at 490 nm on a BioTek 
Synergy 2 plate reader (BioTek, Winooski, VT) as per the manufacturer’s instructions. 
Because of the non-enzymatic, auto-reductive potential of NAC, the MTS assay was 
unable to be utilized for evaluating WA/NAC co-treatment studies given the nature of the assay 
mechanism, as described by the manufacturer. As such, the CellTiter-Glo luminescent assay 
(Promega, Fitchburg, WI) was utilized instead to measure cell viability by ATP levels. Cells 
were plated in 96-well plates followed by treatment with NAC after 6 h and WA 1 h later. After 
72 h, assay reagent was prepared as per the instructions, and 50 uL was added to each well. The 
luminescent signal was given 10-20 minutes to equilibrate and quantified by the BioTek Synergy 
2 plate reader. 
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2.3.3 Cell cycle analysis 
 
Cells were plated at an amount previously determined, based on the growth 
characteristics of individual cells, to have a high enough yield without achieving complete 
confluency upon harvest and were allowed to grow overnight. Cells were treated with 
appropriate concentrations of WA and, where indicated, pre-treated with 5 mM NAC. Upon the 
completion of treatment, cells were trypsinized, collected, resuspended in 0.43 mL of 4 °C 1x 
PBS followed by 1mL of -20 °C ethanol for a 70% ethanol fixative solution, and stored at -20 
°C. To analyze, stored cells were collected by centrifugation, resuspended in 1x PBS containing 
40 µg/mL PI and 100 µg/mL RNase, and incubated at -37 °C for 30 minutes before being 
analyzed by flow cytometry (BD LSRII; Becton Dickinson, San Diego, CA). Analysis of these 
results examined only viable cells without DNA fragmentation to establish the distribution of the 
true cell cycle in living cells. 
 
 2.3.4 Analysis of cell death 
 
Staining phosphatidylserine on the outer leaflet of the cell membranes on apoptotic cells 
and DNA staining by PI in necrotic and late apoptotic cells was performed to assess WA-induced 
cell death. Cells were plated and treated as indicated for cell cycle analysis. Upon the completion 
of treatment, cells were trypsinized, collected, and washed once in Annexin binding buffer (150 
mM NaCl, 5 mM KCl,1 mM MgCl2.6H2O, 1.8 mM CaCl2.2H2O, 10 mM HEPES, and 2% (v/v) 
FBS). Cells were stained with Annexin V-FITC and PI according to the manufacturer’s 
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instructions (BD Biosciences, San Diego, CA) for 20 minutes at 4 °C before being washed twice 
and resuspended in binding buffer. Cells were immediately analyzed by flow cytometry on a BD 
LSRII.  
 
2.3.5 Western blotting 
 
 Cells were plated and treated in the manner outlined for cell cycle analysis. Proteins were 
collected, quantified, separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS–PAGE), and electrotransfered onto a Hybond nitrocellulose membrane as previously 
described in Samadi, et al. (Samadi et al., 2011). Actin levels were assessed to ensure equal 
loading and transfer of proteins. All studies were repeated for accuracy. 
 Primary rabbit antibodies against poly(ADP-ribose) polymerase (PARP; #9542; 1:1000), 
caspase 3 (#9665; 1:1000), caspase 7 (#9492; 1:1000), caspase 9 (#9502; 1:1000), cyclin B1 
(#4138; 1:2000), p-ERK1/2 (Thr202/Tyr204; #4377; 1:1000), Akt (#9272; 1:1000), p-Akt 
(Ser473; #4058; 1:1000), c-Met (#4560; 1:500), p-c-Met (Tyr1234/1235; #3077; 1:500), 
epidermal growth factor receptor (EGFR; #4267; 1:1000), p70 S6 kinase (#2708; 1:500), p-p70 
S6 kinase (Thr389; #9234; 1:1000), mTOR (#2972; 1:1000), p-mTOR (Ser2448; #2971; 1:1000), 
Her2/ErbB2 (#2165; 1:1000), 4E-BP1 (#9644; 1:1000); p-4E-BP1 (Thr37/46; #2855; 1:1000), 
tuberin/TSC2 (#4308; 1:1000), p-tuberin/TSC2 (Thr1462; #3617; 1:1000), AMPKα (#2603; 
1:1000), and p-AMPKα (Thr172; #2535; 1:1000) and primary mouse antibodies against HSP27 
(#2402; 1:2000), caspase 8 (#9746; 1:1000), and p-EGFR (Tyr1068; #2236; 1:1000) were 
acquired from Cell Signaling Technology (Beverly, MA). Total- and phospho-antibodies against 
p70 S6 kinase were used to detect p85 S6 kinase (phospho-Thr412) given the known cross-
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reactivity of the antibodies. Rabbit antibodies against HSP90 (SPA-836; 1:1000), HSP32/heme 
oxygenase 1 (SPA-894; 1:1000), and heat shock factor 1 (HSF1; ADI-SPA-901; 1:1000) were 
acquired from Enzo Life Sciences (Farmingdale, NY) or its affiliates along with the rat antibody 
for Grp94 (SPA-850; 1:1000) and the mouse antibody for HSP70 (ADI-SPA-810; 1:1000). The 
mouse antibody Trap1 (MA1-010; 1:1000) was purchased from Affinity Bioreagents (Pierce 
Biotechnology, Rockford, IL). A mouse total actin antibody (MAB1501; 1:50,000) to be used as 
a control was acquired from EMD Millipore (Billerica, MA). A mouse antibody against Raf-1 
(sc-7267; 1:250), a goat antibody against p-Raf-1 (Ser338; sc-12358; 1:250), and a rabbit 
antibody against ERK1/2 (sc-154; 1:5000) were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA). Donkey anti-rabbit IgG HRP (sc-2313; 1:5000), goat anti-mouse IgG HRP (sc-2005; 
1:5000), and goat anti-rat IgG HRP (sc-2032; 1:5000) secondary antibodies were also purchased 
from Santa Cruz Biotechnology. Given primary antibody species specificity, Western analysis 
was completed in the human U87 and U251 cells lines. 
 
2.3.6 Detection of ROS 
 
The accumulation of intracellular ROS, particularly peroxides like H2O2, was determined 
using CM-H2DCFDA (Molecular Probes, Grand Island, NY), a general oxidative stress indicator 
that fluoresces upon oxidation. Cells were preloaded with 20 µM CM-H2DCFDA in 1x dPBS at 
37 °C for 1 h, washed once with phenol red-free DMEM containing 10% FBS and 1% 
penicillin/streptomycin, and plated in 96-well plates in phenol red-free media at 40,000 cells/well 
for GL26 and 20,000 cells/well for U87. After 30 minutes, cells were treated with WA, NAC, or 
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both. Measurements were taken on a BioTek Synergy 2 plate reader at 4 h with excitation and 
emission filters of 485 nm and 528 nm, respectively. 
Detection of mitochondrial superoxide present at a given timepoint was examined by 
MitoSOX Red (Molecular Probes, Grand Island, NY), an indicator reagent that fluoresces upon 
oxidation by superoxide radicals. Cells were plated and allowed to attach and grow overnight. 
Pre-treatment with 5mM NAC occurred 1 h before treatment with 5 µM WA. Cells were 
harvested 4 h after WA addition, washed once with 1x dPBS, and stained with 5 µM MitoSOX 
Red in 1x dPBS for 30 minutes at 37 °C. Cells were washed twice with 1x dPBS and run on a 
BD LSRII flow cytometer (Becton Dickinson, San Diego, CA) with excitation and emission 
filters of 488 nm and 580 nm, respectively, to assess mean fluorescence intensity. 
 
2.3.7 Statistical analysis 
 
GraphPad (GraphPad Inc., San Diego, CA) was used to generate best-fit sigmoidal dose response 
curves for IC50 determination. Comparisons of differences between two or more means were 
determined by Student’s unpaired t-test (2 means) via a standard statistical analysis software 
package (SPSS version 17.0; SPSS Inc, Chicago, IL). The level of significance was set at p < 
0.05. Data are presented as mean values with error bars denoting standard deviation. All studies 
were minimally performed in triplicate unless otherwise noted. 
 
2.4 Results 
 
2.4.1 Withaferin A reduces cell proliferation and viability in GBM cells 
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 To investigate the general biological effect of WA in GBM cells, three cell lines (U87, 
U251, and GL26) were incubated with increasing concentrations of WA or a DMSO control for 
72 h. Cell number and viability were subsequently determined by using the MTS assay (Figure 
2-1). WA dose escalation reduced cell proliferation and viability. By GraphPad analysis, the IC50 
values of WA were determined to be 1.07 ± 0.071 µM, 0.69 ± 0.041 µM, and 0.23 ± 0.015 µM 
for U87, U251, and GL26 cells, respectively. 
 
2.4.2 Withaferin A induces G2/M cell cycle arrest in GBM cells in a dose-dependent manner 
 
 In order to establish the nature of the anti-proliferative response to WA, distribution of 
the cell cycle phases of glioblastoma cells was assessed by flow cytometry at 24 h. WA induced 
a dose-dependent shift in cell cycle arrest from the G0/G1 checkpoint to G2/M arrest. Maximal 
shift to G2/M arrest above baseline was observed at 0.75 µM in U87 cells (12.0% G2/M in 
controls increasing to 63.4% with treatment), 1.5 µM in U251 cells (19.1% baseline to 49.7% 
with treatment), and 0.5 µM in GL26 cells (21.7% baseline to 58.7% with treatment (Figure 2-
2A). Doses above these optimal levels showed a somewhat diminished G2/M cell cycle shift. 
The shift to G2/M cell cycle arrest is accompanied by a depletion of cells in the G0/G1 phase and 
a relative increase in S phase as observed in the U87 (11%) and GL26 (14%), whereas the S 
phase proportion in U251 cells was largely unchanged (Figure 2-2A). 
 To confirm these findings, the G2/M-specific protein cyclin B1, which is elevated during 
G2/M cell cycle arrest, was evaluated by Western blot analysis for increases in expression with  
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Figure 2-1. 
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Figure 2-1. U87, U251, and GL26 cells were incubated with increasing concentrations of WA or 
a DMSO control for 72 h and then assessed by MTS assay. WA dose escalation reduced cell 
proliferation and viability with IC50 values of 1.07 ± 0.071 µM, 0.69 ± 0.041 µM, and 0.23 ± 
0.015 µM for U87, U251, and GL26 cells, respectively.  
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Figure 2-2.  
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Figure 2-2. A) Cells stained with propidium iodide and analyzed by flow cytometry revealed 
that WA induces a dose-dependent G2/M cell cycle arrest with an optimal range of such a 
response at 24 h. Maximal induction of arrest above baseline was observed at 0.75 µM, 1.5 µM, 
and 0.5 µM for U87, U251, and GL26 cells, respectively. Adjacent histograms display 
representative examples of these peak values in each cell line. B) G2/M arrest was confirmed by 
Western blotting for cyclin B1. At 24 h, U87 and U251 cells demonstrated dose-dependent 
induction of cyclin B1 with highest levels at 1 µM and 2.5 µM, respectively.  
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WA treatment. At 24 h, both U87 and U251 cells demonstrated a dose-dependent induction of 
cyclin B1 expression with maximal expression levels observed at 1 µM and 2.5 µM WA, 
respectively (Figure 2-2B). Flow cytometry identified sustained G2/M cell cycle arrest at both 48 
h and 72 h with Western analysis up to 48 h supporting those findings (data not shown). 
 
2.4.3 Withaferin A induces GBM cell death 
 
 To further characterize the anti-proliferative effects of WA, annexin V and propidium 
iodide (PI) dual staining on flow cytometry was used to evaluate the ability of WA to induce cell 
death through apoptotic and necrotic mechanisms. Figure 2-3A illustrates that increases in WA 
concentration corresponded with enhanced cell death in U87, U251, and GL26 cells at 24h. 
While all cell lines demonstrated evidence of an apoptotic response indicated by annexin V 
staining, U87 cells appear to also exhibit increased levels of necrosis with treatment as indicated 
by staining with PI only. From baseline measurements of 3.9-5.9%, total cell death at 3 µM WA 
treatment was 51.4% for U87 cells (9.0% early apoptosis; 18.4% late apoptosis; 24.0% necrosis), 
24.4% for U251 cells (12.0% early apoptosis; 9.9% late apoptosis; 2.5% necrosis), and 31.7% for 
GL26 cells (4.4% early apoptosis; 22.2% late apoptosis; 5.1% necrosis). Upon doubling the 
concentration to 6 µM, total cell death increased to 86.9% for U87 cells (3.4% early apoptosis; 
55.5% late apoptosis; 28.0% necrosis), 47.1% for U251 cells (9.7% early apoptosis; 32.5% late 
apoptosis; 4.9% necrosis), and 83.1% for GL26 cells (0.6% early apoptosis; 74.1% late 
apoptosis; 8.4% necrosis). Further induction of apoptosis was observed at 48 h (data not shown). 
 In order to confirm that these cells were undergoing an apoptotic response, protein levels 
of mitochondrial/intrinsic procaspase 9, extrinsic procaspase 8, effector procaspases 3 and 7, and  
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Figure 2-3. A) Cells stained with propidium iodide and annexin V-FITC and analyzed by flow 
cytometry revealed that increasing WA concentrations correspond with enhanced cell death in 
U87, U251, and GL26 cells at 24 h. Adjacent dot plots display representative examples of each 
cell line. B) Induction of apoptosis was confirmed by Western blotting in U87 and U251 cell 
lines. WA treatment resulted in reduction in the levels of uncleaved initiator caspases 8 and 9 as 
well as effector caspases 3 and 7. Further, PARP cleavage was observed at 2.5 and 5 µM in both 
lines.  
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downstream PARP cleavage were examined by Western blotting (Figure 2-3B). With increasing 
concentrations of WA, a reduction in the levels of all uncleaved caspases was observed at 5 µM 
in both U87 and U251 cells at 24 h. Procaspases 3, 7, and 8 demonstrated reduced levels at WA 
concentrations below 5 µM in U87 cells. Finally, PARP cleavage was observed at both 2.5 and 5 
µM WA in both U87 and U251 cell lines. These data confirm that WA-mediated cytotoxicity at 
concentrations above IC50 is in part due to induction of apoptosis in these GBM cells. 
 
2.4.4 Withaferin A alters normal protein expression and activation in the Akt/mTOR and MAPK 
pathways 
 
Given the inhibition of proliferation and induction of cell death observed with WA 
treatment, several proteins associated with the Akt/mTOR and mitogen-activated protein kinase 
(MAPK) growth, proliferation, and survival pathways as well as key surface membrane proteins 
that signal to each pathway, known to be important in glioma and other cancers (Wen and 
Kesari, 2008), were screened in U87 and U251 cells for total expression and activation via 
phosphorylation status at 24 h post-treatment (Figure 2-4). Total levels of Akt and mTOR were 
reduced with increasing concentrations of WA. Akt and mTOR phosphorylation were dose-
dependently diminished in U87 cells, but only p-mTOR was decreased in U251 cells. Total 
levels of p70 S6K (downstream of mTOR) and its nuclear isoform p85 S6K were largely 
unchanged in both cell lines with enhanced downregulation only observed in p85 S6K at 5 µM 
WA in U87 cells. Low-dose WA induced phosphorylation of both proteins, but this was reduced 
and/or further depleted upon achieving levels of 0.5 µM WA and above. Expression of total 
levels of the translation-repressor 4E-BP1 (also downstream of mTOR) was markedly  
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Figure 2-4. Following WA treatment, an array of proteins associated with the Akt/mTOR and 
MAPK growth, proliferation, and survival pathways as well as surface membrane proteins that 
signal to each pathway were screened via Western blotting in U87 and U251 cells for total 
expression and activation via phosphorylation status at 24 h post-exposure in order to help 
evaluate the molecular changes corresponding with cellular observations. Alterations in 
expression are observed in both pathways and with the cell surface receptors.  
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increased in U87 cells with elevated levels of inhibitory phosphorylation upon increasing WA 
concentration. In contrast, U251 cells exhibited decreased levels of both total and phosphorylated 
forms of 4E-BP1 with WA treatment suggesting an overall inhibitory alteration to the 
Akt/mTOR signaling pathway. Negative regulator of the pathway, AMPKα, was sustained or 
upregulated in total levels at all WA concentrations tested with the exception of 5 µM in U87 
cells. Another negative regulator, the tumor suppressor tuberin/TSC2, was sustained in U87 cells 
and upregulated in U251 cells up to 1 µM WA before diminishing at increased concentrations. 
However, activation of both tuberin/TSC2 and AMPKα via phosphorylation was observed at 
WA levels as low as 0.1-0.25 µM and maintained at higher doses. Peak levels were observed 
between 0.5-2.5 µM in a cell-dependent manner. 
Next, the effect of WA on the MAPK cascade was assessed since others have previously 
implicated WA as an inducer of a MAPK-mediated stress response (Mandal et al., 2008; Samadi 
et al., 2010b). In the U87 and U251 cells, total levels of ERK1/2 were unchanged with WA 
treatment over 24 h, but p-ERK1/2 levels were elevated with increasing concentrations of WA 
up to 2.5 µM and then diminished at 5 µM (Figure 2-4). In contrast to U87 cells, which express 
both p-ERK1 and p-ERK2 at comparable levels with treatment, p-ERK2 predominates 
expression with WA treatment of U251 cells. Additionally, total levels of upstream Raf-1 were 
diminished at 2.5-5 µM WA but activation of this protein by phosphorylation of serine 338 was 
observed in a dose-dependent manner with increasing WA concentrations. 
EGFR, Her2/ErbB2, and c-Met are commonly amplified and/or mutated surface proteins 
in glioblastoma and signal both the MAPK and Akt/mTOR pathways. As such attempts have, 
previous attempts have been made to therapeutically target these proteins (Wullich et al., 1993; 
Potti et al., 2004; Puputti et al., 2006; Guessous et al., 2010; Berezowska and Schlegel, 2011). In 
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both GBM cell lines, total levels of EGFR, Her2/ErbB2, and c-Met were decreased at 24h with 
increasing WA levels with the exception of c-Met upregulation from 0.25-2.5 µM WA (Figure 2-
4). Phosphorylation of EGFR increased with WA treatment, whereas c-Met phosphorylation was 
slightly elevated over controls at low WA doses but was downregulated at higher WA 
concentrations. 
 
2.4.5 Withaferin A elevates pro-oxidant potential in GBM cells and induces a cellular oxidative 
stress response 
 
WA-induced apoptosis in several cancer types was recently described as being mediated 
by ROS generation (Malik et al., 2007; Widodo et al., 2010; Hahm et al., 2011; Mayola et al., 
2011). Given the role ROS are known to play in a variety of cancer chemotherapeutic agents 
(Antosiewicz et al., 2008; Wondrak, 2009; Tew and Townsend, 2011), we examined whether the 
oxidation status of glioblastoma cells was altered by WA. The production of peroxide-type 
radicals with CM-H2DCFDA and mitochondrial accumulation of superoxide radicals with 
MitoSOX Red was measured in U87 and GL26 cells at 4 h post-WA exposure. GL26 and U87 
cell lines demonstrated elevated oxidation status in response to increasing concentrations of WA. 
Peroxides rose 29.4% in GL26 cells (p = 0.01) and 90.5% in U87 cells (p = 0.003) compared to 
controls (Figure 2-5A) while mitochondrial superoxide increased 10.9% (p = 0.002) and 10.8% 
(p = 0.03) above control at 5 µM, respectively (Figure 2-5B). In order to determine the nature of 
this response, cells were simultaneously incubated with 5 mM of the thiol antioxidant NAC, 
described as both a redox buffer and ROS scavenger (Deneke, 2000; Mayola et al., 2011). NAC 
significantly reduced peroxide generation in WA-treated cells and returned levels to near- 
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Figure 2-5. A) Generation of peroxide-type radicals like H2O2 following exposure to increasing 
concentrations of WA were quantified with CM-H2DCFDA staining in U87 and GL26 cells at 4 
h. B) Mitochondrial accumulation of superoxide radicals was assessed by flow cytometry with 
MitoSOX Red staining in U87 and GL26 cells at 4 h post-exposure to 5µM WA. Elevated 
oxidation status observed in (A) and (B) was reduced or completely eliminated by concurrent 
treatment with the thiol antioxidant N-acetyl-L-cysteine (5 mM). C) An array of proteins 
associated with the heat shock stress response were screened via Western blotting in U87 and 
U251 cells 24 h and 48 h post-treatment of WA. Upregulation was consistently observed with 
HSP70 and HSP32 in a dose- and time-dependent manner (C and D) with alterations in other 
proteins displaying a cell-specific response. Expression of the transcription factor HSF1 was 
decreased across both cell lines. *p < 0.05  
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baseline in both GL26 cells (p = 0.006) and U87 cells (p = 0.001). NAC reduced levels of 
mitochondrial superoxide radicals but failed to do so within statistical significance, and levels 
remained significantly elevated in U87 cells, despite being reduced compared to WA alone. 
Induction of a heat shock response was also recently described in cells via a 
luminescence reporter assay following WA exposure (Santagata et al., 2012). Consistent with 
other models of oxidative stress (Ansari et al., 2011; Qiao et al., 2012), we observed that WA 
modulates heat shock protein expression levels at both 24 h and 48 h in U87 and U251 cells 
(Figure 2-5C). While total levels of HSP90 and its isoforms Trap1 and GRP94 were not 
consistently or significantly altered with changing WA concentration, HSP70 and HSP32 (heme 
oxygenase 1) were markedly upregulated while HSF-1 was potently downregulated with 
increasing WA concentration in both a dose-dependent and time-dependent manner (Figures 2-
5C and 2-5D). Dose-dependent reduction of HSF1 corresponded with an increase in the higher 
molecular weight phosphorylated fraction of the total protein remaining. Moderate induction of 
HSP27 was observed predominantly at 48 h with cell line-dependent diminished expression at 5 
µM, the highest concentration examined. 
 
2.4.6 Pre-treatment with a thiol-antioxidant protects GBM cells from the anti-proliferative and 
cytotoxic effects of withaferin A 
 
To determine if the elevated oxidation state induced by WA is responsible for the 
apoptotic and anti-proliferative effects observed in vitro, proliferation and apoptosis in the GBM 
cells were examined in the context of co-treatment with NAC. Consistent with the MTS assay 
data previously generated, WA was shown to diminish cell viability in a dose dependent manner 
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with the highest potency being demonstrated in GL26 cells. Pre-treatment with 0.5, 1, and 5 mM 
NAC enhanced the resulting cell viability, abrogating the anti-proliferative effects of WA such 
that with 5 mM NAC pretreatment, the anti-proliferative effects of WA were completely 
eliminated at up to 6 µM doses in the U87, U251, and GL26 cell lines (Figure 2-6A). 
Next, the effects of WA on both cell cycle arrest and apoptosis were evaluated by flow 
cytometry in the context of NAC pretreatment. As previously described, flow cytometry with 
WA was performed following 1 h pre-treatment with NAC in U87, U251, and GL26 cells. 
Analysis of the cell cycle data revealed that NAC pretreatment was able to completely prevent 
cell cycle shift to G2/M arrest following 1 µM WA treatment at 24 h (Figure 2-6B). This was 
supported by a lack of dose-dependent increases in expression of cyclin B1 by Western analysis 
at 24 h when NAC was used in combination with WA (Figure 2-6D). Furthermore, dual staining 
with PI and Annexin V revealed that NAC pre-treatment completely eliminated all dose-
dependent apoptosis and necrosis associated with WA treatment (Figure 2-6C). This observation 
was then confirmed by a lack of PARP cleavage associated with increasing WA concentration 
when cells were pre-treated with NAC (Figure 2-6D). 
Finally, WA-mediated effects on heat shock response were evaluated following 
pretreatment with 5 mM NAC.  As shown in Figure 2-6D, NAC pre-treatment effectively 
prevented induction of HSP70 and HSP32 at 24 h post-exposure while limiting depletion of 
HSF1 following WA treatment. 
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Figure 2-6. N-acetyl-L-cysteine effectively prevented the WA-mediated decrease in viability by 
the ATP-quantifying CellTiter-Glo assay (A), G2/M cell cycle arrest by propidium iodide 
staining (B), and cell death by propidium iodide/annexin V-FITC dual staining (C). (D) These 
findings corresponded with Western analysis for molecular markers of G2/M arrest (cyclin B1) 
and apoptosis (PARP cleavage) as well as a complete prevention of the heat shock stress 
response with 5 mM NAC pretreatment. *p < 0.05 
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2.5 Discussion 
 
Over the past decade, WA has emerged as a promising anti-cancer chemotherapeutic 
agent. Its effects in cancer cells have been described as anti-proliferative, pro-apoptotic, and anti-
angiogenic (Mohan et al., 2004; Singh et al., 2007; Mandal et al., 2008; Oh et al., 2008; Stan et 
al., 2008; Oh and Kwon, 2009; Shah et al., 2009; Koduru et al., 2010; Samadi et al., 2010a; Yu et 
al., 2010). To date, however, the detailed mechanism of action of WA in malignant gliomas has 
not been well-elucidated. The results presented in this study demonstrate for the first time that 
WA is effectively able to induce a dose-dependent progression of G2/M cell cycle arrest 
followed by apoptosis-mediated cell death in glioblastoma cells. Reduction in both initiator 
caspases 8 and 9 suggests that WA can dually activate both extrinsic and intrinsic apoptotic 
pathways, consistent with previous findings in myeloid leukemia (Malik et al., 2007). Such 
effects appear to be a result of enhanced cellular oxidative stress generated by these compounds 
which can be completely abrogated by pretreatment with NAC. This oxidative stress with WA 
treatment also leads to induction of several heat shock proteins associated with cellular stress as 
well as alteration of the MAPK and Akt/mTOR growth and proliferation pathways including 
several of their corresponding surface receptors EGFR, Her2/ErbB2, and c-Met. 
Pharmacological induction of oxidative stress has emerged as an intriguing means by 
which to mount an anti-cancer effect. It is thought that pro-oxidant intervention can alter the 
redox homeostasis of cancer cells, already stressed by exposure to constitutively high levels of 
ROS not observed in normal cells, by shifting the balance to a state of cytotoxicity (Laurent et 
al., 2005; Cabello et al., 2007). In fact, many investigational chemotherapeutics with redox 
potential have recently been explored in preclinical and clinical settings (Wondrak, 2009; Tew 
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and Townsend, 2011). Such an oxidative stress mechanism has also been demonstrated to 
effectively induce the proteotoxic stress of protein unfolding/misfolding, resulting in a 
downstream secondary cytotoxicity that likely preferentially affects these already susceptible 
cancer cells that may warrant exploration in the WA model (Xu et al., 2011; Qiao et al., 2012). 
In our experiments, induction of HSP70, HSP32, and HSP27 with WA treatment follows 
previous models of oxidative stress (Ansari et al., 2011; Qiao et al., 2012) and lends further 
credence to the pro-oxidant potential of this drug compound. 
HSF1, a transcription factor that plays a major role in the expression of heat shock 
proteins, has been proposed to be a potentially important target in cancer therapy (Au et al., 
2009). While control of HSF1, the major mediator of the observed stress response, has been 
well-studied, regulation of its stability and turnover remains unclear (Hu and Mivechi, 2011). As 
such, it remains unknown if WA directly induces HSF1 degradation or if the resulting decrease 
in expression is due to some cellular feedback mechanism following its role as a transcription 
factor to induce heat shock protein expression. Here, we demonstrate that WA may represent a 
pharmacological means by which to downregulate total HSF1 protein levels. 
 In contrast to studies with other cancer models, superoxide radicals do not appear to be 
highly elevated in glioblastoma cells upon WA exposure as measured by MitoSOX Red staining, 
however peroxide-type radicals are elevated in as detected by CM-H2DCFDA (Hahm et al., 
2011; Mayola et al., 2011). As noted in Figure 2-5B, it is unclear if the transient but statistically 
significant elevation in superoxide detected (11% in both cells lines examined) is physiologically 
relevant. Given that the majority of oxidants measured are known to be potential downstream 
products of superoxide, it is possible that these GBM cells express elevated levels of enzymes 
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like superoxide dismutase, either inherently or as a byproduct of maintenance in cell culture 
(Evans et al., 2004a; Evans et al., 2004b). 
 Our data indicate that the thiol reactivity and/or enhanced oxidation state associated with 
WA treatment can be fully sequestered by NAC and is likely the main mechanism responsible 
for the cytotoxic effects generated by WA, however, it remains unknown whether WA directly 
releases and/or induces ROS or if its thiol-reactive properties shift the normal balance of 
oxidation by altering the responsible cellular regulation. While WA has previously been 
demonstrated to bind directly to thiols of certain proteins including HSP90 (Yu et al., 2010; 
Santagata et al., 2012), the specificity of such binding has not yet been fully explored. Given the 
maintained and sometimes elevated levels of certain proteins and signaling pathways evaluated 
in this study, we hypothesize that some proteins and pathways in gliomas are more susceptible to 
the effects of WA, whether through direct binding or secondary effects, resulting in dysfunction 
and degradation. 
Although multiple groups, including ours, have demonstrated the ability of WA to 
downregulate Akt signaling via its total levels and phosphorylation status in several cancer 
models (Oh et al., 2008; Oh and Kwon, 2009; Samadi et al., 2010a; Samadi et al., 2010b), no 
reports describe its effects on other proteins in the Akt/mTOR signaling pathway. In this study, 
WA shifts the balance of such signaling into an inhibitory state, likely representing a plausible 
means by which the compound limits growth and proliferation in glioma. Because the tumor 
suppressor phosphatase and tensin homolog (PTEN) is inactivated by genetic alterations in 
approximately 60% of GBMs, including the cell lines U87 and U251 (Lee et al., 2011), leading 
to constitutive activation of the Akt/mTOR pathway, the relevance of targeting this pathway is 
important (Koul, 2008; Lino and Merlo, 2011).. Hyperactivated Akt has been shown to result in 
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uncontrolled cell cycle progression and protection from apoptosis (Nogueira et al., 2008). 
Decreases in the total and phosphorylated levels of Akt, mTOR, p70 S6K, and p85 S6K as 
observed here with WA treatment represent direct prevention of the pathway’s proliferative 
effects. In the presence of cellular stress, AMPK suppresses mTOR through phosphorylation of 
the tumor suppressor tuberin/TSC2 or the mTOR subunit Raptor (Mihaylova and Shaw, 2011). It 
has previously been shown that AMPK activation contributes to apoptosis in glioblastoma cells 
(Zhang et al., 2010). Upon WA exposure, GBM cells exhibit activating phosphorylation of both 
tuberin/TSC2 and the catalytic alpha subunit of AMPK. 
The ability of WA to induce phosphorylation of proteins in the MAPK cascade such as 
ERK1/2 and the isoforms p38 and JNK has been previously demonstrated in several other cancer 
models (Mandal et al., 2008; Samadi et al., 2010b). While activation of ERK is generally 
regarded as a pro-survival attribute and may represent a compensatory mechanism of the cells to 
stress, it has also been shown as a potential pro-apoptotic signal which may explain its role here. 
In this study, activation of ERK1/2 with WA treatment was observed in the setting of increasing 
levels of PARP cleavage and caspase activitation. WA has previously been demonstrated to 
induce apoptosis through activation of the p38 MAPK (Mandal et al., 2008), so further 
exploration of ERK’s role in WA-induced cell-death in gliomas is warranted. 
This study provides new insight into the potent anti-cancer activity of WA against 
glioblastomas. The findings presented suggest that the underlying mechanism of WA’s 
antiproliferative, pro-apoptotic, and cell-cycle arresting action are mainly due to its induction of 
oxidative stress and a stress response by the cells leading to alterations in the expression and 
signaling of several major pathways, especially the Akt/mTOR proliferative pathway. While this 
drug has great potential to be a novel therapeutic for the treatment of gliomas, future in vivo 
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studies will determine how these mechanistic effects translate biologically and the role of WA in 
clinical applications for patients with glioblastoma multiforme. 
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Chapter 3 
 
Oxidative cytotoxic agent withaferin A resensitizes 
temozolomide-resistant glioblastomas via MGMT depletion 
and induces apoptosis through Akt/mTOR pathway 
inhibitory modulation 
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3.1 Abstract 
 
Temozolomide (TMZ) has remained the chemotherapy of choice in patients with 
glioblastoma multiforme (GBM) primarily due to the lack of more effective drugs. Tumors, 
however, quickly develop resistance to this line of treatment creating a critical need for 
alternative approaches and strategies to resensitize the cells. Withaferin A (WA), a steroidal 
lactone derived from several genera of the Solanaceae plant family has previously demonstrated 
potent anti-cancer activity in multiple tumor models. Here, we examine the effects of WA 
against TMZ-resistant GBM cells as a monotherapy and in combination with TMZ. WA 
prevented GBM cell proliferation by dose-dependent G2/M cell cycle arrest and cell death 
through both intrinsic and extrinsic apoptotic pathways. This effect correlated with depletion of 
principle proteins of the Akt/mTOR and MAPK survival and proliferation pathways with 
diminished phosphorylation of Akt, mTOR, and p70 S6K but compensatory activation of 
ERK1/2. Depletion of tyrosine kinase cell surface receptors c-Met, EGFR, and Her2 was also 
observed. WA demonstrated induction of N-acetyl-L-cysteine-repressible oxidative stress as 
measured directly and through a subsequent heat shock response with HSP32 and HSP70 
upregulation and decreased HSF1. Finally, pretreatment of TMZ-resistant GBM cells with WA 
was associated with O6-methylguanine-DNA methyltransferase (MGMT) depletion which 
potentiated TMZ-mediated MGMT degradation. Combination treatment with both WA and TMZ 
resulted in resensitization of MGMT-mediated TMZ-resistance but not resistance through 
mismatch repair mutations. These studies suggest great clinical potential for the utilization of 
WA in TMZ-resistant GBM as both a monotherapy and a resensitizer in combination with the 
standard chemotherapeutic agent TMZ. 
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3.2 Introduction 
 
According to the American Cancer Society, over 23,000 new cases of brain and other 
nervous system tumors will be diagnosed in 2013 in the United States (ACS, 2013). High grade 
gliomas, such as anaplastic astrocytoma and glioblastoma multiforme (GBM), account for 
approximately 38% of primary brain tumors, and to date, treatment options have remained 
limited. Following optimal surgical debulking, radiation therapy alone has been shown to 
increase mean survival time of GBM patients from approximately six months to only one year 
(Gillingham and Yamashita, 1975; Onoyama et al., 1976; Sheline, 1977). Concomitant and 
adjuvant temozolomide (TMZ) with surgical debulking and radiotherapy represents the most 
effective approved treatment in GBM patients but still only yields a 2.5 month median survival 
benefit and two year survival rate of 26.5% (Stupp et al., 2002; DeAngelis, 2005; Stupp et al., 
2005; Taphoorn et al., 2005; Chamberlain et al., 2007). 
The efficacy of TMZ is most frequently influenced by the methylation status of 
the MGMT (O6-methylguanine-DNA methyltransferase) gene promoter (Paz et al., 2004; Hegi et 
al., 2005). In patient tumors with an unmethylated promoter, the MGMT protein is expressed and 
repairs the major O6-methylguanine cytotoxic DNA lesions caused by TMZ, essentially 
eliminating its anti-cancer efficacy (Hansen et al., 2007; Kitange et al., 2009). Fifty-five to sixty-
five percent of glioma patients do not display tumor phenotypes favorable for treatment with 
TMZ, and those that do often quickly acquire resistance through acquisition of MGMT or 
mismatch repair (MMR) deficiencies that allow tolerance of the lesion (Chamberlain, 2010; 
Quick et al., 2010; Zhang et al., 2012c). 
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To date, experimental targeted therapies against proteins such as epidermal growth factor 
receptor (EGFR), mammalian target of rapamycin (mTOR), and PI3 kinase have yielded 
disappointing responses in GBM patients despite promising pre-clinical findings (Wen and 
Kesari, 2008; Quick et al., 2010). Combined with the limitations of TMZ, this defines a critical 
need for improved diagnostic and therapeutic approaches for patients with both inherent and 
acquired TMZ resistance to either promote resensitization of the malignancy to TMZ or exploit 
unrelated vulnerabilities. 
The 28-carbon steroidal lactone withaferin A (WA), extracted from several genera of the 
Solanaceae plant family, has emerged as a promising anti-cancer chemotherapeutic agent with 
thiol-reactive and oxidative properties that exploit redox alterations in cancer cells (Malik et al., 
2007; Widodo et al., 2010; Hahm et al., 2011; Mayola et al., 2011; Santagata et al., 2012; Zhang 
et al., 2013). As such, it has demonstrated the ability to modulate many pathways involved in 
promoting cancer progression including specific proteins like heat shock protein (HSP) 90, Akt, 
NFκB, and the estrogen receptor (ER) (Mohan et al., 2004; Singh et al., 2007; Mandal et al., 
2008; Oh et al., 2008; Stan et al., 2008; Oh and Kwon, 2009; Shah et al., 2009; Koduru et al., 
2010; Samadi et al., 2010a; Yu et al., 2010; Grogan et al., 2013). Promising anti-tumor efficacy 
has been observed in prostate, thyroid, breast, melanoma, ovarian, cervical, and brain cancer 
models (Vyas and Singh, 2014). 
Here, we follow-up on our previous findings outlining the efficacy of WA in TMZ-
sensitive glioblastoma cells lines to demonstrate its potential role as a novel therapeutic option 
against resistant tumors as both a single agent therapy and a TMZ-resensitizer through MGMT 
modulation. 
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3.3 Materials and methods 
 
3.3.1 Cell culture and general reagents 
 
U87, U251, and T98G GBM cell lines of human origin were grown in Dulbecco’s 
modified Eagle’s medium (DMEM #11995-065; Gibco, Grand Island, NY) supplemented with 
10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) and 1% penicillin/streptomycin 
(Sigma-Aldrich, St. Louis, MO) in a 37°C humidified atmosphere of 5% CO2 in air. An 
additional human GBM cell line, U138, was maintained in equivalent media additionally 
supplemented with 2% L-glutamine (200 mM; Sigma-Aldrich), 1% MEM-vitamin (100x; 
Hyclone, Logan, UT), and 1% MEM nonessential amino acids (Sigma Aldrich). The TMZ 
resistant cells U87TMZ and U251TMZ were derived as previously described via TMZ dose 
escalation from the parental U87 and U251 cells, respectively (Nadkarni et al., 2012). 
TMZ was generously provided by the NCI Developmental Therapeutics Program 
(Bethesda, MD) and was stored as a 100mM stock solution in DMSO at -80 °C. WA (99% pure 
by HPLC) was extracted, isolated, and stored as a 20 mM stock solution in DMSO at -80 °C as 
previously described (Samadi et al., 2010b). Propidium iodide (PI), RNase, N-acetyl-L-cysteine 
(NAC), protease inhibitor cocktail, and MEK inhibitor PD98059 were acquired from Sigma-
Aldrich (St. Louis, MO). Annexin V-FITC was obtained from BD Biosciences (San Diego, CA). 
Caspase 8 inhibitor Z-IETD-FMK and caspase 9 inhibitor Z-LEHD-FMK were obtained from 
R&D Systems (Minneapolis, MN). 
 
3.3.2 MTS assay 
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To determine the IC50 values of WA, all cell lines were seeded in 96-well plates at a 
density of 2,500 cells/well, treated with 0.025-3 µM WA, and incubated for 72 h. Cell number 
and viability were quantified by the colorometric CellTiter96 Aqueous MTS assay (Promega, 
Fitchburg, WI) at 490 nm on a BioTek Synergy 2 plate reader (BioTek, Winooski, VT) as per the 
manufacturer’s instructions. 
To assess combinational effects of WA and TMZ, cells were plated in 75 cm
2
 flasks and 
allowed to grow overnight. Cells were treated with 0.5-2 µM WA and harvested at 24, 48, and 72 
h post-treatment (60-80% confluency) for seeding in 96-well plates at densities of 500-10,000 
cells/well. Following a 6 h incubation period, 10-50 µM and 100-500 µM TMZ were added to 
each well of the TMZ-sensitive and TMZ-resistant cells, respectively. After 48-144 h, cell 
number and viability were quantified by the MTS assay as described above. 
 
3.3.3 CellTiter-Glo luminescent assay 
 
To circumvent the auto-reductive potential of NAC that interferes with the MTS assay 
reagent, studies evaluating combination treatment with NAC and WA were completed with the 
CellTiter-Glo luminescent assay (Promega, Fitchburg, WI) measuring cell viability by adenosine 
triphosphate (ATP) levels. U251TMZ and U87TMZ cells were seeded at a density of 2,500 
cells/well in white-chambered 96-well plates and allowed to incubate for 6 h before treatment 
with 1-5 mM NAC. After 1 h, 0.5-6 µM WA was added to each well. After 72 h, assay reagent 
was prepared and added as per the manufacturer’s instructions, and the plates were evaluated on 
the BioTek Synergy 2 plate reader. 
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 3.3.4 Cell cycle analysis 
 
U251TMZ and U87TMZ cells were plated and allowed to grow overnight to 30-50% 
confluency. Cells were treated with 0.125-4 µM WA for 24 h. Cells were then collected, 
resuspended in 0.43 mL of 4 °C 1x PBS followed by 1 mL of -20 °C ethanol, and maintained at -
20 °C for a minimum of 24 h. Finally, cells were then pelleted by centrifugation, resuspended in 
1x PBS with 40 µg/mL PI and 100 µg/mL RNase, and incubated at 37 °C for 30 minutes before 
analysis by flow cytometry (BD LSRII; Becton Dickinson, San Diego, CA). Data analysis 
included only singlet living cells not displaying DNA fragmentation. 
 
 3.3.5 Apoptosis studies 
 
Cells were plated as described for cell cycle analysis, treated with 1-6 µM WA, and pre-
treated for 1 h with 5 mM NAC where indicated. After 24 h, cells were collected and washed 
once with Annexin binding buffer as previously described (Grogan et al., 2013). Staining 
phosphatidylserine on the outer leaflet of the cell membranes on apoptotic cells with Annexin V-
FITC and DNA staining by PI in necrotic and late apoptotic cells was performed to assess WA-
induced cell death. Cells were stained with both compounds according to the manufacturer’s 
instructions (BD Biosciences, San Diego, CA) for 15 minutes at 4 °C and washed twice with 
Annexin binding buffer. Cells were resuspended in buffer and immediately analyzed by flow 
cytometry on the BD LSRII.  
 
75 
 
3.3.6 Immunoblotting 
 
 Cells were plated in the manner outlined for cell cycle analysis and treated with 0.5-5 µM 
WA. Where indicated, cells were either pre-treated with 5 mM NAC, 50 µM PD98059, 50 µM 
Z-IETD-FMK, or 50 µM Z-LEHD-FMK for 1 h or post-treated with 100-300 µM TMZ 24 h 
after WA. After 24-48 h, proteins were collected in lysis buffer (40 mM HEPES, 2 mM EDTA, 
10 mM sodium pyrophosphate decahydrate, 10 mM β-glycerophosphate disodium salt 
pentahydrate, 1% triton X-100 supplemented with 100 µM phenylmethylsulfonyl fluoride, 1 mM 
Na3VO4, and 2 µL/mL protease inhibitor cocktail), quantified, separated by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), and electrotransfered onto a Hybond 
nitrocellulose membrane as previously described in Samadi, et al. (Samadi et al., 2011). 10-80 
µg of protein sample was utilized per lane. Actin levels were used to ensure equal loading and 
transfer of proteins. All studies were repeated for accuracy. 
Primary rabbit antibodies against MGMT (#2739; 1:1500), MSH2 (#2017; 1:1000), and 
MSH6 (#3996; 1:1000) and primary mouse antibody against MLH1 (#3515; 1:1000) were 
acquired from Cell Signaling Technology (Beverly, MA). Primary mouse antibody against p-
H2A.X (Ser139; #613401; 1:1000) was purchased from Biolegend (San Diego, CA). Additional 
primary and secondary antibodies were utilized as previously described at dilutions ranging from 
1:250-1:5000 and 1:5000-1:20000, respectively (Grogan et al., 2013). 
 
3.3.7 Evaluation of reactive oxygen species 
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The accumulation of intracellular peroxide-type reactive oxygen species (ROS) in 
U251TMZ and U87TMZ cells was determined using the general oxidative stress indicator CM-
H2DCFDA (Molecular Probes, Grand Island, NY) that fluoresces upon oxidation. Cells were 
incubated at 37 °C in 1x dPBS containing 20µM CM-H2DCFDA for 1 h to allow for indicator 
preloading and plated in 96-well plates in phenol red-free DMEM at 20,000 cells/well. After 30 
minutes, 1-5 µM WA and/or 5 mM NAC was added to the wells. Fluorescence was assessed on 
the BioTek Synergy 2 3 h post-treatment with excitation and emission filters of 485 nm and 528 
nm, respectively. 
  
3.3.8 Statistical analysis 
 
GraphPad Prism 6 (version 6.02; GraphPad Inc., San Diego, CA) was used to generate best-fit 
non-linear sigmoidal dose response curves for IC50 determination. Comparisons of differences 
between two or more means/values were determined by Student’s unpaired t-test via the 
statistical functions of GraphPad Prism and Microsoft Excel 2010 software (version 
14.0.6129.5000; Microsoft Corporation Redmond, WA). Densitometry, where indicated, was 
completed using ImageJ software (version 1.46r; Bethesda, MD). Combination studies compared 
drug efficacy within normalized WA treatment arms. Data are presented as mean values with 
error bars denoting standard deviation or standard error of the mean where appropriate. Unless 
otherwise noted, all experiments were performed minimally in triplicate. The level of 
significance was set at p < 0.05. 
 
3.4 Results 
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3.4.1 Characterization of TMZ-resistant cell lines  
 
 U251 and U87 resistant sub-lines (U251TMZ and U87TMZ) were generated by exposing 
parental lines to increasing concentrations (30-300 µM) of TMZ over an 8-week period, pooling 
the resulting colonies, and confirming resistance as previously described (Nadkarni et al., 2012). 
Reduced TMZ effectiveness in established lines T98G and U138 has been previously confirmed 
(Ryu et al., 2012). Characterization of these cell lines demonstrated the absence of MGMT and 
the presence of mismatch repair proteins MLH1, MSH2, and MSH6 in parental U251 and U87 
cells (Figure 3-1A). MGMT expression was observed in U251TMZ, T98G, and U138 cells but 
not U87TMZ. Compared to parental U87 cells, U87TMZ displayed lower levels of all three 
MMR proteins screened, suggesting the mechanism of U87TMZ resistance is due to 
heterogeneic deletion or mutation of these proteins. 
 
3.4.2 Diminished cell proliferation and viability following withaferin A exposure 
 
To evaluate the general cytotoxic effect of withaferin A, parental and resistant 
glioblastoma cells were treated with increasing concentrations of WA (0.025-3 µM) for 72 h 
with resulting cell number and viability determined by MTS assay (Figure 3-1B). WA dose 
escalation reduced cell proliferation and viability. By GraphPad analysis, the IC50 values of TMZ 
resistant sub-lines U251TMZ and U87TMZ were lower compared to parental lines, 
demonstrating increased efficacy. IC50 values were determined to be 0.766 ± 0.045 µM, 0.357 ±  
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Figure 3-1.  
  
79 
 
Figure 3-1. A) Characterization of TMZ-resistant cells U251TMZ, U87TMZ, T98G, and U138 
compared to parental U251 and U87 cells. U251 and U87 cell lines demonstrated the absence of 
MGMT and the presence of mismatch repair proteins MLH1, MSH2, and MSH6. MGMT 
expression was observed in U251TMZ, T98G, and U138 cells but not U87TMZ. U87TMZ 
displayed lower levels of all three MMR proteins screened compared to parental U87 cells. B) 
All cell lines were incubated with increasing concentrations of WA for 72 h and then assessed by 
MTS assay. WA dose escalation reduced cell proliferation and viability with IC50 values of 0.766 
± 0.045 µM, 0.357 ± 0.019 µM, 1.050 ± 0.062 µM, 0.657 ± 0.134 µM, 1.027 ± 0.105 µM, and 
0.610 ± 0.279 µM for U251, U251TMZ, U87, U87TMZ, T98G, and U138 cells, respectively. 
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0.019 µM, 1.050 ± 0.062 µM, 0.657 ± 0.134 µM, 1.027 ± 0.105 µM, and 0.610 ± 0.279 µM for 
U251, U251TMZ, U87, U87TMZ, T98G, and U138 cells, respectively. 
 
3.4.3 Induction of G2/M cell cycle arrest by withaferin A in a dose-dependent manner 
 
 Distribution of phases of the cell cycle was assessed by flow cytometry at 24 h. 
Consistent with the anti-proliferative effects seen in the MTS assays, WA treatment induced 
G2/M phase accumulation of U251TMZ and U87TMZ cells in a dose-dependent manner, 
demonstrating a key cellular response to WA exposure. WA induced a dose-dependent shift in 
cell cycle arrest from the G0/G1 checkpoint to G2/M arrest with minimal change in the 
percentage of cells in S phase (Figure 3-2A). Maximal shift to G2/M arrest above baseline was 
observed at 1.5 µM in U87TMZ cells (17.8% G2/M in controls increasing to 42.5% with 
treatment; p = 0.0001) and 2 µM in U251TMZ cells (43.1% baseline to 72.3% with treatment; p 
= 0.0001) (Figure 3-2B). Doses above this level demonstrated diminished deviation from control 
with a return to higher G0/G1 and lower G2/M but also increased DNA fragmentation observed 
in the sub-G0/G1 region (data not presented). 
 Additionally, cyclin B1, a protein that displays G2/M phase-specific elevation, was 
evaluated by Western blotting to provide molecular confirmation of increases in G2/M cell cycle 
arrest. At 24 h, dose-dependent induction of cyclin B1 was observed in both U87TMZ and 
U251TMZ cells with maximum expression levels observed at 1 µM and 2.5 µM WA, 
respectively, corresponding with flow cytometry findings (Figure 3-2C). Cyclin B1 levels 
displayed similar peak expression levels at 48 h but with a more blunted response. 
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Figure 3-2. 
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Figure 3-2. A) Ability to induce cell cycle modulation was assessed by flow cytometry at 24 h 
revealing that WA treatment results in dose-dependent G2/M cell cycle arrest. Maximum arrest 
was observed at 2 µM and 1.5 µM for U251TMZ and U87TMZ cells, respectively. B) 
Histograms demonstrate cell cycle distribution for U251TMZ and U87TMZ cells at 
concentrations up to those yielding maximal arrest. C) Arrest in G2/M phase was molecularly 
confirmed by immunoblotting for cyclin B1 at 24-48 h. Highest levels of cyclin B1 were observed 
at 2.5 µM and 1 µM WA for U251TMZ and U87TMZ cells, respectively, confirming flow 
cytometry findings.  
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3.4.4 Withaferin A induces cell death through both the intrinsic and extrinsic apoptotic pathways 
 
 PI and Annexin V-FITC dual staining analysis with flow cytometry was used to further 
characterize the anti-proliferative effects of WA by assessing levels of apoptosis and necrosis 
following drug exposure. After 24 h of 1-3 µM WA, U87TMZ and U251TMZ cells 
demonstrated increases in Annexin V-only staining representative of early apoptotic processes 
with increases in dual staining representative of late apoptosis present at higher concentrations 
(2-6 µM) (Figures 3-3A and 3-3B). U87TMZ cells alone appear to also show mild increases in 
levels of necrosis with WA exposure as demonstrated by staining with PI only. Total positive 
staining of control U87TMZ and U251TMZ cells was 8.2% and 4.0% but increased to 45.5% (p 
= 0.01: 14.7% early apoptosis; 23.0% late apoptosis; 7.7% necrosis) and 17.1% (p = 0.0004: 
9.1% early apoptosis; 6.9% late apoptosis; 1.0% necrosis) with 2 µM WA, respectively. 6 µM 
WA elevated total cell death to 80.0% for U87TMZ (p < 0.0001: 4.9% early apoptosis; 62.6% 
late apoptosis; 12.5% necrosis) and 51.8% for U251TMZ cells (p < 0.0001: 4.0% early 
apoptosis; 44.6% late apoptosis; 3.1% necrosis). 
Molecular confirmation of an apoptotic response was conducted by Western blotting for 
cleaved and/or total levels of the following proteins: extrinsic procaspase 8, 
mitochondrial/intrinsic procaspase 9, effector procaspases 3 and 7, and downstream poly(ADP-
ribose) polymerase (PARP) cleavage (Figure 3-3C). At 24 h, increasing concentrations of WA 
resulted in progressively decreased levels of all procaspases and PARP, suggesting both intrinsic 
and extrinsic routes of apoptotic cell death. Maximum levels of cleaved caspase 8 were observed 
at 1-2.5 µM WA for U251TMZ and 0.5-1 µM WA for U87TMZ while highest levels for cleaved  
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Figure 3-3. A) WA treatment induced apoptotic cell death in U251TMZ and U87TMZ cells with 
increasing concentrations. 1-3 µM WA induced early apoptotic processes with increasing levels 
of late apoptosis observed at all concentrations examined. Only U87TMZ demonstrated elevated 
necrosis with treatment. B) Dot plots demonstrating propidium iodide and Annexin V-FITC 
staining show representative examples from both cell lines utilized. C) An apoptotic mechanism 
was confirmed by Western blotting for total and cleaved initiator caspases 8 and 9, effector 
caspases 3 and 7, and downstream PARP. Uncleaved proteins were decreased with increasing 
WA concentration. U251TMZ and U87TMZ cells demonstrated optimal concentrations for 
caspase cleavage with highest levels of PARP cleavage observed in both lines at 5 µM WA. D) 
U251TMZ cells were pretreated with 50 µM of either caspase 8 inhibitor Z-IETD-FMK or 
caspase 9 inhibitor Z-LEHD-FMK for 1 h followed by 2.5 µM WA for 24 h to determine if WA-
driven apoptosis was intrinsically or extrinsically mediated. Inhibition of both caspase 8 and 9 
reduced WA-induced cleavage of caspases 3 and 7 as well as PARP.  
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caspases 3 and 7 were observed at 5 µM WA for U251TMZ and 1-2.5 µM WA for U87TMZ. 
PARP cleavage increased up to 5 µM in both cell lines, the maximum concentration utilized, and 
suggests that the absence of cleaved caspases despite depletion of the procaspase form at high 
WA concentrations can be explained by a time-dependent nature of caspase signaling in which 
the upstream cleaved caspases are ultimately degraded following their activity. 
To further evaluate the nature of the intrinsic and extrinsic apoptotic processing in WA-
induced cytotoxicity, U251TMZ cells were pretreated with 50 µM of either caspase 8 inhibitor 
Z-IETD-FMK or caspase 9 inhibitor Z-LEHD-FMK for 1 h followed by 2.5 µM WA for 24 h. 
Pretreatment with both inhibitors resulted in a return to baseline for both cleaved caspase 3 and 
PARP levels and decreased amounts of cleaved caspase 7 compared to WA alone (Figure 3-3D). 
Inhibitors alone resulted in negligible changes. These data support that cytotoxicity at WA 
concentrations above IC50 involves induction of intrinsically- and extrinsically-mediated 
apoptosis in the GBM cell lines tested. 
 
3.4.5 Withaferin A modulates the Akt/mTOR and MAPK pathways 
 
Proteins in and related to the Akt/mTOR and mitogen-activated protein kinase (MAPK) 
pathways are key to proliferation and survival of  GBM cells and other cancers  (Wen and 
Kesari, 2008). These proteins were evaluated by Western blotting at 24-48 h post-treatment in 
U251TMZ and U87TMZ cells in order to evaluate WA activity against total and phosphorylated 
protein levels as a potential mechanism for the anti-proliferative effects observed (Figure 3-4A). 
At 24 h, total levels of Akt and mTOR were decreased between ~1-5 µM WA with minimal 
changes occurring in total p70 S6 kinase (S6K) in both cells lines. However, activation of each  
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Figure 3-4. A) Key proteins of the survival and proliferation PI3K/Akt/mTOR and MAPK 
pathways as well as common surface tyrosine kinase receptors were evaluated by 
immunoblotting for total levels and activation by phosphorylation following treatment with WA 
at 24-48 h in U251TMZ and U87TMZ cells. Total levels of specific proteins in both pathways 
were decreased, but reduction of protein activation was only observed in the PI3K/Akt/MAPK 
pathway whereas phosphorylation of Raf-1 and ERK1/2 was increased. B) To determine the 
nature of MAPK pathway activation, U251TMZ and U87TMZ cells were pretreated with 50 µM 
of the MEK inhibitor PD98059 for 1 h followed by 2.5 µM WA for 6 h or 24 h. PD98059 
increased ERK1/2 phosphorylation but reduced WA-induced phosphorylation of ERK1/2 in a 
time-dependent manner. WA alone induced caspase 3 and PARP cleavage in both cell lines in a 
time-dependent manner that was increased when combined with MEK inhibitor. This 
demonstrates that MAPK pathway activation with WA was acting in a pro-survival signal rather 
than contributing to apoptosis.  
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protein via phosphorylation (p-Akt Ser473, p-mTOR Ser2448, and p-p70 S6K Thr389) was 
similarly reduced over this range. Phosphorylation at Thr412 of the nuclear isoform of p70 S6K, 
p85 S6K, was also reduced with increasing WA concentration (data not shown). These effects 
were observed through the 48 h timepoint and demonstrate an inhibitory effect of WA on the 
Akt/mTOR growth pathway. Additionally, phosphorylation (Thr172) of AMPKα, the catalytic 
subunit of a negative regulator of the Akt/mTOR pathway that responds to cellular stressors, was 
increased with WA treatment, peaking at 1 µM in U251TMZ cells (Supplemental Figure 3-1). 
Despite depletion of total levels of the downstream tumor suppressor TSC2, phosphorylation at 
Thr1462 was enhanced or maintained at all WA concentrations tested in U251TMZ cells. In 
contrast to previous observations in parental U87 cells (Grogan et al., 2013), total and phospho- 
levels of AMPKα were decreased in U87TMZ cells despite maintenance of p-TSC2 levels 
(Supplemental Figure 3-1). 
The MAPKKK Raf-1 and the MAPK ERK2 were assessed to evaluate the effects of WA 
on the primary proliferative MAPK pathway (Figure 3-4A). Total Raf-1 levels decreased at ~2.5-
5 µM in both U251TMZ and U87TMZ cells, however, activating phosphorylation of the protein 
at Ser338 increased over the same concentration range. Downstream, minimal changes were 
observed in total ERK2 levels, but phosphorylation of ERK1/2 (Thr202/Tyr204) was notably 
increased in a dose-dependent manner in both cell lines with a maximum level achieved at 2.5 
µM WA in each at both 24 h and 48 h. Given that phosphorylation of MAPK proteins is typical 
of a pro-survival response yet WA instead induces apoptosis in GBM cells, the MAPK pathway 
was further explored to determine if its activation was necessary for the induction of apoptosis or 
simply a compensatory pro-survival response. U251TMZ and U87TMZ cells were pretreated 
with 50 µM of the MAPKK MEK inhibitor PD98059 for 1 h followed by 2.5 µM WA for 6h or 
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24 h. Pretreatment with the inhibitor alone resulted in increased ERK1/2 phosphorylation but 
limited WA-induced phosphorylation in a time-dependent manner (Figure 3-4B). Alterations in 
apoptosis were assessed by cleaved caspase 3 and cleaved PARP levels. WA alone induced 
observable caspase 3 and PARP cleavage at 24 h in both cell lines and PARP cleavage alone at 
6h in U87TMZ. However, cleaved caspase 3 and PARP levels were increased when combined 
with the MEK inhibitor at 24 h in U251TMZ and 6 h in U87TMZ, demonstrating that MAPK 
pathway activation with WA treatment appears to represent a compensatory response to the 
apoptotic effects induced by the compound. 
Finally, the tyrosine kinase receptors EGFR, Her2/ErbB2, and c-Met, known to signal to 
both the Akt/mTOR and MAPK pathways, were evaluated due to their status as common 
amplified, mutated, and/or drug-targeted surface proteins in GBM (Wullich et al., 1993; Potti et 
al., 2004; Puputti et al., 2006; Guessous et al., 2010; Berezowska and Schlegel, 2011). Total 
levels of EGFR and Her2/ErbB2 in both U251TMZ and U87TMZ decreased with 2.5-5 µM WA 
treatment at 24 h and 48 h while total levels of c-Met decreased at 5 µM (Figure 3-4A). 
Interestingly, increased phosphorylation of Tyr1068 on EGFR was observed at 2.5-5 µM 
depending on the cell line as well as increased phosphorylation of Tyr1234/1235 on c-Met in 
U87TMZ cells up to 2.5 µM WA at 48 h. Phosphorylation of c-Met was otherwise 
downregulated with WA treatment in both lines. 
 
3.4.6 Withaferin A elevates oxidative status and induces a heat shock stress response in TMZ-
resistant cells 
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We have previously demonstrated the ability of WA to elevate oxidative potential and 
ROS-mediated cell death in TMZ-sensitive GBMs (Grogan et al., 2013). TMZ has also been 
demonstrated to produce ROS that result in inhibitory activation of AMPK (Zhang et al., 2010). 
We therefore evaluated the nature and ability of WA to continue to induce ROS in TMZ-resistant 
U87TMZ and U251TMZ cells. Peroxide-type radical production was monitored with CM-
H2DCFDA conversion at 3 h post-WA exposure. Both cell lines showed statistically significant 
increased detectible CM-H2DCFDA fluorescence with increasing WA exposure. ROS levels rose 
20.9% (p = 0.001), 36.6% (p = 0.002), and 38.8% (p = 0.01) in U251TMZ and 21.3% (p = 
0.003), 40.6% (p = 0.004), 47.3% (p = 0.001) in U87TMZ cells at 1, 3, and 5 µM WA compared 
to control, respectively (Figure 3-5A). The thiol antioxidant and ROS scavenger NAC was added 
simultaneously with WA and was shown to nearly complete abrogate WA-generated ROS, 
further demonstrating the nature of the effect. 
Various models of oxidative stress are known to be associated with a heat shock response 
via induction of several HSPs (Ansari et al., 2011; Qiao et al., 2012), and alteration of HSPs 
were previously reported following WA treatment (Khan et al., 2012; Grogan et al., 2013). 
Treatment with WA yielded a unique pattern of HSP expression modulation in U251TMZ and 
U87TMZ cells (Figure 3-5B). Total levels of HSP32/heme oxygenase 1 and HSP70, but not 
HSP90, were observed to increase with increasing concentrations of WA at 24 h. HSP27 was 
depleted at 24 h with 5 µM WA in both cell lines but remained largely unchanged in U251TMZ 
and mildly elevated in U87TMZ with other concentrations at 24 h. The transcription factor heat 
shock factor 1 (HSF1) showed dose-dependent reduction in expression between 1-5 µM WA. 
Pretreatment with 5 mM NAC virtually eliminated all modulation of proteins in the heat shock 
system (Figure 3-5B). 
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Figure 3-5. A) The peroxide ROS indicator CM-H2DCFDA was preloaded into U251TMZ and 
U87TMZ cells prior to WA exposure to determine alterations in oxidative potential. Elevations 
in signal that were observed with increasing concentrations of WA at 3 h were reduced or 
completely absent with co-treatment of 5mM NAC. B) Treatment with WA resulted in the 
induction of an NAC-repressible cellular stress heat shock response. Proteins associated with 
cellular stress and heat shock were evaluated by immunoblotting at 24 h and revealed elevated 
levels of HSP32 and HSP70, known to be upregulated in response to oxidative stress, but 
decreased transcription factor HSF1 with increasing WA exposure that could be completely 
eliminated with 5 mM NAC pretreatment. NAC also prevented induction of cyclin B1 and 
cleavage of PARP. Functionally, NAC pretreatment reduced the anti-proliferative (C) and pro-
cytotoxic (D) effects of WA as assessed by the CellTiter-Glo assay at 72 h and flow cytometry at 
24 h, respectively. *p < 0.05, **p < 0.01, ***p < 0.001  
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Functionally, WA-induced depletion of ATP levels, a marker of reduced cellular viability 
in the CellTiter-Glo assay, could be reduced or completely eliminated with 1-5 mM NAC 
pretreatment (p < 0.0001) (Figure 3-5C). Such effects were seen with up to 6 µM WA, the 
highest concentration examined. Additionally, re-evaluation of cell death by flow cytometry as 
previously described following pretreatment with 5 mM NAC showed the elimination of death-
associated PI and Annexin V staining normally induced by 5 µM WA (p < 0.01) (Figure 3-5D). 
This was supported by blockage of PARP cleavage via NAC pretreatment (Fig. 3-5B). 
Additionally, WA-mediated cyclin B1 induction was blocked by NAC, demonstrating the 
prevention of G2/M cell cycle arrest seen with WA treatment. 
 
3.4.7 Withaferin A resensitizes TMZ-resistant GBM cells to TMZ through MGMT depletion 
 
Expression of MGMT is associated with TMZ resistance in GBMs and therefore is an 
attractive target for TMZ resistance resensitization and prevention (Kitange et al., 2009). WA 
demonstrated the ability to induce depletion of MGMT at 48 h in cell lines (U251TMZ, T98G, 
and U138) utilizing MGMT as the primary means of TMZ resistance (Figure 3-6A). U251TMZ 
and U138 cells showed progressive depletion of MGMT from 0.5-10 µM WA with 
approximately 5-fold and 20-fold less compared to control by 5 µM, respectively. At 5 µM WA 
treatment, there was a 43% reduction in MGMT in T98G cells with complete elimination by 10 
µM. U87TMZ cells, however, failed to express MGMT altogether. 
To determine if these findings extended to functional resensitization of resistant cells to 
WA, two cells lines resistant through MGMT (U251TMZ and T98G) and one cell line displaying 
MGMT-independent resistance (U87TMZ) were treated with WA for 24 h followed by TMZ and  
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Figure 3-6.  
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Figure 3-6. A) WA treatment reduced protein levels of MGMT in TMZ-resistant U251TMZ, 
T98G, and U138 cell lines at 48 h. MGMT was not observed in U87TMZ. B) 24 h pretreatment 
with WA resensitized MGMT-expressing U251TMZ and T98G cells to TMZ in a dose-
dependent manner as assessed by a normalized MTS assay, but no resensitization was observed 
in MGMT-deficient U87TMZ cells. C) TMZ-resistant cells were treated with WA for 24 h 
followed by TMZ exposure for an additional 24 h. Pretreatment with WA potentiated and/or 
synergized with TMZ to induce further depletion of MGMT in MGMT-expressing lines. 
Increasing WA concentrations yielded higher levels of p-H2A.X and cleaved PARP in all cell 
lines, but only T98G demonstrated WA-mediated increased levels with TMZ exposure. *p < 
0.05, **p < 0.01, ***p < 0.001  
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evaluated with the MTS assay (Figure 3-6B). Both U251TMZ and T98G showed statistically 
significant decreases in cell viability when 1, 1.5, or 2 µM WA was combined with 300 or 500 
µM TMZ. Pretreatment with 2 µM WA followed by 300 µM TMZ yielded a 32% (p < 0.0001) 
and 34% (p = 0.004) relative decrease in U251TMZ and T98G cell viability compared to TMZ 
or WA alone, respectively. In contrast, U87TMZ cells only demonstrated a statistically 
significant enhancement of combination therapy over TMZ alone – only 6% additional reduction 
in relative viability – with a 2 µM WA and 300 µM TMZ combination (p = 0.02). 48 h 
pretreatment with WA also demonstrated enhanced effect with significant elimination of the 
benefit by 72 h pretreatment (data not shown). WA pretreatment did not prevent TMZ efficacy in 
TMZ sensitive U251 and U87 parental cells (Supplemental Figure 3-2A). 
Because TMZ also depletes MGMT (D'Atri et al., 2000), the effect of WA and TMZ 
combination on MGMT levels was evaluated. Combination therapy demonstrated dose-
dependent synergy or potentiation to reduce total levels of MGMT in U251TMZ, T98G, and 
U138 MGMT-expressing cells (Figure 3-6C). At 1 µM WA in U251TMZ and U138 cells and 2.5 
µM WA in T98G cells, minimal decreases and/or increases of MGMT levels were observed. The 
addition of 300 µM TMZ for 24 h resulted in 43%, 52%, and 34% reduction in MGMT protein 
levels compared to TMZ alone in U251TMZ, T98G, and U138 cells, respectively. 
Phosphorylation of H2A.X as a marker of double strand DNA damage and cleavage of 
PARP during apoptosis were evaluated to look for molecular evidence of combinational efficacy. 
Both markers were elevated in the setting of increasing concentrations of WA in U251TMZ, 
T98G, U138, and U87TMZ cells. However, PARP cleavage was then diminished at the high 
levels of U87TMZ and U138 cells suggesting non-apoptotic cell death or very late apoptosis at 
this timepoint. Addition of TMZ was observed to increase p-H2A.X and PARP cleavage in only 
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T98G, particularly at 1 µM WA. Interestingly, despite similar or increased levels of cleaved 
PARP within WA treatment groups, levels of uncleaved PARP increased with TMZ treatment in 
each of the TMZ groups but not control in U251TMZ and T98G cells. Given the reported 
oxidative effect induced by TMZ (Zhang et al., 2010), markers of oxidative stress including 
HSP32, HSP70, and p-AMPKα as well as the AMPK-influenced downstream phosphorylation of 
mTOR were evaluated to determine if combination of WA and TMZ demonstrated enhanced 
oxidative effect in GBM. While WA increased HSP32 and HSP70 levels in all lines and TMZ 
enhanced phosphorylation of AMPKα in U138, combination therapy did not result in additional 
effect and failed to further diminish mTOR activation (Supplemental Figure 3-2B). 
 
3.5 Discussion 
 
 While WA has demonstrated effectiveness as a promising new therapeutic agent in a 
variety of cancer types including TMZ-sensitive GBM, this work is the first to explore its 
efficacy in a known model of drug-resistance. Here, we show for the first time that WA induces 
a potent cytotoxic effect against temozolomide resistant GBMs resulting in G2/M arrest and 
apoptosis from both the intrinsic and extrinsic systems. These findings correspond with the 
elevation of cellular oxidative potential and inhibitory modulation of the Akt/mTOR pathway but 
not the MAPK pathway. 
Since its approval by the FDA, TMZ remains the standard-of-care chemotherapeutic 
agent in the treatment of primary GBM. Exposure to this agent results in DNA adducts such as 
O6-methylation of guanine which, if not removed by MGMT, can mispair with thymine. Cells 
with intact MMR undergo futile cycles of attempted repair with resultant replication-associated 
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DNA double strand breaks, G2/M arrest, and ultimately apoptosis (Hirose et al., 2003). Targeting 
mechanisms of DNA damage repair with various inhibitors, such as those of PARP and ataxia 
telangiectasia mutated (ATM), has provided potentially beneficial strategies in enhancing TMZ 
effect, but comparatively limited effort has gone into addressing both inherent and acquired 
resistance to TMZ by MGMT expression or, less frequently, MMR mutation in GBM. Despite 
about half of patients displaying tumor phenotypes not conducive to TMZ use, it remains a first-
line agent, demonstrating the need for better tumor screening techniques. Furthermore, initially 
responsive tumors are often quick to develop resistance to this line of therapy (Chamberlain, 
2010; Quick et al., 2010).  
 Several experimental agents used to resensitize resistant cancer cells to TMZ or other 
alkylating agents – such as valproic acid (Sztajnkrycer, 2002; Weller et al., 2011; Ryu et al., 
2012), O
6
-benzylguanine (Baer et al., 1993; Kaina et al., 2010), IL-24 (Zheng et al., 2008), and 
silencing oligonucleotides (Citti et al., 1996; Xie et al., 2011; Kreth et al., 2013) – possess little 
practical intrinsic anti-cancer cytotoxic properties or clinical applicability, however, some do 
have the potential for adverse effects in the patient. Alternatively, dose-dense TMZ scheduling, 
used to deplete MGMT levels quickly to enhance TMZ effects, has yielded disappointing 
outcomes in several clinical trials (Strik et al., 2012). In this study, WA acted as both an 
inherently cytotoxic agent and an enhancer of the efficacy of TMZ in MGMT-driven resistant 
cell lines while maintaining TMZ sensitivity in parental lines. Such data conceptually support the 
utility of combination therapy WA with TMZ in the first-line treatment of GBM. Such an 
approach should maximize anti-cancer activity across broad tumor heterogeneity. Importantly, 
while tumors with resistance due to MMR mutation may not be resensitized to TMZ by WA, the 
presence of a second cytotoxic chemotherapeutic agent may provide significant benefit in the 
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context of ineffective TMZ treatment. It remains to be fully explored whether increased levels of 
p-H2A.X observed with WA treatment are a result of direct DNA damage, perhaps through an 
oxidative mechanism, or rather a known byproduct observed during cellular apoptosis for DNA 
fragmentation (Rogakou et al., 2000), however, preliminary results in breast cancer support a 
caspase-mediated mechanism (data not published). Elevated total PARP with increasing TMZ in 
the presence of WA in MGMT-expressing lines may indicate the necessity for increased base 
excision repair (BER) during combination therapy, alluding to induction of DNA damage as a 
reason for combinational efficacy which will need to be validated by further scientific 
investigation. 
 Several studies have implicated the role of WA in the disruption of HSP90 chaperone 
functions through binding to the C-terminus of HSP90 (Yu et al., 2010; Grover et al., 2011). 
While direct evidence of such an inhibitory effect has not yet been established, downstream 
depletion of various HSP90-related client proteins suggests that WA may indeed act at least in 
part as a novel HSP90 inhibitor. This could explain and support the wide-ranging effects 
observed in this study, including the depletion in total levels of known HSP90 client proteins 
such as Akt, mTOR, Raf-1, and EGFR. By depleting these key regulatory client proteins of 
HSP90, the normal signaling axes of multiple proliferative pathways are simultaneously 
modulated. MGMT, which is depleted in the presence of WA, has not, however, been reported as 
a client protein of HSP90. Indeed, current studies demonstrate that total levels of MGMT are not 
impacted by the widely-utilized HSP90-inhibitor 17-AAG until high concentrations (1-2 µM) are 
achieved, suggesting that its stability and function are not directly maintained by HSP90 (data 
not shown). Santagata, et al. demonstrated the thiol reactivity of WA (Santagata et al., 2012), and 
our results implicate an oxidative mechanism, representing an alternative means by which 
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MGMT and other non-HSP90 client proteins may be targeted for degradation by WA. 
Interestingly, valproic acid, which diminishes MGMT levels, has also been shown to cause 
oxidative stress in glioma cell lines (Fu et al., 2010). 
 Induction of oxidation has become a promising mechanism by which to target cancer. 
Alterations in the redox potential of cancer cells due to various molecular turnover and quick 
replication results in increased cellular stress that can be exploited to shift cells into a state of 
cytotoxicity (Laurent et al., 2005; Cabello et al., 2007). This approach circumvents traditional 
therapeutic options such as antigen-targeting and DNA-damaging agents that have received the 
most attention but are often rendered useless due to rapid development of resistance. In GBM, 
such traditional agents have been explored in patients but have yielded unimpressive results in 
clinical trials largely due to the development of tumor mutations that limit the effectiveness 
and/or relevance of a particular targeted therapeutic (Wen and Kesari, 2008; Quick et al., 2010). 
In the present study, thiol-reactivity and oxidation by WA resulted in depletion of 
proteins in the Akt/mTOR and MAPK pathways including many cell surface receptors either 
through direct interaction or as a downstream effect of the inhibition of other proteins. As noted 
previously, other reports have shown additional pathways effected. Such an ability to target 
multiple pathways simultaneously with a single compound has great potential to generate an 
enhanced anti-cancer effect while reducing the development of resistance to a particular target. 
The ability to modulate multiple components of the Akt/mTOR pathway simultaneously 
provides a novel and important mechanism by which WA can manifest its beneficial effects 
against GBMs. Because of mutations in proteins like the tumor suppressor phosphatase and 
tensin homolog (PTEN), this pathway is frequently overactivated in GBM to drive proliferation, 
as shown in both U251 and U87 cells (Koul, 2008; Lee et al., 2011; Lino and Merlo, 2011). 
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Interestingly, while we previously showed activation of AMPKα and downstream tumor 
suppressor TSC2 which act to inhibit mTOR in both U251 and U87 parental cells (Grogan et al., 
2013), U87TMZ appears to have lost the ability to act through this pathway which suggests 
direct inhibition of the Akt/mTOR axis. 
 WA treatment yields subsequent induction of the MAPK pathway as demonstrated by 
activating phosphorylation of EGFR, Raf-1, and ERK1/2. Previous studies have shown that 
reactive oxygen species generated by epoxide-containing compounds in GBM cells are 
responsible for the phosphorylation of ERK1/2 which then drives apoptosis (Wu et al., 2011). In 
contrast, inhibition of this pathway prior to WA exposure yields enhanced apoptosis, suggesting 
that the activation of the MAPK pathway is a compensatory pro-survival response to apoptotic 
shifts in the cell and may be a therapeutic target that would synergistically enhance the efficacy 
of WA in future combinational therapy studies. 
 The studies presented here provide an important framework for the utilization of WA in 
TMZ-resistant GBM as both a monotherapy and as a resensitizer in combination with the 
standard chemotherapeutic agent TMZ. WA demonstrates an oxidative mechanism that leads to 
anti-proliferative and pro-apoptotic effects largely through Akt/mTOR pathway modulation. 
Simultaneously, depletion of MGMT allows for enhanced activity of TMZ. While future pre-
clinical animal studies will be necessary to determine its translational potential in GBMs, 
evidence is supportive of a future clinical potential for the utilization of WA across the 
heterogeneic spectrum of glioma patients. 
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Supplemental Figure 3-1.  
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Supplemental Figure 3-1. WA treatment resulted in depletion of total protein levels in both 
AMPKα and TSC2 at 24-48 h in both U251TMZ and U87TMZ cells. U87TMZ cells also 
demonstrated reduced phosphorylation of AMPKα in contrast to previous findings in U87 
parental cells. U251TMZ cells display dose-dependent activating phosphorylation of AMPKα 
and downstream TSC2. 
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Supplemental Figure 3-2.  
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Supplemental Figure 3-2. A) 24 h WA pretreatment did not prevent TMZ efficacy in TMZ-
sensitive U251 and U87 parental cells as assessed by a normalized MTS assay, suggesting a lack 
of inhibition of functional MMR. In U251 cells, WA mildly sensitized cells to TMZ, but no 
sensitization was observed in U87 cells. B) Given a described oxidative component of TMZ 
therapy through activation of AMPKα, markers of oxidation were assessed during combination 
therapy of WA and TMZ in TMZ-resistant cells. HSP32 and HSP70, known to be upregulated in 
response to oxidative stress, increased with WA treatment to a maximal level but were not 
further modulated by the presence of TMZ. Treatment with TMZ only resulted in elevated p-
AMPKα in only U138 cells, but WA failed to further increase this phosphorylation in 
combination with TMZ. This was confirmed downstream by failure to further inhibit mTOR 
activation with combination therapy, suggesting efficacy of such treatment was not due to 
potentiated or synergized elevation in oxidation status. **p < 0.01  
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Chapter 4 
 
Withaferin A is a novel inhibitor of the Wnt/β-catenin 
signaling pathway in medulloblasoma through proteasome-
mediated degradation of TCF/LEF 
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4.1 Abstract 
 
Pediatric medulloblastoma (MB) is a challenging tumor to approach therapeutically given 
significant tumor heterogeneity across patients. While current treatment options have led to an 
approximately 70% 5-year survival rate in children and adolescents, the off-target toxicity of 
these agents frequently manifests with chronic quality-of life impairments in these vulnerable 
patients, identifying a need for novel therapeutic options. Withaferin A (WA) has demonstrated 
notable anti-cancer efficacy against multiple cancer types through several oncogenic pathways, 
but its modulation of Wnt/β-catenin signaling, overactive in 10-15% of MB, has not been 
explored. Here, WA inhibited MB cell proliferation through dose-dependent G2/M cell cycle 
arrest and induction of apoptosis. Treatment with WA was demonstrated to function as a novel 
direct inhibitor of Wnt signaling as assessed by TOP FLASH reporter activity. Reduced 
signaling was mediated through proteasomal degradation the TCF/LEF transcription factors 
TCF1, TCF3, TCF4, and LEF1 and reduced interaction with β-catenin without significant 
alterations of β-catenin level or localization. This was associated with a reduction in total and 
phosphorylated levels of Akt and mTOR but elevations in inhibitory p-GSK-3β which was 
demonstrated pharmacologically to be independent of remaining Akt activity. Consistent with 
previous findings in other models, WA treatment resulted in N-acetyl-L-cysteine-repressible 
cellular oxidation and dissociation of HSP90/Cdc37. While TCF/LEF members were not 
observed to directly associate with HSP90 or Cdc37, each was decreased following inhibition of 
HSP90 with N-terminal inhibitor 17-AAG, suggesting an indirect role for HSP90 in their 
stability. Taken together, these findings show both intriguing translational potential for WA as a 
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therapeutic agent against MB and other Wnt-driven cancers and a novel role for HSP90 in Wnt 
signaling, each warranting further exploration. 
 
4.2 Introduction 
 
Central nervous system (CNS) tumors, including the grade IV medulloblastoma (MB) of 
the posterior fossa, are the most common solid tumors of childhood, accounting for 
approximately 20% of all pediatric malignancies (Linabery and Ross, 2008). Medulloblastomas 
represent 25-30% of these primary lesions in children but can arising in individuals of all ages 
(Khatua et al., 2012). Although the 5-year survival rate for medulloblastomas in both children 
and adolescents is around 70%, therapeutic challenges remain to simultaneously address both 
treating the tumor and ensuring a high long-term quality of life in the pediatric patient population 
(Smoll, 2012). Current standards of care include surgical resection followed by craniospinal 
radiation and chemotherapeutic agents such as vincristine, lomustine, cyclophosphamide, 
carboplatin, and cisplatin (Khatua et al., 2012). However, because of significant morbidities 
associated with these agents, it has been reported that long-term survivors of childhood 
medulloblastoma suffer from endocrine, cognitive, and neurological complications with 
significant deficits in daily psychosocial functioning including driving, employment, 
independent living, and personal relationships (Boman et al., 2009; Frange et al., 2009). 
Medulloblastomas are categorized in several unique molecular subgroups based on tumor 
genetics, cell histology, growth, and clinical outcome including sonic hedgehog (SHH), 
Wingless (Wnt), group 3, and group 4 (Northcott et al., 2012). SHH and Wnt are named due to 
upregulation and overactivation of these key signaling pathways. Specifically, the Wnt subgroup 
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of MB patients is characterized by aberrant overactivation of the canonical Wnt/β-catenin 
signaling pathway, often through inactivating mutations of the adenomatous polyposis coli 
(APC) and Axin1/2 proteins or overexpression of β-catenin (Kim et al., 2011). Although the Wnt 
subgroup represents 10-15% of total MB patients and is characterized by long-term survival rates 
of 90%, the challenges of conventional therapy persist with current patient morbidity and 
mortality largely due to the complications of therapy and the development of secondary 
malignancies rather than recurrence of the MB (Ellison et al., 2011; Kim et al., 2011; Taylor et 
al., 2012; Remke et al., 2013). 
While a number of inhibitors have been identified that alter Wnt signaling at various 
points in the cascade (Voronkov and Krauss, 2013), only four agents are currently in human 
clinic trial against any malignacy: olaparib (poly(ADP-ribose) polymerase (PARP)/tankyrase 
inhibitor), veliparib (PARP/tankyrase inhibitor), LGK974 (porcupine inhibitor), and OTSA101-
DTPA-90Y (radiolabeled antibody against frizzled-10) (MacDonald et al., 2014). Only PARP 
inhibition, described to destabilize β-catenin through Axin (Waaler et al., 2012), is under trial for 
MB with the latter two therapies failing to target the appropriate location in the signaling cascade 
given the mutations of MB. Given the heterogeneic nature of the disease supported by multiple 
subgroup classifications, there is a critical need for novel therapeutics that function to both target 
this critical aberrant signaling to maximize Wnt subgroup effect while maintaining generalized 
anti-tumor cytotoxicity in other subgroups lacking these specific signaling alterations. 
Withaferin A (WA) is a cytotoxic steroidal lactone identified in several species of the 
Solenceae plant family that has demonstrated the ability to modulate multiple signaling pathways 
key to cancer proliferation and survival (Vanden Berghe et al., 2012; Vyas and Singh, 2014). 
Notably, in the brain tumor glioblastoma multiforme (GBM), WA functioned to reduce total and 
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phosphorylated levels of key oncogenic proteins in the Akt/mammalian target of rapamycin 
(mTOR) signaling pathway (Grogan et al., 2013; Grogan et al., 2014). The Akt/mTOR pathway 
establishes cross-talk with the Wnt/β-catenin pathway through glycogen synthase kinase-3β 
(GSK-3β) such that activation of Akt produces inhibitory phosphorylation of GSK-3β, a 
reduction in the phosphorylation of β-catenin, and enhanced stability of β-catenin. As such, 
inhibition of PI3 kinase (PI3K)/Akt signaling has been shown to inhibit the Wnt/β-catenin 
pathway in MB (Baryawno et al., 2010). We hypothesized that WA could act as a novel inhibitor 
of the Wnt pathway in MB by a similar mechanism. To date, WA has not been explored as a 
Wnt/β-catenin signaling inhibitor nor examine against MB. 
Studies by our group and others have suggested that modulation of the Akt/mTOR 
pathway and the other diverse findings associated with WA treatment may be due to two 
underlying mechanisms which are explored here in MB: enhanced cellular oxidation (Malik et 
al., 2007; Widodo et al., 2010; Hahm et al., 2011; Mayola et al., 2011; Santagata et al., 2012; 
Grogan et al., 2013; Grogan et al., 2014) and inhibition of the heat shock protein (HSP) 90 
protein chaperone axis including its disruption of its interactions with co-chaperone cell division 
cycle protein 37 (Cdc37) (Yu et al., 2010; Gu et al., 2014). Previous studies have identified that 
HSP90 associates with Wnt/β-catenin pathways proteins Axin1, GSK-3β, and β-catenin but that 
its inhibition only resulted in a cell line-dependent depletion of GSK-3β (Cooper et al., 2011; Liu 
et al., 2012). p53-regulated HSP90 function was shown to enhance Wnt signaling, but this was 
likely an indirect effect through phosphorylation of Akt and GSK-3β (Okayama et al., 2014). 
Direct inhibition of the Wnt/β-catenin pathway through HSP90 inhibition has not been 
demonstrated previously. 
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In this study, we explored the general cytotoxicity of WA, including evaluation of its 
described oxidative and HSP90 inhibitory effects, as a potential chemotherapeutic for MB and 
demonstrate for the first time that it functions in-part as a potent inhibitor of the canonical Wnt 
signaling pathway. Interestingly, our studies provide evidence that WA induces degradation of 
the transcription factor (TCF)/lymphoid enhancer-binding factor (LEF) family of transcription 
factors critical in Wnt signaling to inhibit pathway activity directly rather than through 
Akt/mTOR pathway cross-talk via GSK-3β. Maintenance of TCF/LEF proteins was shown to be 
indirectly dependent on HSP90 function with WA inducing disruption of the HSP90/Cdc37 
interaction. 
 
4.3 Materials and methods 
 
4.3.1 Cell culture and general reagents 
 
Four human pediatric medulloblastoma cell lines were acquired. DAOY adherent cells 
were obtained from American Type Culture Collection (ATCC; Manassas, VA). ONS76 
adherent cells were generously donated by Dr. Michael D. Taylor (The Hospital for Sick 
Children, Toronto, Ontario, Canada), and D425(MED) and D283(MED) semi-
adherent/suspension cells were kindly provided by Dr. Darell D. Begner (Duke University, 
Durham, NC). All cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM 
#11995-065; Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; 
Sigma-Aldrich, St. Louis, MO), 1% penicillin/streptomycin (Gibco), 2% L-glutamine (200 mM; 
Gibco), 1% MEM-vitamin (100x; Hyclone, Logan, UT), and 1% MEM nonessential amino acids 
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(Sigma Aldrich) at a 37 °C humidified atmosphere of 5% CO2 in air. Cells were utilized in 
experiments upon achieving exponential growth phase. Withaferin A was isolated as previously 
described (Samadi et al., 2010b). Propidium iodide (PI), RNase, N-acetyl-L-cysteine (NAC), and 
puromycin dihydrochloride were acquired from Sigma-Aldrich, Annexin V-FITC was obtained 
from BD Biosciences (San Diego, CA), and MG132 was purchased from Selleckchem (Houston, 
TX). 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) was obtained from LC 
Laboratories (Woburn, MA). 
 
4.3.2 MTS assay 
 
Cells were plated at 2,000-4,000 cells/well in 50 µL in a 96-well plate and allowed to 
adhere and/or settle. After 6 h, cells were treated with various concentrations of WA to bring the 
total well volume to 100 µL and allowed to incubate for 72 h. Cell viability and proliferation was 
evaluated with the addition of the colorometric CellTiter96 Aqueous MTS assay reagent as per 
the manufacturer’s instructions (Promega, Fitchburg, WI). Reagent was allowed to incubate with 
the cells for 1-4 h in a cell line-dependent manner, and absorbance was quantified at 490 nm on a 
BioTek Synergy 2 plate reader (BioTek, Winooski, VT). 
 
4.3.3 CellTiter Glo assay 
 
The CellTiter-Glo luminescent assay (Promega, Fitchburg, WI) was used to evaluate cell 
viability and proliferation through assessment of cellular ATP levels in experiments with the 
NAC pretreatment due to its reducing properties. Cells were plated as outlined in the MTS assay 
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in a white-walled 96-well plate. Where indicated, cells were pretreated with NAC for 1 h 
followed by WA. After 72 h, assay reagent was added to the wells as per the manufacturer’s 
instructions and gently shaken for 10 minutes in the dark at room temperature. Well 
luminescence was measured on the BioTek Synergy 2 plate reader. 
 
4.3.4 Cell cycle analysis 
 
Cells were plated to ~50% confluency in the adherent lines or 125,000 cells/mL in the 
suspension lines and treated with various concentrations of WA for 24 h. At that time, total cells 
were collected, pelleted, fixed/permeablized, and stained with PI as previously described 
(Grogan et al., 2013). Cells were analyzed by flow cytometry on a BD LSRII (Becton Dickinson, 
San Diego, CA). Only living cells without DNA fragmentation were gated. 
 
4.3.5 Apoptosis evaluation 
 
Cells were plated and treated as described for cell cycle analysis. After 24 h, all cells 
were collected and processed as previously described (Grogan et al., 2013). Briefly, cells were 
washed once in Annexin binding buffer and subsequently stained with PI and Annexin V-FITV 
as per the manufacturer’s instructions (BD Biosciences, San Diego, CA) for 20 minutes at 4 °C. 
Stained cells were washed twice with the Annexin binding buffer, resuspended in 400 µL of the 
buffer, and immediately analyzed by flow cytometry on the BD LSRII. 
 
4.3.6 Immunoblotting 
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For general Western blotting, cells were plated as previously described for cell cycle 
analysis before treatment with WA or 17-AAG. Where indicated, cells were pre-treated with 5 
mM NAC for 1 h. After 24 h, cells were harvested, and proteins were isolated in lysis buffer (40 
mM HEPES, 2 mM EDTA, 10 mM sodium pyrophosphate decahydrate, 10 mM β-
glycerophosphate disodium salt pentahydrate, 1% triton X-100 supplemented with 100 µM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM Na3VO4, and 2 µL/mL protease inhibitor 
cocktail), quantified, separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS–PAGE), and transferred onto a Hybond nitrocellulose membrane as previously described 
(Samadi et al., 2011). 10-50 µg of protein sample was loaded per lane. Equal loading and 
transfer of sample was confirmed by blotting for actin levels. Studies were repeated for accuracy. 
For nuclear and cytoplasmic fractionation of proteins, cells were grown and harvested as 
described. Washed cells were lysed in harvest buffer (10 mM HEPES pH 7.9, 50 mM NaCl, 0.5 
M sucrose, 0.1 mM EDTA, and 0.5% triton X-100), incubated on ice for 5 minutes, and pelleted 
at 1,000 rpm. The supernatant was collected as the cytoplasmic fraction. The pellet was 
resuspended for one wash with buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA) and subsequently repelleted. The supernatant was discarded. The pellet was then 
resuspended in buffer C (10 mM HEPES pH 7.9, 500 mM NaCl, 0.1 mM EDTA, 0.1 mM 
EGTA, 0.1% NP-40), vortexed periodically while incubating on ice for 15 minutes, and 
centrifuged at 14,000 rpm for 10 minutes at 4 °C. The supernatant was collected as the nuclear 
fraction. Proteins in the two fractions were quantified, prepared, separated, and immunoblotted 
identically to what was previously described. Histone H4 was used as a nuclear-only control. All 
buffers were supplemented with 100 µM PMSF, 1 mM Na3VO4, and 2 µL/mL protease inhibitor. 
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Triton X-100 soluble and insoluble fractionation was completed with triton soluble buffer 
(50 mM Tris-HCl pH 6.8, 150 mM NaCl, 1mM EDTA, 1 mM EGTA, 1% triton X-100) and 
insoluble buffer (50 mM Tris-HCl pH 6.8, 2% SDS) as previously described (Chen et al., 2008) 
supplemented with 100 µM PMSF, 1 mM Na3VO4, and 2 µL/mL protease inhibitor cocktail. In 
brief, cells were pre-treated with proteasome inhibitor MG132 for 1 h followed by WA for 24 h. 
Cells were collected as previously described, lysed with triton soluble buffer, and centrifuged at 
14,000 rpm for 20 minutes at 4 °C. The supernatant was collected as the soluble fraction. The 
pellet was resuspended, washed once with soluble buffer, and repelleted by centrifuged at 14,000 
rpm for 10 minutes. The pellet was resuspended in triton insoluble buffer and subsequently 
ground with a pestle, vortexed, and heated at 100 °C repeatedly for ~15 minutes to promote 
dissolution of the pellet. Any remaining debris was removed by centrifugation, and the 
supernatant was collected as the insoluble fraction. Proteins in the two fractions were prepared 
and evaluated as described above. 
Primary rabbit antibodies against β-catenin (#9562; 1:1000), p-β-catenin 
(Ser33/37/Thr41; #9561; 1:1000), TCF1 (#2203; 1:1000), TCF3 (#2883; 1:1000), TCF4 (#2569; 
1:1000), LEF1 (#2230; 1:1000), GSK-3β (#9315; 1:1000), p-GSK-3β (Ser9; #9323; 1:1000), c-
myc (#9402; 1:1000), c-Met (#4560; 1:500), and Cdc37 (#4793; 1:1000) and primary mouse 
antibodies against Cyclin D1 (#2926; 1:500) and histone H4 (#2935; 1:1000) were acquired from 
Cell Signaling Technology (Danvers, MA). Primary rabbit antibody for Axin2 (#MA5-15015; 
1:1000) was acquired from Pierce Biotechnology (Rockford, IL). Primary mouse antibodies for 
survivin (sc-17779; 1:100) and FLAG (F1804; 1:1000) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and Sigma-Aldrich, respectively. Secondary mouse anti-rabbit 
conformation specific HRP antibody (#5127; 1:1000) was obtained from Cell Signaling 
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Biotechnology and used for blotting in appropriate immunoprecipitation blotting. All other 
primary and secondary antibodies were used as previously described (Grogan et al., 2013). 
 
4.3.7 Reactive oxygen species measurement 
 
WA-mediated production of intracellular reactive oxygen species (ROS), particularly 
peroxides like H2O2, was measured through fluorescent conversion of the general oxidative 
stress indicator CM-H2DCFDA (Molecular Probes, Grand Island, NY). All MB cells lines were 
preloaded with 20 µM CM-H2DCFDA in 1x PBS at 37 °C for 1 h, washed once with phenol red-
free DMEM supplemented with all aforementioned additives, and resuspended in the same 
medium. Cells were plated at 40,000 cells/well in a 96-well plate and treated with WA ± NAC 
after 30 minutes. Evaluation of fluorescence was completed on a BioTek Synergy 2 plate reader 
after 3-4 h with excitation and emission filters of 485 nm and 528 nm, respectively. 
 
4.3.8 TOP/FOP FLASH reporter assay 
 
A luciferase reporter vector for Wnt/β-catenin signaling activity through TCF/LEF DNA 
binding sites, TOP FLASH, and its negative control, FOP FLASH, along with vectors for wild-
type (WT) β-catenin and overactive mutant S33Y-β-catenin (Kolligs et al., 1999) were 
generously provided by Dr. Eric R. Fearon (University of Michigan, Ann Arbor, MI). DAOY 
cells were transfected in bulk with reporter construct TOP FLASH or FOP FLASH and a renilla 
luciferase construct at a ratio of 100:1 along with either β-catenin vector or a pcDNA3 control 
vector using Lipofectamine 2000 (Life Technologies, Carlsbad, CA) as per the manufacturer’s 
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instructions and plated at 7,500 cells/well in a white-walled 96-well plate (50 ng reporter, 0.5 ng 
renilla, and 400 ng respective β-catenin construct per well in 150 µL). The transfection and gene 
expression were allowed to occur over 24 h before the cells were treated with WA. Reporter and 
renilla luciferase activity were quantified after 24 h with the Dual-Luciferase Reporter Assay 
System (Promega) on a BioTek Syngery NEO plate reader (Winooski, VT). Each reaction was 
carried out in triplicate, and sample well values were normalized to the renilla signal. 
 
4.3.9 Transfections 
 
DAOY cells were transfected with S33Y-β-catenin-FLAG or a pcDNA3 vector and a 
puromycin cassette at a 12:1 ratio (6 µg:500 ng in a 6 cm dish) using Lipofectamine 2000 as per 
the manufacturer’s instructions (Life Technologies). The cells were selected with 1.5 ug/mL 
puromycin, and surviving colonies were pooled. To verify expression of the S33Y-β-catenin, 
Western blotting for the attached FLAG-tag was carried out. The transfected cells were used as a 
model of constitutively active Wnt signaling for the outlined assays. 
 
4.3.10 Real-time polymerase chain reaction (RT-PCR) 
 
DAOY Vector or S33Y cells were plated, treated with WA, and harvested as described 
for cell cycle analysis. RNA was isolated using Qiagen RNeasy Mini Kit as per the 
manufacturer’s instructions (Venlo, Limburg, Netherlands). Quality of the RNA was confirmed 
using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA), and 400 ng of 
each RNA was transformed to cDNA with the High Capacity RNA-to-cDNA Kit as per the 
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manufacturer’s instructions (Applied Biosystems, Foster City, CA) using a MyCycler Thermal 
Cycler (Bio-Rad Laboratories, Hercules, CA). Power SYBR Master Mix (Applied Biosystems) 
was combined with 10 ng of cDNA according to the manufacturer’s directions, and the following 
primer pairs were used for amplification of mRNA/cDNA for survivin: sense 5’-
GGCATGGGTGCCCCGACGTTG-3’ and antisense 5’-CAGAGGCCTCAATCCATGGCA-3’ 
(Ikeguchi et al., 2002), cyclin D1: sense 5’-GCCGCAATGACCCCGCACGATTTC-3’ and 
antisense 5’-TGCCTGGGCCCCTCAGATGTCCACACGT-3’ (Seki et al., 2006), and GAPDH: 
sense 5’-TGATGACATCAAGAAGGTGGTGAAG-3’ and antisense 5’-
TCCTTGGAGGCCATGTGGGCCAT-3’ (Evron et al., 2012) (Invitrogen, Carlsbad, CA). RT-
PCR was carried out in a ViiA7 Real-Time PCR System (Applied Biosystems) with the standard 
SYBR Green amplification settings. 
 
4.3.11 Co-immunoprecipitation (co-IP) 
 
DAOY cells were plated, allowed to adhere overnight, and grown to ~50% confluency 
before treatment with WA. For co-IP of TCF/LEF proteins from IPed β-catenin, cells were 
treated with 5 µM WA for 4-8 h before cells were trypsinized, washed twice with 1x PBS, and 
pelleted. Pelleted cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with 100 µM PMSF, 1 mM 
Na3VO4, and 2 µL/mL protease inhibitor cocktail. Proteins were isolated and quantified as 
described for immunoblotting. 750 µg of each protein sample was brought to 300 µL in RIPA 
buffer, and 3 µL of anti-β-catenin antibody (1:100, Pierce Biotechnology #MA1-10056) was 
added to each tube except for a no-antibody control tube with untreated cell lysate. Tubes were 
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rocked at 4°C overnight before the addition of 20 µL of protein A/G PLUS-Agarose beads (Santa 
Cruz Biotechnology) for 2 h. Beads were washed 4x with RIPA buffer, and proteins were eluted 
with the addition of SDS buffer as used in immunoblotting for 10 minutes at 100 °C. Beads were 
cleared by centrifugation, and the supernatant was evaluated by immunoblotting. 
Co-IP of Cdc37 from HSP90 was similar to this procedure but utilized cells treated for 4 
h with varying concentrations of WA collected in a buffer consisting of 20 mM Tris HCl (pH 
7.4), 100 mM NaCl, 2 mM DTT, 20 mM sodium molybdate dihydrate, and 0.5% NP-40 
supplemented with 100 µM PMSF, 1 mM Na3VO4, and 2 µL/mL protease inhibitor cocktail. 2 
mg of protein was IPed with 25 uL of anti-HSP90β antibody (1:12; Invitrogen #379400), and 
IPed proteins were isolated using 25 µL of protein G magnetic bead system as described by the 
manufacturer (Pierce Biotechnology). Proteins were eluted with the addition of SDS buffer as 
used in immunoblotting for 15 minutes rocking at room temperature. 
 
4.3.12 Immunocytochemistry (ICC) 
 
DAOY and ONS76 cells were plated to ~50% confluency in 8-well chamber slides 
(Nalge Nunc International, Penfield, NY) and treated with 1-2.5 µM WA for 24 h. Cells were 
fixed in 4% PBS-buffered paraformaldehyde at room temperature for 30m and washed three 
times with 1x PBS. Cell membranes were de-permeablized for 15 minutes in 1x PBS containing 
0.3% triton X-100 and subsequently blocked in 5% goat serum (Cell Signaling Technology) in 
1x PBS containing 0.15% triton X-100 shaking for 1 h. Cells were exposed to primary antibody 
in blocking solution overnight at 4 °C. Primary antibodies included TCF1 (1:50; Cell Signaling 
#2203), LEF1 (1:100; Cell Signaling #2230), and β-catenin (1:200; Pierce Biotechnology #MA1-
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10056). After three washes with 1x PBS, secondary antibody (1:1000; anti-rabbit IgG Fab2 
Alexa Fluor 555, Cell Signaling #4413; Anti-mouse IgG Fab2 Alexa Fluor 488, Cell Signaling 
#4408) was added to each well for 1 h at room temperature followed by an additional three 
washes. Coverslips were mounted on each slide with ProLong Gold Antifade with DAPI (Cell 
Signaling Technology), allowed to dry, and visualized on a Leica DM IRB microscope (Wetzlar, 
Germany) with Metamorph Basic software (version 7.7.3.0.; Molecular Devices; Sunnyvale, 
CA). 
 
4.3.13 Data and statistical analysis 
 
GraphPad Prism 6 (version 6.02; GraphPad Inc., San Diego, CA) was used to generate 
best-fit non-linear sigmoidal dose response curves for IC50 determination. Comparisons of 
differences between two or more means/values were determined by Student’s unpaired t-test via 
the statistical functions of GraphPad Prism or Microsoft Excel 2010 software (version 
14.0.6129.5000; Microsoft Corporation Redmond, WA). Densitometry, where indicated, was 
completed using ImageJ software (version 1.46r; Bethesda, MD). RT-PCR data was compared 
via the ∆∆Ct method. Data are presented as mean values with error bars denoting standard 
deviation or standard error of the mean where appropriate. The levels of significance were set at 
*p < 0.05, **p < 0.01, and ***p < 0.001. 
 
4.4 Results 
 
4.4.1 WA reduces viability and proliferation of MB 
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General cytotoxicity and anti-proliferative effects induced by WA were evaluated by the 
MTS assay after 72 h exposure. IC50 values were determined to be 168.5 µM ± 7.3, 518.4 µM ± 
28.8, 661.7 µM ± 73.9, and 614.4 µM ± 71.1 in DAOY, ONS76, D425, D283 MB cell lines, 
respectively, representing reduced cell number and viability with sub-micromolar concentrations 
(Figure 4-1A). 
 
4.4.2 WA prevents cell proliferation through G2/M cell cycle arrest 
 
To examine the nature of the observed anti-proliferative effect of WA in MB, shifts in 
cell cycle distribution were analyzed by flow cytometry after 24 h (Figure 4-1B and 4-1C). 
Supporting the general cytotoxicity of the MTS assay, WA demonstrated the ability to induce 
large elevations in the fraction of MB cells in G2/M, suggesting arrest of the cell cycle. DAOY 
cells demonstrated a peak G2/M fraction of 77.6% at 0.5 µM compared to a baseline control of 
22.2% (p = 0.004) and a statistically significant (p < 0.05) elevation from 0.5-1 µM. Similarly, 
ONS76 cells demonstrated a peak G2/M fraction of 59.4% at 1 µM compared to a baseline 
control of 25.3% (p = 0.002) and a statistically significant (p < 0.05) elevation from 0.75-2 µM. 
The fraction of cells in S-phase was slight diminished, but G2/M elevation was shown to be 
largely at the expense of G0/G1. WA levels above those inducing peak G2/M arrest showed 
diminishing responses with increasing concentration. These findings were also observed in D425 
and D283 cells (Supplemental Figure 4-1A). 
Induction of G2/M cell cycle arrest was molecularly confirmed through evaluation of 
G2/M-specific protein cyclin B1 (Figure 1D). Both DAOY and ONS76 cells showed WA dose- 
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Figure 4-1. A) IC50 values were determined by MTS assay to be 168.5 µM ± 7.3, 518.4 µM ± 
28.8, 661.7 µM ± 73.9, and 614.4 µM ± 71.1 in DAOY, ONS76, D425, D283 MB cell lines, 
respectively. B) Cells stained with propidium iodide and analyzed by flow cytometry revealed 
that WA induces a dose-dependent G2/M cell cycle at 24 h. Maximal induction of arrest above 
baseline was observed at 0.5 µM in DAOY and 1 µM in ONS76. C) Cell cycle arrest 
corresponded with induction of G2/M-specific protein cyclin B1 with highest levels at 0.5 µM 
and 2.5 µM in DAOY and ONS76, respectively. D) Histograms depict representative examples 
for the cell cycle distribution of control (white/transparent) and WA-treated (grey) DAOY and 
ONS76 cells at concentrations inducing a peak effect. E) DAOY and ONS76 cells stained with 
propidium iodide and annexin V-FITC and analyzed by flow cytometry revealed that WA 
induced a dose-dependent increase of cell death with a progressive shift from early apoptosis to 
late apoptosis at 24 h. F) The presence of WA-induced apoptotic processes in DAOY and 
ONS76 was confirmed by Western blotting that demonstrated dose-dependent reduction in 
initiator procaspases 8 and 9 and effector procaspases 3 and 7. Downstream cleavage of PARP 
was observed by 0.25 µM and 2.5 µM in DAOY and ONS76 cells, respectively. G) Dot plots 
display representative examples of each cell line demonstrating a progressive shift from early to 
late apoptosis with increasing WA concentration. *p < 0.05, **p < 0.01, ***p < 0.001 
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dependent induction of the protein with peak levels observed at 0.5 and 2.5 µM, respectively, 
supporting the flow cytometry data indicating that G2/M elevation is achieved at lower doses in 
DAOY. These findings were supported with D425 cells (Supplemental Figure 4-1B). 
 
4.4.3 WA induces dose-dependent cell death through apoptosis 
 
Induction of cellular death through apoptotic and necrotic mechanisms was assessed by 
flow cytometry with annexin V-FITC/PI staining to further characterize the general cytotoxic 
effects observed from WA. WA induced dose-dependent cellular death with increasing 
concentrations in both DAOY and ONS76 cells (Figures 4-1E and 4-1F). Elevation in early 
apoptosis through annexin V-only staining was notable at low concentrations for DAOY (1-3 
µM) at 24 h with increases in dual staining indicative of late apoptosis observed at the higher 
concentrations evaluated in both DAOY (1-6 µM) and ONS76 (4-6 µM). Each cell line also 
demonstrated small increases in the PI-only necrotic population with increasing concentrations 
that did not reach above 11.5% and 7.3% in DAOY and ONS76, respectively. Total cell death 
staining in control DAOY and ONS76 was 8.0% and 8.7% but elevated to 43.9% (p < 0.001; 
9.4% early apoptosis, 6.9% necrosis, 27.6% late apoptosis) and 15.9% (p = 0.100; 3.7% early 
apoptosis, 2.9% necrosis, 9.3% late apoptosis) with 3 µM WA, respectively. Cell death was 
further increased with 6 µM WA to 63.2% (p < 0.001; 5.6% early apoptosis, 11.2% necrosis, 
46.3% late apoptosis) and 85.5% (p < 0.001 ; 0.8% early apoptosis, 7.3% necrosis, 77.4% late 
apoptosis), respectively. Consistent with the MTS findings, ONS76 cells required higher WA 
concentrations than DAOY to achieve cytotoxicity. D425 and D283 cells also exhibited dose-
dependent elevations in cell death (Supplemental Figure 4-1C). 
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The role of apoptotic processes was confirmed molecularly through protein evaluation of 
procaspase and poly(ADP-ribose) poylmerase biomarkers (Figure 4-1G). Consistent with our 
previous report that WA-mediated apoptosis in GBM is driven through both the 
mitochondrial/intrinsic and extrinsic apoptotic pathways, WA treatment of DAOY and ONS76 
MB cells resulted in depletion of extrinsic procaspase 8, intrinsic procaspse 9, and effector 
caspases 3 and 7 upon exposure to approximately 0.5-2.5 µM WA for 24 h with higher 
concentrations consistently required for ONS76 to achieve the same effect. Downstream 
cleavage of PARP was observed by 0.25 µM and 2.5 µM in DAOY and ONS76 cells, 
respectively. Procaspase depletion and PARP cleavage were also observed in D425 and D283, 
however, PARP cleavage was notably less in D283, consistent with flow cytometry findings 
suggesting a greater necrotic role (Supplemental Figure 4-1D). Together, these data support the 
role of apoptosis in the induction of WA-mediated cell death. 
 
4.4.4 WA promotes an NAC-repressible elevation in cellular oxidation 
 
Elevation of the oxidative potential has been a previously described effect in several 
cancer cell lines following WA treatment and has been suggested to play a partial role in its 
overall cytotoxicity profile. Therefore, the presence and role of WA-generated oxidative stress 
was evaluated to determine if it could be functionally extended into a MB model. Peroxide-type 
reactive oxygen species (ROS) were measured following 3-4 h WA treatment through activating 
conversion of preloaded CM-H2DCFDA to a fluorescent byproduct (Figure 4-2A). ROS were 
elevated at 1, 3, and 5 µM WA by 5.3% (p = 0.031), 16.3% (p < 0.001), and 33.8% (p = 0.009) 
in DAOY and 14.6% (p = 0.037), 37.8% (p = 0.07), and 94.2% (p = 0.048), respectively.  
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Figure 4-2.  A) Increases in the concentration of WA generated peroxide-type radicals like H2O2 
as quantified by CM-H2DCFDA fluorescent conversion in DAOY and ONS76 cells at 3-4 h 
post-treatment. 5 mM NAC thiol antioxidant completely abrogated the elevation in ROS. B) 
Consistent with a cellular oxidative stress response, HSP32 and HSP70 were induced with 
increasing WA treatment with corresponding depletion of transcription factor HSF1 in both 
DAOY and ONS76. Total levels of HSP90 remained largely unchanged in both lines. C) 
Pretreatment of DAOY and ONS76 cells with 5 mM NAC eliminated WA-induced upregulation 
of HSP32 and HSP70 and the decrease of HSF1. Similarly, NAC abrogated the cleavage of 
PARP and induction of cyclin B1, demonstration reduction in the molecular apoptotic and 
checkpoint processes. D) DAOY and ONS76 cell viability assessed by ATP levels in the 
CellTiter Glo assay was increased with NAC pretreatment in the presence of WA. E) WA-
mediated induction of overall cell death assessed by flow cytometry of total propidium iodide 
and annexin V-FITC staining was eliminated with NAC pretreatment. NAC alone had no effect 
on cell viability. *p < 0.05, **p < 0.01, ***p < 0.001 
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Pretreatment with the thiol antioxidant NAC (5 mM) completely abrogated the elevation of ROS. 
The pattern of NAC-repressible dose-dependent increases in cellular oxidative potential was also 
observed in D425 and D283 cells (Supplemental Figure 4-2A). 
Elevation in oxidative potential following WA was supported molecularly by the 
induction of HSPs as has been previously described. Consistent with an oxidative stress-induced 
heat shock response, DAOY and ONS76 cells displayed dose-dependent increases in HSP70 and 
HSP32/heme oxygenase 1 with minimal changes in HSP90 levels by 0.1-0.25 µM and 0.5-1 µM 
WA after 24 h, respectively (Figure 4-2B). Transcription factor heat shock factor 1 (HSF1), a 
regulator of HSP70 expression, was reduced with an inverse correlation to HSP70 upregulation. 
Pretreatment with 5 mM NAC completely eliminated induction of the WA-mediated heat shock 
response (Figure 4-2C). This pattern of altered protein levels was also confirmed to occur in 
D425 and D283 (Supplemental Figures 4-2B and 4-2C). 
WA cytotoxicity in MB was functionally reduced or eliminated following pretreatment 
with NAC. General cellular cytotoxicity was evaluated at 72 h by the ATP-measuring CellTiter-
Glo luminescent assay. Pretreatment with 1 mM NAC showed retention of viability in both 
DAOY (p < 0.05) and ONS76 (p < 0.01) up to the highest WA concentration evaluated (6 µM), 
but reduction in cell viability was completely abrogated with 5mM NAC (DAOY: p < 0.01; 
ONS76: p < 0.001) (Figure 4-2D). Similarly, cell death evaluated by annexin V-FITC/PI staining 
at 24 h revealed that 5 mM NAC pretreatment completely eliminated the effects of 5 µM WA in 
both DAOY (p < 0.001) and ONS76 (p = 0.070) (Figure 4-2E). Cells treated with NAC ± WA 
were not statistically different than control. NAC-mediated reduction of cell death was 
confirmed in D425 (p < 0.001) and D283 (p < 0.001) cells (Supplemental Figure 4-2D and 4-
2E). Molecularly, diminished apoptosis was supported by the elimination of PARP cleavage with 
130 
 
NAC pretreatment. Similarly, NAC abrogated the cyclin B1 induction of 24 h WA treatment, 
suggesting the prevention of G2/M cell cycle arrest (Figure 4-2C; Supplemental Figure 4-2C). 
Together, these results suggest that WA may manifest its effects in MB through oxidation and 
thiol reactivity, either directly or indirectly. 
 
4.4.5 WA induces inhibitory phosphorylation of GSK-3β independent of alterations in Akt/mTOR 
pathway signaling 
 
Previous studies have demonstrated that WA can functionally alter signaling and total 
proteins levels within the PI3K/Akt/mTOR proliferation pathway (Oh et al., 2008; Oh and 
Kwon, 2009; Samadi et al., 2010a; Samadi et al., 2010b; Grogan et al., 2013; Grogan et al., 
2014). This pathway has been well-described in altering the Wnt/β-catenin signaling pathway, an 
important and over-active cascade in a subset of MB patients, through inhibition of GSK-3β to 
prevent proteasomal degradation of β-catenin (Baryawno et al., 2010). As such, the effects of 
WA on total and phosphorylated protein levels in the Akt/mTOR cascade were evaluated along 
with the resulting manifestations on GSK-3β and β-catenin. 
Akt/mTOR signaling in MB cells lines DAOY, ONS76, D425, and D283 demonstrated 
variable downstream responses to WA exposure after 24 h (Figure 4-3A). With the exception of 
unchanged Akt levels in ONS76, total levels of Akt and mTOR were reduced in all cell lines in a 
dose-dependent manner with complete depletion of Akt occurring at 2.5-5 µM WA. Complete 
elimination of mTOR was observed at 2.5 µM in DAOY and D425 but was not achieved by 5 
µM in ONS76 and D283 despite reduction. Activating phosphorylation of Akt (Ser473) and 
mTOR (Ser2448) similarly patterned the loss of total protein except for a failure to decrease p- 
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Figure 4-3. A) Akt/mTOR signaling in MB cells lines DAOY, ONS76, D425, and D283 
demonstrated variable downstream responses to WA exposure after 24 h. All lines demonstrated 
reduction or maintenance of total and phosphorylated/active levels of Akt (Ser473) and mTOR 
(Ser2448) with WA treatment. While total p70 S6K was reduced or sustained in all cell lines, 
activation of p70 S6K through phosphorylation (Thr389) demonstrated significant variability 
with DAOY and D425, the cell lines with the highest WA-mediated Akt and mTOR depletion, 
demonstrating reductionand ONS76 and D283 potently inducing this phosphorylation. Despite 
diminished p-Akt, phosphorylation of GSK-3β (Ser9) was significantly induced with minimal 
changes in total β-catenin levels. B) Pharmacological inhibition of PI3K, upstream of Akt, with 
LY294002 or wortmannin was conducted 1 h prior to WA treatment to evaluate the 
responsibility of residual p-Akt for phosphorylating GSK-3β. Rapamycin, an inhibitor of mTOR 
downstream of Akt, was used as a pathway control. All inhibitors failed to prevent WA-induced 
phosphorylation of GSK-3β, demonstrating that that the observation was independent of Akt 
signaling. 
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mTOR in D283 by 5 µM WA. Downstream of mTOR, total p70 S6K was reduced or sustained in 
all cell lines. However, activation of p70 S6K through phosphorylation (Thr389) demonstrated 
significant variability. DAOY and D425, the cell lines with the highest WA-mediated Akt and 
mTOR depletion, displayed consistent reduction of p-p70 S6K initiating at 0.5 µM and 2.5 µM, 
respectively. In contrast, p-p70 S6K was potently induced through 5 µM WA in ONS76 despite 
decreases in total protein and through 2.5 µM WA in D283 before reduction at 5 µM in the latter. 
This suggests either maintained or enhanced activity of Akt/mTOR signaling despite diminished 
phosphorylation or the presence of alternative and compensatory cell-specific signaling. 
Despite decreased or sustained levels of p-Akt in all cell lines with WA treatment, 
inhibitory phosphorylation of GSK-3β (Ser9), a target of Akt, was induced in all lines by 0.5-1 
µM (Figure 4-3A). Total levels of GSK-3β were largely maintained except at high doses in D425 
which also resulted in a loss of p-GSK-3β. Consistent with active GSK-3β normally functioning 
to promote the proteasomal degradation of β-catenin, total levels of β-catenin after 24 h WA 
treatment remained largely consistent with minimal increases and/or decreases in a cell-
dependent manner. 
In order to determine if phosphorylation of GSK-3β was a result of residual Akt activity 
following WA exposure, pharmacological inhibition of PI3K, upstream of Akt, with LY294002 
or wortmannin was conducted prior to WA treatment. Rapamycin, an inhibitor of mTOR 
downstream of Akt, was used as a pathway control. All inhibitors failed to prevent WA-induced 
phosphorylation of GSK-3β, demonstrating that that the phenomenon was likely independent of 
Akt signaling (Figure 4-3B). Treatment with the inhibitors alone actually induced mild to 
moderate phosphorylation of GSK-3β, suggesting compensatory activation of the Wnt pathway 
through an alternate mechanism. As expected, WA-induced p-GSK-3β correlated with 
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diminished phosphorylation of β-catenin (Ser33/37/Thr41), a marker for degradation, and 
maintenance of total protein levels. Interestingly, LY294002 and rapamycin pretreatment before 
2.5 µM WA in DAOY cells promoted diminished β-catenin despite not altering its 
phosphorylation. 
 
4.4.6 WA inhibits the Wnt/β-catenin signaling pathway 
 
To evaluate if inhibition of GSK-3β and maintenance of β-catenin levels following WA 
treatment led to altered signaling in the Wnt/β-catenin pathway, the TOP/FOP FLASH reporter 
assay was employed to determine pathway activation and function (Figure 4-4A). DAOY cells 
were co-transfected with either the TOP FLASH or FOP FLASH reporter and a renilla luciferase 
control as well as WT-β-catenin, the constitutively active S33Y-β-catenin mutant, or a vector 
control. After 24 h, cells were treated with 1 µM WA for an additional 24 h and quantified. 
Negatively control reporter FOP FLASH failed to demonstrate significant signal induction under 
all conditions. While vector DAOY cells displayed minimal endogenous TOP FLASH reporter 
activation, the addition of extra WT and S33Y β-catenin increased reporter activation 17.1- and 
118.8-fold, respectively. Treatment with WA reduced WT-β-catenin signal by 46.4% (p = 0.073) 
and S33Y-β-catenin signal by 64.1% (p < 0.001), showing that WA, in part, acts as an inhibitor 
of the Wnt/β-catenin signaling pathway. This is in contrast to the findings that demonstrate the 
stabilization of β-catenin following WA treatment and suggests that this retention of β-catenin 
may be a cellular compensatory attempt to maintain pathway activity despite downstream 
inhibition. 
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Figure 4-4. A) WA reduced activity of the TOP FLASH luciferase reporter assay for Wnt 
signaling activity after 24 h when activated with excess WT-β-catenin and constitutively the 
active S33Y-β-catenin mutant in DAOY cells. Negative control reporter FOP FLASH yielded 
minimal luminescent signal. All signals were normalize to the renilla control. B) Protein levels of 
known Wnt signaling target genes (axin2, survivin, cyclin D1, c-myc, and c-Met) were reduced 
in DAOY Vector, DAOY S33Y, and ONS76 cells with increasing exposure to WA for 24h. C) 
mRNA levels of Wnt signaling target genes survivin and cyclin D1 were evaluated through RT-
PCR following 24 h WA treatment in DAOY Vector and DAOY S33Y cells. Consistent with the 
protein levels, both genes demonstrated a dose-dependent decrease in transcription of mRNA for 
each gene. *p < 0.05, **p < 0.01, ***p < 0.001 
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Protein levels of known Wnt signaling target genes (Axin2, survivin, cyclin D1, c-myc, 
and c-Met) were subsequently assessed to further evaluate and confirm functional manifestations 
of the inhibition. DAOY cells were stably transfected with S33Y-β-catenin (“DAOY S33Y”) or 
vector (“DAOY Vector”) to establish a model of constitutively active Wnt signaling. DAOY 
Vector, DAOY S33Y, and ONS76 cells were treated with WA for 24 h and evaluated by 
Western blotting. Each target protein was reduced in a dose-dependent manner with initial 
efficacy seen between 1-2.5 µM in both DAOY lines and 1-5 µM in ONS76, supporting 
inhibition of Wnt signaling (Figure 4-4B). Decreases in these proteins were also confirmed in 
D425 and D283 (Supplemental Figure 4-3A). 
To ensure protein decreases were not simply due to WA-induced degradation, 
transcriptional level evaluation was performed through RT-PCR to quantify mRNA for target 
genes survivin and cyclin D1 following WA treatment in DAOY Vector and DAOY S33Y cells 
(Figure 4-4C). Consistent with the protein levels, 1 µM and 2.5 µM WA decreased mRNA levels 
of survivin in DAOY Vector by 47.4% (p = 0.012) and 82.5% (p = 0.004), respectively, and in 
DAOY S33Y by 34.0% (p = 0.162) and 73.0% (p = 0.028), respectively. Also supported by 
protein reduction, mRNA for cyclin D1 was decreased only at 2.5 µM WA by 75.5% in DAOY 
Vector (p = 0.019) and 40.4% in DAOY S33Y (p = 0.105). 
 
4.4.7 WA disrupts Wnt signaling through depletion of TCF/LEF transcription factors and 
without blocking nuclear translocation of β-catenin 
 
Having established functional inhibition of the Wnt signaling pathway with WA 
treatment despite the maintenance of total levels of β-catenin, the inhibitory mechanism of WA 
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on downstream Wnt signaling was evaluated. In addition to decreases of β-catenin levels, Wnt-
specific signaling reduction can manifest through failure of β-catenin to translocate to the 
nucleus or subsequently associated with the necessary transcription factor of the TCF/LEF 
family. 
Changes in nuclear translocation of β-catenin in the presence of WA were assessed by 
nuclear and cytoplasmic protein fractionation of DAOY Vector and S33Y lines (Figure 4-5A). 
Consistent with the initial evaluation of β-catenin following WA treatment in DAOY cells, total 
levels of the endogenous protein were slightly diminished but largely unchanged after 24 h. In 
both lines, nuclear levels of total β-catenin were decreased at 5µM WA with slight increases in 
cytoplasmic levels compared to 2.5 µM WA, suggesting possible disruption of translocation at 
high doses. However, this was associated with slight reduced nuclear histone H4, and it is 
unclear if the small shift is mechanistically relevant at a high concentration of WA. Similarly, 
total levels of nuclear S33Y-β-catenin, observed only in the DAOY S33Y line, were reduced 
only at 5 µM WA, but this was also observed in the cytoplasmic fraction, suggesting a global 
decrease rather than alterations in translocation. Further, reduced levels of cytoplasmic WT- and 
S33Y-β-catenin at 1-2.5 µM WA were not matched in the nuclear fraction, demonstrating 
maintained translocation and localization of remaining β-catenin with WA treatment. ICC of β-
catenin with DAPI in DAOY and ONS76 cells confirmed minimal changes in nuclear β-catenin 
levels up to 2.5µM WA (Figure 4-5B; Supplemental Figure 4-3B). 
Upon entering the nucleus, β-catenin is known to function as a co-activator that 
associates with members of the TCF/LEF transcription factor family to promote transcription of 
Wnt pathway target genes (Voronkov and Krauss, 2013). Because failure of β-catenin to 
associate with these factors prevents proper activation of transcription at these target genes, total  
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Figure 4-5.  
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Figure 4-5. A) Changes in nuclear translocation of β-catenin in the presence of WA were 
assessed by nuclear and cytoplasmic protein fractionation of DAOY Vector and DAOY S33Y 
lines. Total levels of the endogenous protein were slightly diminished after 24 h. In both lines, 
nuclear levels of total β-catenin were decreased at 5 µM WA with slight increases in cytoplasmic 
levels compared to 2.5 µM WA, suggesting possible disruption of translocation at high doses. 
Similarly, total levels of nuclear S33Y-β-catenin, observed only in the DAOY S33Y line, were 
reduced only at 5 µM WA in both fractions. B) ICC of β-catenin (green) with DAPI (blue) in 
DAOY cells confirmed minimal changes in nuclear β-catenin levels. C) Total levels of TCF/LEF 
transcription factors TCF1, TCF3, TCF4, and LEF1 were assessed in DAOY Vector, DAOY 
S33Y, and ONS76. In each cell line, all proteins, including both detected isoforms of TCF4, 
were notable depleted by WA in a dose-dependent manner after 24 h. LEF1 was not detected in 
ONS76. D and E) ICC of TCF1 and LEF1 (red) in DAOY cells revealed diminished staining 
intensity and/or a shift from the nucleus to the cytoplasm after 1-2.5 µM WA for 24 h. F) Co-IP 
experiments revealed decreased β-catenin association with TCF/LEF members after treatment 
with 5 µM WA for up to 8 h, demonstrating that reductions in total proteins also corresponded 
with diminished functional interactions. 
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levels of TCF/LEF family members TCF1, TCF3, TCF4, and LEF1 were assessed in DAOY 
Vector, DAOY S33Y, and ONS76. In each cell line, all proteins, including both detected 
isoforms of TCF4, were notable depleted by 1µM WA after 24 h with near-complete elimination 
by 5 µM except for both TCF3 and the 79kDa TCF4 isoform in ONS76. LEF1 was not detected 
in ONS76 (Figure 4-5C). Depletion of each protein was confirmed in the additional MB cell 
lines D425 and D283 (Supplemental Figure 4-3C). 
ICC of TCF1 and LEF1 in DAOY cells revealed diminished staining intensity and/or 
altered cellular localization of the proteins after 1-2.5 µM WA (Figures 4-5D and 4-5E). Control 
cells showed near-complete overlap of nuclear DAPI staining and both TCF1 and LEF1. 
Treatment with WA induced diffusion of both proteins into the cytoplasmic region with 
diminished nuclear staining intensity. While negative for LEF1, ONS76 cells demonstrated the 
same pattern of TCF1 alteration (Supplemental Figure 4-3D). 
Depletion and delocalization of TCF/LEF proteins would be expected to diminish 
transcription of Wnt signaling target genes given a reduced transcription factors available for β-
catenin association upon entering the nucleus. Co-IP was conducted to evaluate β-catenin 
association with TCF/LEF members after treatment with WA (Figure 4-5F). DAOY cells were 
treated with 5 µM WA for up to 8 h. At 8 h, total levels of TCF1, TCF3, and LEF1 input were 
decreased 82.8%, 75.1%, and 71.9% normalized to actin, respectively. Conversely, total β-
catenin was elevated by 50.9%. IPed β-catenin showed levels of TCF1, TCF3, and LEF1 that 
were decreased 70.1%, 58.1%, and 56.1% normalized to β-catenin, respectively. This confirms 
that total depletion of TCF/LEF proteins also resulted in functional reduction of the association 
between these transcription factors and β-catenin. 
 
142 
 
4.4.8 WA-mediated degradation of TCF/LEF proteins is mediated by the proteasome 
 
Triton X-100 fractionation and pretreatment with proteasome inhibitor MG132 were 
completed to further define WA-mediated alterations in TCF/LEF localization and degradation 
(Figure 4-6A). Triton soluble proteins are largely regarded as functional, stable molecules, 
whereas the insoluble fraction contains labile and aggregated proteins. Treatment of DAOY and 
ONS76 cells with 2.5 µM WA for 24 h resulted in a depletion of triton soluble proteins with 
variable accumulation in the insoluble fraction. Exploration of these findings suggested that early 
timepoints (defined relatively in part by dose and cell line sensitivity) following treatment with 
WA shifted proteins from the soluble to insoluble fractions with later timepoints resulting in 
absolute depletion in both fractions (data not shown). Consistent with previous reports, MG132 
blocked normal protein turnover, inducing cellular stress and a shift of proteins to the insoluble 
fraction (Kawahara et al., 2008). Cells pretreated with MG132 before WA demonstrated 
enhanced retention of all TCF/LEF proteins in the insoluble fraction at 24 h, including proteins 
that were depleted by WA in both the soluble and insoluble fractions and demonstrating the 
proteasome-dependent manner of WA-mediated TCF/LEF degradation. 
 
4.4.9 TCF/LEF proteins require functional HSP90 for stability and WA disrupts the 
HSP90/Cdc37 interaction in MB 
 
Previous reports have suggested that WA may disrupt the association between HSP90 
and co-chaperone Cdc37, thereby altering normal HSP90 function and resulting in widespread 
protein misfolding and degradation. We evaluated this finding through co-IP in DAOY cells, and  
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Figure 4-6.  
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Figure 4-6. A)  DAOY and ONS76 cells were pretreated with the proteasome inhibitor MG132 
followed by WA for 24 h, and cellular proteins were fractionated by triton X-100 solubility. 
Treatment with 2.5 µM WA or 20 µM MG132 for 24 h resulted in a depletion of triton soluble 
TCF/LEF proteins with variable accumulation in the insoluble fraction. Cells pretreated with 
MG132 before WA demonstrated enhanced retention of all TCF/LEF proteins in the insoluble 
fraction at 24 h, including proteins that were depleted by WA in both the soluble and insoluble 
fractions and demonstrating the proteasome-dependent manner of WA-mediated TCF/LEF 
degradation. B) Co-IP experiments in DAOY cells demonstrated that WA reduced the 
association between HSP90 and Cdc37 after a 4 h treatment. Total input Cdc37 was not 
decreased with treatment. C) Treatment of DAOY cells with the N-terminal HSP90 inhibitor 17-
AAG demonstrated dose-dependent decreases in total levels of TCF1, TCF3, TCF4, and LEF1 
but not β-catenin. TCF1 and TCF3 showed notably enhanced reduction by approximately 250 
nM. 
  
145 
 
indeed, WA reduced the association between HSP90 and Cdc37. After 4 h, 0.5 µM and 2.5 µM 
WA reduced IPed Cdc37 by 63.7% and 76.2%, respectively, compared to IPed HSP90 (Figure 4-
6B). Total input Cdc37 was not decreased with treatment. 
To date, members of the TCF/LEF family have not been described as HSP90 client 
proteins or known to associate with Cdc37. Co-IP for TCF1, TCF3, TCF4, and LEF1 with 
HSP90 and Cdc37 was unable to identify any direct association between these proteins (data not 
shown). However, treatment of DAOY cells with the N-terminal HSP90 inhibitor 17-AAG 
demonstrated dose-dependent decreases in total levels of TCF1, TCF3, TCF4, and LEF1 up to 
modest doses (1 µM) but not β-catenin (Figure 4-6C). TCF1 and TCF3 showed notable reduction 
by approximately 250 nM. These findings suggest that while HSP90 and Cdc37 may not directly 
associate with TCF/LEF members, intact HSP90 function is indirectly necessary for their 
stability. Combined with the identification that WA works in part through disruption of the 
HSP90 axis, these findings implicate a potential mechanism involving HSP90 for WA-driven 
alterations in Wnt/β-catenin signaling. 
 
4.5 Discussion 
 
WA has been demonstrated to be a potent cytotoxic agent in a multitude of cancer 
models. In this study, we are the first to demonstrate that this efficacy extends to the treatment of 
MB and is manifested at least in-part through direct inhibition of the oncogenic Wnt/β-catenin 
signaling pathway resulting in dose-dependent G2/M cell cycle arrest and ultimately apoptosis. 
Inhibition of this signaling pathway was determined to be a result of proteasome-mediated 
146 
 
degradation of transcription factors from the TCF/LEF family. Consistent with previous findings 
in other models, WA treatment resulted in cellular oxidation and dissociation of HSP90/Cdc37. 
WA was demonstrated to function as a novel inhibitor of the Wnt/β-catenin signaling 
pathway through downstream depletion and altered localization of TCF/LEF resulting in 
diminished association with transcription activator β-catenin. Significant inhibition of reporter 
TOP FLASH signaling in a model of constitutively active β-catenin as well as decreased Wnt 
target mRNA and protein product were observed upon 24 h exposure to 1 µM WA, consistent 
with levels necessary to decrease TCF/LEF proteins. Concentrations necessary to demonstrate 
these findings were within the cytotoxically relevant dosing range, supporting that this inhibition 
was not a high dose off-target drug effect. This study thoroughly evaluated the effects of WA at 
different levels of the Wnt signaling cascade and demonstrated that this inhibition is not driven 
by reduced total β-catenin levels or failure of β-catenin to translocate to the nucleus. 
While WA also plays a role in altering normal Akt/mTOR signaling in MB, this pathway 
is not responsible for inhibiting signaling of the Wnt/β-catenin pathway. Pharmacological 
inhibition of PI3K failed to reduce phosphorylation of GSK-3β or alter levels of β-catenin, 
suggesting that any remaining Akt activity that was not eliminated with WA treatment was not 
responsible for this inhibition. It is likely that inhibition of GSK-3β, perhaps through the 
upstream Wnt signaling protein dishevelled, is a compensatory response to the downstream 
inhibition of the pathway and an attempt by the cells to overcome this bottleneck. Indeed, GSK-
3β phosphorylation was induced at low levels (0.5-1 µM WA) consistent with doses at which 
TCF/LEF are depleted and suggesting a compensatory effect. Further exploration of the 
inhibition of GSK-3β is necessary to explain and potentially exploit this finding. On the whole, 
signaling through the Akt and mTOR proteins was shifted to an inhibitory state with reduced 
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and/or unchanged total and phosphorylated levels. However, in contrast to what has been 
observed in GBM Akt/mTOR signaling (Grogan et al., 2013; Grogan et al., 2014), downstream 
signaling to p70 S6K resulted in inconsistent activation/inhibition of the protein compared to 
GSK-3β inhibition and TCF/LEF depletion, suggesting a greater role of Wnt signaling inhibition 
in MB.  
While a number of inhibitors have been identified that alter Wnt signaling at various 
points in the cascade (Voronkov and Krauss, 2013), only four agents are currently in human 
clinic trials not exclusively for MB: olaparib (PARP/tankyrase inhibitor), veliparib 
(PARP/tankyrase inhibitor), LGK974 (porcupine inhibitor), and OTSA101-DTPA-90Y 
(radiolabeled antibody against frizzled) (MacDonald et al., 2014). Only PARP inhibition, 
described to destabilize β-catenin through Axin (Waaler et al., 2012), is under trial for MB with 
the latter two therapies failing to target the appropriate location in the signaling cascade given 
the mutations in MB. Such an approach, however, loses utility in presence of significantly 
overexpressed β-catenin or otherwise mutated β-catenin and/or APC (Voronkov and Krauss, 
2013). Of note is the fact that WA alters Wnt signaling at the transcriptional level by targeting 
the ultimate transcription factors of the pathway. As such, it avoids the potential development of 
resistance through upstream rerouting or mutations of the Wnt and Akt/mTOR signaling 
pathways. In this way, WA functions differently than currently available therapeutics and avoids 
these potential therapeutic pitfalls. Several small molecules have been identified that limit the 
association of the TCF/LEF members with β-catenin, but to-date, these have not been explored 
clinically (Voronkov and Krauss, 2013). Similarly, other compounds have been identified that 
directly disrupt or induce degradation of β-catenin. 
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Exploration of HSP90 inhibition as a means to disrupt the Wnt pathway therapeutically 
has not yet been explored. HSP90 was show to interact with Axin1, GSK-3β, and β-catenin but 
its inhibition resulted in a cell line-dependent depletion of GSK-3β only, indicating that it likely 
fails to function at that level of the cascade (Cooper et al., 2011; Liu et al., 2012). Further, 
depletion of GSK-3β would be expected to promote stabilization of β-catenin and subsequent 
activation of the pathway. The present study supports previous findings that WA disrupts the 
interaction between HSP90 and Cdc37, a co-chaperone protein necessary for localizing target 
kinases of the kinome with HSP90 for folding (Karnitz and Felts, 2007), and demonstrates this 
finding in MB for the first time (Yu et al., 2010). Further alterations of the HSP90 axis beyond 
this observation have remained unexplored. While direct interaction of HSP90 and Cdc37 with 
members of TCF/LEF was unable to be demonstrated by co-IP, the importance of functional 
HSP90 to promote the stability of the TCF/LEF members, likely indirectly, was identified 
through treatment with the established N-terminal HSP90 inhibitor 17-AAG and subsequent 
depletion of these transcription factors. TCF/LEF members in the absence of β-catenin have been 
shown to interact with co-repressors like Groucho, C-terminal binding protein (CtBP), and 
histone deacetylase (HDAC) with the latter being a known HSP90 modulator (Kekatpure et al., 
2009; Voronkov and Krauss, 2013). The role of HSP90 and/or Cdc37, if any, in the stability and 
function of these proteins remains largely unexplored, especially Cdc37 which is thought to 
primarily associate with kinome proteins instead. However, if inhibition of HSP90 function 
results in a failure of the repressor complex or any of the numerous associated proteins to 
adequately sequester TCF/LEF and result in its delocalization or degradation. Such a hypothesis 
may explain our findings that TCF/LEF bound to β-catenin is somewhat less readily degraded 
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compared to total levels. Further exploration of the role of HSP90/Cdc37-mediated stabilization 
of TCF/LEF directly or indirectly is necessary. 
TCF3 is considered to be a repressor of the Wnt signaling transcription and is noted to be 
less responsive to WA than activator LEF1 as well as context-dependent TCF1 and TCF4 (Arce 
et al., 2006; Voronkov and Krauss, 2013). TCF3 is more potently decreased by 17-AAG 
compared to the others. It is hypothesized that differences in currently undefined Cdc37-
dependence of the system or non-HSP90 axis effects of WA are likely responsible for this 
difference and will need to be defined in future studies. However, given the eventual decrease of 
all TCF/LEF members following WA treatment, it is unclear if this pattern is functionally 
relevant on the context of general disarray. 
Interestingly, ethacrynic acid was previously identified as an inhibitor of Wnt signaling  
through direct targeting and binding of LEF1 that could be blocked by NAC (Lu et al., 2009). 
Our findings demonstrate the thiol-reactive and oxidative properties of WA, the latter perhaps a 
secondary result of the thiol reactivity, which may also play a more direct role in the depletion of 
the TCF/LEF members. WA was previously shown to induce depletion of O
6
-methylguanine-
DNA methyltransferase (MGMT), a non-HSP90 client protein with known susceptibility to 
oxidation (Fu et al., 2010; Ryu et al., 2012; Grogan et al., 2014). Further study is necessary to 
determine if WA can directly interact with TCF/LEF proteins like ethacrynic acid, but while WA 
exposure yields numerous alterations and depletions of cellular proteins, previous reports 
utilizing biotinylated WA for protein pull-down have identified that WA protein-binding is 
specific to a limited subgroup including HSP90 and vimentin rather than broad-spectrum non-
specific associations (Bargagna-Mohan et al., 2007; Yu et al., 2010). Further exploration of the 
implications of the demonstrated general oxidative effects of WA on TCF/LEF is also necessary 
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as published reports on the effects of oxidation on TCF/LEF members is lacking. One study 
utilized hydrogen peroxide treatment to assess oxidative stress on Wnt signaling and 
demonstrated that it decreased the amount of nuclear β-catenin and resulted in diminished 
TCF/LEF-mediated transcription (Shin et al., 2004). It did not, however, directly identify any 
effects on TCF/LEF members. Failure of WA to significantly alter nuclear translocation of β-
catenin suggests that oxidation may be a byproduct of a greater mechanism, supporting a direct 
or HSP90-mediated role for depletion of TCF/LEF by WA. 
While the clinical importance of these findings has yet to be evaluated, they predict that 
WA may be an effective treatment option for MB patients by targeting multiple critical signaling 
pathways including Wnt/β-catenin which is known to be overactive in a significant subgroup of 
these patients. Wnt signaling overactivation is most frequently regarded to occur though an 
increase in total β-catenin, largely through overexpression of β-catenin itself or a failure to 
properly degrade normal production of the protein through mutations in regulators like APC, 
including in colorectal cancer as well as MB (Polakis, 2012). However, overexpression of 
members of the TCF/LEF family like LEF1, which is potently targeted by WA, has also been 
demonstrated as poor prognostic and disease progression marker in B-cell chronic lymphocytic 
leukemia (CLL) and a potential option for a targeted therapeutic (Lu et al., 2009; Erdfelder et al., 
2010a; Erdfelder et al., 2010b; Wu et al., 2012). Taken together, this suggests potential 
therapeutic value of WA in Wnt signaling-altered cancers beyond MB. Indeed, previous reports 
have shown efficacy of WA in colon cancer models despite not evaluating Wnt signaling 
modulation (Jayaprakasam et al., 2003). Importantly, WA exhibits intrinsic cytotoxicity 
independent of Wnt signaling. Therefore, while utilization of WA against cancers such as MB or 
colorectal cancer with frequent overactivation of the Wnt pathway may prove to be beneficial, it 
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retains potential utility for the population of patients with tumors lacking such characteristics for 
which it may be challenging to screen prior to the initiation of therapy, including the other MB 
subgroups representing ~85% of patients. 
In this study, we identify the cytotoxic nature of WA against pediatric MB cells for the 
first time. WA was identified to act as a novel and unique inhibitor of the Wnt/β-catenin 
signaling pathway, overactivated in one of the MB subgroups, with associated induction of 
oxidation and modulation of the HSP90/Cdc37 interaction. These findings suggest intriguing 
clinical potential of the compound in MB and other cancers in which Wnt signaling is known to 
be overactivated and warrant further translational exploration. 
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Supplemental Figure 4-1.  
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Supplemental Figure 4-1. A) Cells stained with propidium iodide and analyzed by flow 
cytometry revealed that WA induces a dose-dependent G2/M cell cycle at 24 h. Maximal 
induction of arrest above baseline was observed at 1 µM in D425 and 0.5 µM in D283. B) Cell 
cycle arrest corresponded with induction of G2/M-specific protein cyclin B1 with highest levels 
at 1 µM in D425 cells. C) D425 and D283 cells stained with propidium iodide and annexin V-
FITC and analyzed by flow cytometry revealed that WA induced a dose-dependent increase of 
cell death with a progressive increase in late apoptotic/necrotic cells 24 h. D) The presence of 
WA-induced apoptotic processes in D425 and D283 was confirmed by Western blotting that 
demonstrated dose-dependent reduction in initiator procaspase 9 and effector procaspases 3 and 
7. Downstream cleavage of PARP was observed by 1 µM and 0.25 µM in D425 and D283 cells, 
respectively. Overall PARP cleavage was weaker in D283, consistent with flow cytometry 
demonstrating a large necrotic response to treatment. *p < 0.05, **p < 0.01, ***p < 0.001 
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Supplemental Figure 4-2.  
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Supplemental Figure 4-2.  A) Increases in the concentration of WA generated peroxide-type 
radicals like H2O2 as quantified by CM-H2DCFDA fluorescent conversion in D425 and D283 
cells at 3-4 h post-treatment. Pretreatment 5 mM NAC thiol antioxidant completely abrogated the 
elevation in ROS. B) Consistent with a cellular oxidative stress response, HSP32 and HSP70 
were induced with increasing WA treatment with corresponding depletion of transcription factor 
HSF1 in both D425 and D283. Total levels of HSP90 remained largely unchanged in both lines. 
C) Pretreatment of DAOY and ONS76 cells with 5 mM NAC eliminated WA-induced 
upregulation of HSP32 and HSP70 and the decrease of HSF1 in D425 cells. Similarly, NAC 
abrogated the cleavage of PARP and induction of cyclin B1, demonstration reduction in the 
molecular apoptotic and checkpoint processes. D) D425 and D283 cell viability assessed by ATP 
levels in the CellTiter Glo assay was increased with NAC pretreatment in the presence of WA. 
E) WA-mediated induction of overall cell death assessed by flow cytometry of total propidium 
iodide and annexin V-FITC staining was eliminated with NAC pretreatment. NAC alone had no 
effect on cell viability. *p < 0.05, **p < 0.01, ***p < 0.001 
  
156 
 
Supplemental Figure 4-3.  
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Supplemental Figure 4-3. A) Protein levels of known Wnt signaling target genes (axin2, 
survivin, c-myc, and c-Met) were reduced in D425 and D283 cells with increasing exposure to 
WA for 24 h. B) ICC of β-catenin (green) with DAPI (blue) in ONS76 cells demonstrated 
minimal changes in nuclear β-catenin levels and alterations in protein localization after 24 h of 
2.5 µM WA. C) Total levels of TCF/LEF transcription factors TCF1, TCF3, TCF4, and LEF1 
were assessed in D425 and D283. In each cell line, all proteins, including both detected isoforms 
of TCF4, were notable depleted by WA in a dose-dependent manner after 24 h. LEF1 was 
scarcely detected in D283. D) ICC of TCF1 (red) in ONS76 cells revealed diminished staining 
intensity anr a shift from the nucleus to the cytoplasm after 2.5 µM WA for 24 h. 
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Chapter 5 
 
Withaferin A promotes global proteasome-mediated protein 
degradation through oxidation and inhibition of the HSP90 
chaperone axis and is cytotoxically potentiated by inhibition 
of the proteasome 
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5.1 Abstract 
 
Withaferin A (WA), a 28-carbon steroidal lactone isolated from members of the 
Solenceae plant family, has previously demonstrated significant anti-cancer efficacy in multiple 
models through modulation and disruption of numerous oncogenic signaling pathways and 
cellular events. The underlying mechanism behind these diverse effects, however, has been 
incompletely explained. In this study, we follow up on previous findings suggesting that WA 
functions through oxidation and modulation of the HSP90 protein chaperone. WA was 
demonstrated to shift the HSP90/HSP70 balance with HSP70 upregulation and associated 
increase in global protein ubiquitination in U87 and HeLa cancer cells. Similarly, WA treatment 
yielded depletion of known HSP90 client proteins but not non-clients. Interestingly, this was 
associated with no inhibition of intrinsic HSP90 function as evaluated by HSP90-mediated 
glucocorticoid receptor (GR) steroid binding, but WA did induce dissociation of co-chaperone 
Cdc37 from HSP90. This was confirmed by dissociation of Cdc37-dependent Cdk6 but not 
Cdc37-independent GR from HSP90. Overall, WA promoted elevated cellular oxidation and 
glutathione (GSH) depletion. Pretreatment with the thiol antioxidant completely eliminated WA-
induced oxidation and cytotoxicity, but non-thiol antioxidant ascorbic acid failed to prevent 
cytotoxicity despite a reduction in general oxidation. Depletion of cellular GSH with γ-
glutamylcysteine inhibitor L-buthionine-sulfoximine enhanced the effect of WA. WA shifted 
depleted proteins to a triton X-100 insoluble fraction with subsequent degradation through the 
proteasome and, to a lesser extent, the lysosome. Functionally, pretreatment of U87 and HeLa 
cells with proteasome inhibitor MG132 potentiated the cytotoxicity of WA with a resulting 
decrease in proliferation, increased apoptosis, and an accumulation of ubiquitinated proteins. 
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This study further defines the mechanism of WA as a proteotoxic agent through increased 
oxidation and modulation of the HSP90 axis to produce significant proteasome-mediated protein 
degradation. Further exploration is warranted to fully explain the inhibitory effect on the HSP90 
axis and the translational use of combination WA and MG132. 
 
5.2 Introduction 
 
The effective and sustained treatment of cancer remains an elusive and challenging goal 
in the scientific community. While great strides have been made in recent decades to understand 
the biological nature of initiation and progression of the disease at the molecular level, these 
finds have arguably resulted in comparatively fewer breakthroughs in the management and 
treatment of such malignancies. 
Many current standard therapeutic agents target mechanisms necessary for cellular 
replication or susceptibilities of cell cycling, often through induction of DNA damage or 
inhibition of DNA replication (Kamal and Burrows, 2004). While these agents have shown 
benefits in preventing disease progression and extending survival, they are often restricted by the 
development of resistance or dose-limiting toxicity, including those affecting neuropsychological 
and cognitive abilities (Ahles and Saykin, 2001). For example, the platinating agent cisplatin, 
currently one of the most effective broad-spectrum agents, is frequently used in the management 
and treatment of many solid tumors including lung, breast, ovarian, cervical, and testicular 
among many others. However, its administration is associated with significant use-limiting 
toxicity, most notably nephrotoxicity, and the ultimate development of resistance through a 
spectrum of complex mechanisms (Stordal and Davey, 2007; Shen et al., 2012; Markman, 2013; 
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Wensing and Ciarimboli, 2013; Petrelli et al., 2014). Similarly, while the alkylating agent 
temozolomide (TMZ) in combination with radiation currently represents the most efficacious 
therapy for glioblastoma multiforme (GBM) patients and demonstrates limited toxicity, its 
efficacy is often quickly limited by the expression of O
6
-methylguanine-DNA methyltransferase 
(MGMT) (Paz et al., 2004; Hegi et al., 2005). 
Advances in targeted therapy through both biological agents and small molecular 
inhibitors allow for the specific and directed inhibition or modulation of many protein targets and 
pathways including epidermal growth factor receptor (EGFR), vascular endothelial growth factor 
(VEGF), BCR-ABL, and Her2/neu, among others (Stebbing et al., 2000; Herbst, 2004; Kamal 
and Burrows, 2004; Baka et al., 2006; Jakopovic et al., 2014). While this results in 
comparatively less toxicity due to the specificity of the protein target, it is frequently limited by 
the development of resistance through tumor mutations or downregulation of the target protein. 
Additional challenges arise with heterogeneity of target protein expression in the patient 
population and the individual patient throughout the treatment period (Ellis and Hicklin, 2008; 
Wheeler et al., 2010; Wong and Lee, 2012; Huang et al., 2014). These considerable challenges 
demonstrate the need for therapeutic agents that can target multiple oncogenic and resistance 
pathways simultaneously to circumvent the shortcomings of established therapeutic options. 
Heat shock protein (HSP) 90, an evolutionarily well-conserved chaperone protein directly 
responsible for the stability and/or function of over 400 key cellular proteins, represents an ideal 
target for this purpose (Barrott and Haystead, 2013). Inhibition of HSP90 results in the depletion 
of client proteins critical to the proliferation and ultimate survival of cancer cells such as pro-
growth signaling proteins, tyrosine kinases, cell cycle regulators, and steroid receptors (Zhang 
and Burrows, 2004; Powers and Workman, 2006; Sidera and Patsavoudi, 2014). Cancer cells 
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demonstrate enhanced responsiveness to HSP90 inhibition compared to normal tissue due to 
enhanced reliance on HSP90 for stabilization of oncoproteins, localization in stressful 
microenvironments, and selective accumulation of inhibitor in cancer cells (Sidera and 
Patsavoudi, 2014). To date, 17 HSP90 inhibitors, all N-terminal inhibitors of ATPase activity 
have been brought to clinical trial, and while some have shown therapeutic promise despite 
formulation challenges, none have been approved for standard use against any cancer. Further 
development of HSP90 axis modulators, both directly and indirectly through co-chaperones, will 
be necessary to better target this potential vulnerability of cancer. 
Withaferin A (WA), a 28-carbon steroidal lactone isolated from members of the 
Solenceae plant family, has shown promise as an experimental anti-cancer agent by inducing 
protein degradation and subsequently disrupting numerous signaling pathways including those 
served by Akt/mammalian target of rapamycin (mTOR), nuclear factor kappa (NFκB), and 
mitogen-activated protein kinase (MAPK) (Vyas and Singh, 2014). These alterations ultimately 
result in pro-apoptotic, anti-proliferative, and anti-angiogenic manifestations both in vitro and in 
vivo (Vanden Berghe et al., 2012; Vyas and Singh, 2014). While this cytotoxic capacity of WA 
has been well-defined in a broad spectrum of cancer types, the underlying mechanism 
responsible for these observations remains incompletely defined. It has been noted that WA may 
function in part through disruption of the HSP90 chaperone axis either directly or through 
disruption of the HSP90/Cdc37 interaction (Yu et al., 2010; Grover et al., 2011; Gu et al., 2014). 
Cdc37 (cell division cycle protein 37) functions as a co-chaperone to HSP90 and plays a vital 
role in localizing target kinases of the kinome with HSP90 for folding (Karnitz and Felts, 2007). 
Additionally, WA has demonstrated intrinsic thiol-reactivity and oxidizing properties which have 
been thought to, in part, play a role in the spectrum of effects observed (Malik et al., 2007; 
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Widodo et al., 2010; Hahm et al., 2011; Mayola et al., 2011; Santagata et al., 2012; Grogan et al., 
2013). 
In this study, we further define the mechanism of WA responsible for protein depletion 
through oxidation and modulation of the HSP90 axis and demonstrate its therapeutic utility in 
combination with an inhibitor of the proteasome. 
 
5.3 Materials and methods 
 
5.3.1 Cell culture and general reagents 
 
The human GBM cell line U87 was generously provided by Dr. Jann N. Sarkaria (Mayo 
Clinic, Rochester, MN), and the human embryonic kidney cell line 293T was kindly provided by 
Dr. Roland Kwok (University of Michigan, Ann Arbor, MI). The human cervical cancer line 
HeLa was obtained through the American Type Culture Collection (ATCC; Manassas, VA). All 
cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM #11995-065; Gibco, 
Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, 
MO) and 1% penicillin/streptomycin (Gibco), at a 37 °C humidified atmosphere of 5% CO2 in 
air. Medium for HeLa cells was further supplemented with 2% L-glutamine (200 mM; Gibco), 
1% MEM-vitamin (100x; Hyclone, Logan, UT), and 1% MEM nonessential amino acids (Sigma 
Aldrich). WA was isolated as previously described (Samadi et al., 2010b). Propidium iodide (PI), 
DL-buthionine-(S,R)-sulfoximine (BSO), ascorbic acid (AA), N-acetyl-L-cysteine (NAC), 
monochlorobimane, chloroquine diphosphate salt, and puromycin dihydrochloride were acquired 
from Sigma-Aldrich, Annexin V-FITC was obtained from BD Biosciences (San Diego, CA), and 
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MG132 was purchased from Selleckchem (Houston, TX). 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) was obtained from LC Laboratories (Woburn, MA). 
17-AAG resistant HeLa cells were generated through serial escalations in drug exposure 
to the parental HeLa line. Cells were initially exposed to 250 nM 17-AAG and allowed to 
recover. All surviving cells remained pooled. Escalation ultimately reached 5 µM and was 
maintained at this level until the cells were observed to demonstrate minimal change in response 
to the drug. Resistant cells were not treated with 17-AAG for at least one month before any 
functional studies. 
 
5.3.2 MTS assay 
 
HeLa and U87 cells were plated at 1,500 and 3,000 cells/well, respectively, in 100 µL in 
a 96-well plate. After 5-6 h, cells were treated with various concentrations of MG132 for 1 h 
followed by the addition of WA to bring the total well volume to 200 µL. Similarly, parental and 
17-AAG resistant HeLa cells were plated at 1,500 cells/well in 50 µL, allowed to settle for 5-6 h, 
and treated with varying concentrations of WA or 17-AAG. After a 72 h incubation, viable cell 
levels were quantified with the addition of the colorometric CellTiter96 Aqueous MTS assay 
reagent as per the manufacturer’s instructions (Promega, Fitchburg, WI). Reagent was allowed to 
incubate with the cells for 1-2 h, and absorbance was quantified at 490 nm on a BioTek Synergy 
2 plate reader (BioTek, Winooski, VT). 
 
5.3.3 CellTiter Glo assay 
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The CellTiter-Glo luminescent assay (Promega, Fitchburg, WI) was used to evaluate cell 
viability and proliferation through assessment of cellular ATP levels in assays with the use of 
reducing agents that would otherwise interfere with the MTS assay mechanism. Cells were 
plated as outlined in the MTS assay in a white-walled 96-well plate. Where indicated, cells were 
pretreated with AA or NAC for 1h followed by WA. After 72 h, assay reagent was added to the 
wells as per the manufacturer’s instructions and gently shaken for 10 minutes in the dark at room 
temperature. Well luminescence was measured on the BioTek Synergy 2 plate reader. 
 
5.3.4 Evaluation of cell death 
 
HeLa and U87 cells were plated and allowed to adhere and grow to ~50% confluency 
overnight. Cells were then pretreated with MG132 for 1 h followed by WA. DMSO was used as 
a vehicle control for both agents. After 24 h, all cells were collected and processed as previously 
described (Grogan et al., 2013). Briefly, cells were washed once in Annexin binding buffer and 
subsequently stained with PI and Annexin V-FITC as per the manufacturer’s instructions (BD 
Biosciences, San Diego, CA) for 30 minutes at 4 °C. Stained cells were washed twice with the 
Annexin binding buffer, resuspended in 400 µL of the buffer, and immediately analyzed by flow 
cytometry on a Beckman Coulter CyAn ADP analyzer (Brea, CA). 
 
5.3.5 Immunoblotting 
 
For general Western blotting, cells were plated as previously described for the evaluation 
of cell death. Cells were treated with WA or 17-AAG for 24 h and pretreated with 20 µM 
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MG132, 50 µM chloroquine, or 5 mM NAC for 1 h or 500 µM BSO for 24 h where indicated. 
After 24 h, cells were harvested, and proteins were isolated in lysis buffer (40 mM HEPES, 2 
mM EDTA, 10 mM sodium pyrophosphate decahydrate, 10 mM β-glycerophosphate disodium 
salt pentahydrate, 1% triton X-100 supplemented with 100 µM phenylmethylsulfonyl fluoride 
(PMSF), 1 mM Na3VO4, and 2 µL/mL protease inhibitor cocktail), quantified, separated by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), and transferred onto a 
Hybond nitrocellulose membrane as previously described (Samadi et al., 2011). 20-50 µg of 
protein sample was loaded per lane. Equal loading and transfer of sample was confirmed by 
blotting for total actin levels. Studies were repeated for accuracy. 
Triton X-100 soluble and insoluble fractionation was completed with triton soluble buffer 
(50 mM Tris-HCl pH 6.8, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% triton X-100) and 
insoluble buffer (50 mM Tris-HCl pH 6.8, 2% SDS) as previously described (Chen et al., 2008) 
supplemented with 100 µM PMSF, 1 mM Na3VO4, and 2 µL/mL protease inhibitor cocktail. In 
brief, cells were pre-treated with proteasome inhibitor MG132 for 1 h where indicated followed 
by WA for 24 h. Cells were collected as previously described, lysed with triton soluble buffer, 
and centrifuged at 14,000 rpm for 20 minutes at 4°C. The supernatant was collected as the 
soluble fraction. The pellet was resuspended and washed once with soluble buffer and repelleted 
by centrifuged at 14,000 rpm for 10 minutes. The pellet was resuspended in triton insoluble 
buffer and subsequently ground with a pestle, vortexed, and heated at 100 °C repeatedly for ~15 
minutes to promote dissolution of the pellet. Any remaining debris was removed by 
centrifugation, and the supernatant was collected as the insoluble fraction. Proteins in the two 
fractions were prepared and evaluated as described above. For electrophoresis under non-
reducing conditions, β-mercaptoethanol was not added to the SDS loading buffer. 
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Primary antibodies against ubiquitin (#3936; 1:2000), glucocorticoid receptor (GR; 
#12041; 1:500), Akt (#4691; 1:2000), mTOR (#2972; 1:1000), EGFR (#4267; 1:1000), c-myc 
(#9402; 1:1000), Cdk4 (#2906; 1:2000), Cdk6 (3136; 1:1000), BRCA1 (#9010; 1:500), Chk1 
(#2360; 1:1000), GAPDH (#2118; 1:1000), Cdc37 (#4793; 1:1000), PARP (#9542; 1:1000), and 
caspase 3 (#9665; 1:1000) were acquired from Cell Signaling Technology (Danvers, MA). 
HSP40 (#ADI-SPA-400; 1:1000), HSP90 (SPA-836; 1:1000), and HSP70 (ADI-SPA-810; 
1:1000) antibodies were collectively obtained from Enzo Life Sciences (Farmingdale, NY). Total 
actin antibody (#MAB1501; 1:50000) was obtained from EMD Millipore (Billerica, MA), and 
FLAG antibody (F1804; 1:500) was acquired from Sigma-Aldrich. The primary antibodies for 
ERK2 (sc-154; 1:5000)and Raf-1 (sc-7267; 1:250) and the secondary antibodies donkey anti-
rabbit IgG HRP (sc-2313; 1:2500-1:10000) and goat anti-mouse IgG HRP (sc-2005; 1:5000-
1:20000) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
 
5.3.6 Immunocytochemistry (ICC) 
 
U87 and HeLa cells were plated to ~50% confluency in 8-well chamber slides (Nalge 
Nunc International, Penfield, NY) and treated with 1-2 µM WA for 24h. Cells were fixed in 4% 
PBS-buffered paraformaldehyde at room temperature for 30 minutes and washed 3x with 1x 
PBS. Cell membranes were de-permeablized for 15 minutes in 1x PBS containing 0.3% triton X-
100 and subsequently blocked in 5% goat serum (Cell Signaling Technology) in 1x PBS 
containing 0.15% triton X-100 shaking for 1 h. Cells were exposed to primary antibody in 
blocking solution overnight at 4 °C. Primary antibodies included HSP90 (1:100; Cell Signaling 
#4877), HSP70 (1:250; Enzo Life Sciences #SPA-810), and ubiquitin (1:200; Biolegend 
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#646301; San Diego, CA). After three washes with 1x PBS, secondary antibody (1:1000; anti-
rabbit IgG Fab2 Alexa Fluor 555, Cell Signaling #4413; Anti-mouse IgG Fab2 Alexa Fluor 488, 
Cell Signaling #4408) was added to each well for 1 h at room temperature followed by an 
additional 3 washes. Coverslips were mounted on each slide with ProLong Gold Antifade with 
DAPI (Cell Signaling Technology), allowed to dry, and visualized on a Leica DM IRB 
microscope (Wetzlar, Germany) with Metamorph Basic software (version 7.7.3.0.; Molecular 
Devices; Sunnyvale, CA). 
 
5.3.7 Steroid-binding assay 
 
 The GR steroid binding assay was performed as previously described (Murphy et al., 
2011). U87 and HeLa cells were plated to ~50% confluency, treated with WA or 17-AAG, 
collected after 24 h, washed and pelleted, and snap frozen in liquid nitrogen. Homogenization 
HEM buffer (10 mM HEPES pH 7.35, 1 mM EDTA, 20 mM sodium molybdate, 1 mM PMSF, 
1x protease inhibitor cocktail) was added at 1.5 volumes of the pellet, and the protein was 
isolated by centrifugation. FiGR antibody producing cells were purchased at American Type 
Culture Collection (ATCC; Manassas, VA; FiGR ATCC CRL-2173), and ascites was produced 
at the University of Michigan Hybridoma Core as described (Morishima et al., 2003). 50 µL 
murine GR from the lysate of overexpressing SF9 cells as previously produced (Morishima et al., 
2003) was combined with 178 µL TEG buffer (8 mM TES pH 7.6, 4 mM EDTA, 50 mM NaCl, 
10% (v/v) glycerol), 70 µL protein A sepharose (Sigma-Aldrich), and 2 µL FiGR and rotated at 4 
°C for 2 h to promote immunoadsoption of the GR. Immunoadsorbed GR was salt-stripped of 
associated HSP90 complex proteins with 0.625 M NaCl in TEG buffer at 4 °C. After 2 h, the 
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beads were washed with TEG buffer followed by 10 mM HEPES (pH 7.4) and reconstituted in 
50 µL of U87 (185 µg) or HeLa (250 µg) lysate volume-equilibrated amongst treatment samples 
with 5µL of an ATP-regenerating system (10 mM HEPES pH 7.4, 50 mM ATP, 250 mM 
creatine phosphate, 20 mM magnesium acetate, and 100 U/mL creatine phosphokinase). Each 
sample was incubated at 30 °C for 20 minutes with agitation every 2 minutes. After 20 minutes, 
samples were washed twice with TEGM buffer (TEG buffer with 20 mM sodium molybdate). 
To evaluate the steroid binding ability of the immunopellets, each pellet was resuspended 
in 100 µL of HEM buffer with 100 nM [H
3
]dexamethasone (PerkinElmer, Waltham, MA) and 
incubated overnight at 4 °C. Samples were then washed three times with TEGM buffer and 
measured by liquid scintillation spectrometry on a Beckman LS 5000CE counter. Steroid binding 
was identified as counts/minute. Negative and positive controls were control lysate without FiGR 
and 50 µL reticulocyte lysate, respectively. 
 
5.3.8 Co-immunoprecipitation (co-IP) 
 
HeLa cells were plated, allowed to adhere overnight, and grown to ~50% confluency 
before treatment with WA. For co-IP of Cdc37, Cdk6, and GR proteins from IPed HSP90, cells 
were treated with  5µM WA for 1-16 h or 0.5-5 µM WA for 4 h before cells were trypsinized, 
washed twice with 1x PBS, and pelleted. Pelleted cells were lysed in a buffer consisting of 20 
mM Tris HCl (pH 7.4), 100 mM NaCl, 2 mM DTT, 20 mM sodium molybdate dihydrate, and 
0.5% NP-40 supplemented with 100 µM PMSF, 1 mM Na3VO4, and 2 µL/mL protease inhibitor 
cocktail. Proteins were isolated and quantified as described for immunoblotting. 2 mg of each 
protein sample was brought to 300 µL in buffer, and 25 uL of anti-HSP90β antibody (1:12; 
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Invitrogen #379400) was added to each tube except for a no-antibody control tube with untreated 
cell lysate. Tubes were rocked at 4 °C overnight before the addition of 25 µL of protein G 
magnetic bead system as described by the manufacturer (Pierce Biotechnology, Rockford, IL) for 
2 h. Beads were washed 4x with buffer, and proteins were eluted with the addition of SDS buffer 
as used in immunoblotting for 15 minutes rocking at room temperature. Beads were cleared, and 
the supernatant was evaluated by immunoblotting. For immunoblotting, secondary mouse anti-
rabbit conformation specific HRP antibody (#5127; 1:1000) was obtained from Cell Signaling 
Biotechnology and used for blotting in appropriate to limit heavy-chain interference. 
 
5.3.9 Reactive oxygen species (ROS) measurement 
 
WA-mediated production of intracellular ROS, particularly peroxides like H2O2, was 
measured through fluorescent conversion of the general oxidative stress indicator CM-
H2DCFDA (Molecular Probes, Grand Island, NY). U87 cells were preloaded with 20 µM CM-
H2DCFDA in 1x PBS at 37 °C for 1 h, washed once with phenol red-free DMEM supplemented 
with 10% FBS and 1% penicillin/streptomycin, and resuspended in the same medium. Cells were 
plated at 20,000 cells/well in a 96-well plate and treated with WA ± 5 mM NAC or 100 µM AA 
after 30 minutes. Evaluation of fluorescence was completed on a BioTek Synergy 2 plate reader 
after 4 h with excitation and emission filters of 485 nm and 528 nm, respectively. 
 
5.3.10 Determination of glutathione (GSH) levels 
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U87 and HeLa cells were plated at 10,000 cells/well using phenol red-free medium in 50 
µL in a 96-well plate and allowed to adhere overnight before treatment with WA in a 50 µL 
volume. Monoclorobimane, a non-fluorescent compound until reacting with thiols like GSH, was 
made up in DMSO at a stock concentration of 25 mM and diluted to 200 µM in 1xPBS before 
immediately before use. After 6 h of WA exposure, 100 µL of the diluted monoclorobimane was 
added to each well, and plates were incubated at 37 °C for 30 minutes. Evaluation of 
fluorescence, corresponding with free cellular GSH levels, was then completed on a BioTek 
Synergy NEO plate reader excitation and emission filters of 390 nm and 478 nm, respectively. 
 
5.3.11 Transfections 
 
c-myc has previously been shown to require amino acid sites T58 and S62 for 
phosphorylation-directed ubiquitination and subsequent degradation via the proteasome (Gregory 
and Hann, 2000; Sears et al., 2000; Kamemura et al., 2002). 293T cells were transfected with 
pcDNA3-c-myc
T58A/S62A
-FLAG, a mutant for both sites, or the pcDNA3 control vector and a 
puromycin cassette at a 20:1 ratio (4 µg:200 ng in a 6 cm dish) using Lipofectamine 2000 as per 
the manufacturer’s instructions (Life Technologies, Carlsbad, CA). The constructs were 
previously produced as described (Sundberg et al., 2006). The cells were selected with 1.5 
ug/mL puromycin, and surviving colonies were pooled. To verify expression of c-myc
T58A/S62A
, 
Western blotting for the attached FLAG tag was carried out. The transfected cells were used as a 
model of altered proteasomal degradation in the present of WA. 
 
5.3.12 Data and statistical analysis 
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GraphPad Prism 6 (version 6.02; GraphPad Inc., San Diego, CA) was used to generate 
best-fit non-linear sigmoidal dose response curves for IC50 determination. Comparisons of 
differences between two or more means/values were determined by Student’s unpaired t-test via 
the statistical functions of GraphPad Prism or Microsoft Excel 2010 software (version 
14.0.6129.5000; Microsoft Corporation Redmond, WA). Densitometry, where indicated, was 
completed using ImageJ software (version 1.46r; Bethesda, MD). Data are presented as mean 
values with error bars denoting standard deviation or standard error of the mean where 
appropriate. Unless otherwise noted, all experiments were performed minimally in triplicate. The 
levels of significance were set at *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
5.4 Results 
 
5.4.1 Withaferin A alters the HSP90/HSP70 balance to favor HSP70 upregulation and molecular 
ubiquitination 
 
While HSP90 and HSP70 associate in a heteroprotein chaperone complex, it has been 
described that each, when favored, provides a contrasting dominant function in response to the 
presence of misfolded proteins. HSP90 promotes selective protein refolding and function, 
whereas HSP70 mediates aberrant protein degradation.  WA has previously demonstrated the 
ability to reduce total levels of key proteins in multiple signaling pathways, but the underlying 
mechanisms remain incompletely defined. In order to determine if changes in the HSP90/HSP70 
axis are observed with WA treatment, total levels of HSP90 and HSP70 were evaluated in HeLa  
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Figure 5-1.  
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Figure 5-1. A) ICCrevealed dose-dependent increases of HSP70 in both cell lines with visible 
induction throughout the nucleus and cytoplasm occurring at 2 µM WA in HeLa and elevation at 
1 µM in U87 after 24 h. Baseline HSP70 staining was notably higher in U87 compared to HeLa. 
Total HSP90 levels were largely unchanged in HeLa but slightly elevated in U87 with significant 
staining observed at baseline in both lines.  Merged images revealed the shift in the 
HSP90/HSP70 balance toward HSP70 with the predominant red HSP90 staining in control cells 
replaced by the green staining of HSP70 and yellow staining of combined HSP90/HSP70. B) 
Immunocytochemistry results were confirmed by Western blotting demonstrating minimal 
changes in total HSP90 levels but dose-dependent increases in HSP70 and HSP40. C) Dose-
dependent increases of ubiquitin staining with WA treatment were observed in both HeLa and 
U87 after 24 h. Notable aggregation of ubiquitinated proteins was visible at 2 µM WA in both 
lines. 
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and U87 cells by ICC and Western blotting (Figure 5-1A). ICC revealed dose-dependent 
increases of HSP70 in both cell lines with visible induction throughout the nucleus and 
cytoplasm occurring at 2 µM WA in HeLa and elevation at 1 µM in U87. Baseline HSP70 
staining was notably higher in U87 compared to HeLa. Total HSP90 levels were largely 
unchanged in HeLa but slightly elevated in U87 with significant staining observed at baseline in 
both lines.  Merged images revealed the shift in the HSP90/HSP70 balance. Predominant red 
HSP90 staining in control cells was replaced by the notable green staining of HSP70 and yellow 
staining of combined HSP90/HSP70. 
 Western blotting confirmed the ICC observations (Figure 5-1B). Total levels of HSP90 
were predominantly unchanged with WA concentrations up to 5 µM with mild increases noted in 
U87. Consistent with ICC findings, baseline levels of HSP70 were not noted in HeLa cells but 
were observed in U87. HSP70 was significantly induced at 2.5 µM WA in both HeLa and U87. 
Levels in U87 cells were moderately increased between 0.25-1 µM WA. Additionally, HSP40, a 
co-chaperone known to aid in the function of HSP70, was notably elevated from 1-5 µM WA in 
U87 but only 2.5 µM WA in HeLa, consistent with highest levels of HSP70 upregulation. 
 Given the WA-mediated shift toward the HSP70 axis which favors proteasome-mediated 
protein degradation, total cellular ubiquitination, a signaling marker for this degradation, was 
evaluated by ICC following WA treatment. Staining for ubiquitin was increased in a dose-
dependent manner in both HeLa and U87 (Figure 5-1C). By 2 µM, notable aggregates of 
ubiquitination were seen in both cell lines, suggesting accumulation of normal and/or aberrant 
proteins targeted for degradation. 
 
5.4.2 Withaferin A inhibits the HSP90 axis through disruption of the HSP90/Cdc37 interaction 
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Several previous investigations have identified a pattern of protein degradation 
characteristic of HSP90 inhibition following exposure to WA (Samadi et al., 2009; Yu et al., 
2010; Gu et al., 2014). Yu, et al. suggested that WA binds HSP90 and reduces its association 
with co-chaperone Cdc37 but questioned whether alterations in the stability of HSP90 client 
proteins were a result of this disruption or rather inhibition of HSP90 (Yu et al., 2010). To 
evaluate this, the effects of WA were examined in Cdc37-dependent and independent models. 
WA was first demonstrated to induce protein depletion of known HSP90 clients Akt, 
mTOR, Raf-1, EGFR, c-myc, Cdk6, BRCA1, and Chk1 by 2.5 µM in both HeLa and U87 cells 
(Figure 5-2A). In contrast, WA treatment failed to decrease levels of non-HSP90 client proteins 
ERK2, GAPDH, and actin. The role of HSP90 in the stability of each protein was confirmed by 
treating HeLa cells with known HSP90 inhibitor 17-AAG. 
The glucocorticoid receptor (GR) has been well-described as requiring an association 
with HSP90 for its steroid binding activity. In contrast to the androgen receptor, this activity 
does not require the presence of Cdc37 (Rao et al., 2001). HSP90 function was measured through 
the ability of purified GR to bind [
3
H]dexamethasone following re-exposure to cellular lysate 
containing HSP90 and other co-chaperones as previously described (Murphy et al., 2011) (Figure 
5-2B). Lysate was obtained from HeLa and U87 cells treated with vehicle, WA, and 17-AAG for 
24 h. Reticulocyte lysate was used as a positive control and confirmed model efficacy (data not 
shown). WA failed to demonstrate inhibition of HSP90 activity at cytotoxically relevant 
concentrations 2-5 µM and rather displayed elevated promotion of steroid binding by 4-10% and 
49-57% with HeLa and U87 lysates, respectively (p > 0.05 expected 2 µM WA in U87 cells: p = 
0.047). At 10 µM WA, steroid binding in U87 was seen to return to baseline but reduced to 45%  
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Figure 5-2. A) WA treatment for 24 h in U87 and HeLa caused protein depletion of known 
HSP90 clients Akt, mTOR, Raf-1, EGFR, c-myc, Cdk6, BRCA1, and Chk1 but failed to 
decrease levels of non-HSP90 client proteins ERK2, GAPDH, and actin. HSP90-mediated 
stability of each protein was confirmed by treating HeLa cells with known N-terminal HSP90 
inhibitor 17-AAG. B) HSP90 function was measured through the ability of purified GR to bind 
[
3
H]dexamethasone following re-exposure to cellular lysate containing HSP90 and other co-
chaperones treated with WA or 17-AAG for 24 h. WA failed to demonstrate inhibition of HSP90 
activity at cytotoxically relevant concentrations 2-5 µM and rather displayed elevated promotion 
of steroid binding with HeLa and U87 lysates. At 10 µM WA, steroid binding in U87 was seen 
to return to baseline but reduced to 45% of baseline in HeLa. In contrast, 1 µM 17-AAG, a 
positive control for HSP90 inhibition, significantly reduced HSP90-mediated GR steroid binding 
with HeLa and U87 lysates. C and D) Co-IP experiments in HeLa cells using an HSP90 antibody 
pull-down demonstrated that WA reduced the association between HSP90 and Cdc37 in a dose-
dependent manner after 4 h and in a time-dependent manner when exposed to 5 µM WA. Total 
input HSP90 and Cdc37 was not decreased with treatment. Similar to Cdc37, the Cdc37-
dependent client protein Cdk6 was also shown to dissociate with WA treatment, but Cdc37-
independent protein GR did not. Total levels of both Cdk6 and GR were reduced over time. E) A 
17-AAG resistant HeLa cell line was developed and shown to have a 72 h IC50 to 17-AAG of 
1380 nM compared to 21 nM for the parental line, a 66-fold difference. F) In contrast to findings 
with 17-AAG, WA IC50s in the parental and resistant lines were 503 nM and 841 nM, 
respectively, a different of only 1.7-fold. G) Both WA and 17-AAG decreased total levels of 
HSP90 client proteins EGFR, Akt, and Cdk4 and increased the apoptotic cleavage of PARP in 
179 
 
parental HeLa cells, but only WA demonstrated these findings in the resistant line, showing its 
maintained utility. *p < 0.05, **p < 0.01, ***p < 0.001  
180 
 
of baseline in HeLa (p = 0.002). In contrast, 1 µM 17-AAG, a positive control for HSP90 
inhibition, reduced HSP90-mediated GR steroid binding in HeLa and U87 by 99% and 83%, 
respectively (p < 0.001). These findings suggest that WA does not directly inhibit HSP90 
function. 
The ability of WA to alter the association between HSP90 and Cdc37 was confirmed in 
HeLa cells by co-immunoprecipitation for HSP90 (Figures 5-2C and 5-2D). After 4 h WA 
treatment, co-IPed Cdc37 was reduced 36.9% with 1 µM up to 67.0% with 5 µM relative to IPed 
HSP90, demonstrating a dose-dependent effect. Similarly, a time-dependent effect was observed 
by maintaining WA at 5 µM with diminished association from 1-16 h post-treatment. IPed 
Cdc37 was reduced 23.8%, 72.7%, 77.2%, and 99.4% after 2 h, 4 h, 8 h, and 16 h relative to IPed 
HSP90, respectively. Total input HSP90 and Cdc37 remained consistent with WA treatment. 
To further define the importance of this co-chaperone disruption, IPed HSP90 was also 
evaluated for a Cdc37-dependent protein, Cdk6, and a Cdc37-independent protein, GR (Figures 
5-2C and 5-2D) (Lamphere et al., 1997; Rao et al., 2001). Treatment with WA in both dose- and 
time-dependent manners demonstrated a progressive failure of HSP90 to associate with client 
protein Cdk6. This association was completely eliminated after 4 h with 2.5 µM WA. Similarly, 
association was nearly completely eliminated with 5µM WA after 1 h and remained consistently 
reduced at latter timepoints. Total input levels of Cdk6 were constant among samples except for 
5 µM WA at 16 h which demonstrated near-complete elimination of the protein. In contrast, co-
IPed GR in both the dose- and time-dependence studies was maintained under all conditions. 
Interestingly, total input GR was decreased with time and concentration in both experiments with 
near-complete depletion with 5 µM at 16 h, but this did not result in a corresponding decrease in 
HSP90-GR association, suggesting the retention of HSP90 function independent of Cdc37.  
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In contrast to 17-AAG, WA has been shown to associate with the C-terminus of HSP90 
and did not affect molecular ATPase function (Yu et al., 2010). To demonstrate if WA’s unique 
disruption of the HSP90 axis could be utilized in overcoming inhibition to 17-AAG while still 
generating a similar effect, a HeLa cell line resistant to 17-AAG was developed through serial 
escalations in drug exposure. Evaluation of 17-AAG cytotoxicity revealed 72 h IC50 values of the 
parental and resistant lines to be 21 nM and 1380 nM, respectively, for a 66-fold change in 
response (Figure 5-2E). WA sensitivity, however, was only elevated 1.7-fold from 503 nM in the 
parental line to 841 nM in the 17-AAG resistant derivative (Figure 5-2F). 
Maintained cytotoxicity of WA in the 17-AAG resistant line was confirmed molecularly 
through evaluation of HSP90 client proteins EGFR, Akt, and Cdk4 as well as cleavage of the 
apoptotic biomarker PARP (Figure 5-2G). Depletion of the client proteins and increased PARP 
cleavage observed with 1 µM 17-AAG after 24 h in the parental HeLa line was completely 
absent in the resistant line, but WA-mediated client degradation remained consistent with near-
complete elimination by 2.5 µM. WA also maintained the ability to induce PARP cleavage in the 
resistant sub-line. 
 
5.4.3 Cytotoxicity of withaferin A is driven by thiol-reactivity and cellular oxidation 
 
Previous studies have identified an oxidative component resulting from treatment with 
WA (Malik et al., 2007; Widodo et al., 2010; Hahm et al., 2011; Mayola et al., 2011; Santagata 
et al., 2012; Grogan et al., 2013; Grogan et al., 2014). Given that certain proteins are susceptible 
to oxidative stress and may become misfolded, the nature of this oxidative component was 
explored. Treatment of U87 cells with WA resulted in a dose-dependent increase in oxidation as 
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measured by CM-H2DCFDA conversion to a fluorescent product by 4 h (Figure 5-3A). 5 µM 
WA increased fluorescence 1.9-fold (p = 0.038). This enhanced oxidative signal was reduced by 
pretreatment with 100 µM non-thiol antioxidant AA by 17.2% (p = 0.233) and completely 
returned to baseline with 5 mM thiol antioxidant NAC (p = 0.037), suggesting a greater role of 
thiol reactivity in the manifestation of WA’s effects. 
Further evaluation of thiol reactivity and changes in the redox states following WA 
exposure was accomplished through measurements of GSH levels with monochlorobimane 
which fluoresces when conjugated to GSH (Figure 5-3B). GSH is a protective component of 
cells that sequesters thiol reactive agents to prevent cellular damage. After 6 h, 2.5 µM WA 
reduced total cellular glutathione in both HeLa and U87 cells by 41.1% (p < 0.001) and 31.9% (p 
= 0.012), respectively, further indicating WA-mediated thiol reactivity and disruption of the 
redox balance. 
Evaluation of anti-oxidant pretreatment was completed with the CellTier-Glo assay to 
define the functional cytotoxic effects of WA treatment (Figure 5-3C). In the assay, cellular 
viability was assessed by total ATP levels 72 h after treatment. WA alone exhibited significant (p 
< 0.001) reduction in the viability of HeLa and U87 cells at the concentrations tested (2.5-5 µM). 
While 100 µM AA previously reduced WA-mediated oxidation, it was unable to limit 
cytotoxicity, mirroring the cell viability reduction of WA alone. However, 5 mM NAC 
completely abrogated WA cytotoxicity, returning cell viability to baseline and demonstrating the 
predominant thiol reactive mechanism of WA. 
Triton X-100 fractionation under non-reducing conditions was completed to define WA-
mediated redox alterations in HSP90 localization. While triton soluble proteins are largely 
regarded as functional, stable molecules, the insoluble fraction is thought to contain labile and  
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Figure 5-3.  A) WA generated peroxide-type radicals like H2O2 as quantified by CM-H2DCFDA 
fluorescent conversion with increasing concentrations of WA in U87 cells 4 h post-treatment. 
The thiol antioxidant NAC (5 mM) completely abrogated the elevation in ROS, while 100 µM of 
the non-thiol antioxidant AA produced a small reduction in overall oxidation. B) GSH levels 
were measured by monochlorobimane conversion to a fluorescent product in the presence of a 
thiol. WA treatment was shown to significantly reduce GSH levels in both HeLa and U87 after 
treatment for 6 h. HeLa (C) and U87 (D) cell viability was assessed by total ATP levels with the 
CellTiter Glo assay. WA-induced reduction of viability was completely eliminated with NAC 
but not AA pretreatment. E) Triton X-100 fractionation under non-reducing conditions was 
completed to define WA-mediated redox alterations in HSP90 localization. Slower migrating 
proteins aggregates of heterogeneic molecular weight positive for HSP90 were dose-dependently 
increased by WA in the triton insoluble fraction and was reduced with NAC pretreatment. F) In 
contrast, triton insoluble HSP90 aggregation was enhanced by reduction in GSH through 
inhibition of γ-glutamylcysteine synthetase by BSO. *p < 0.05, **p < 0.01, ***p < 0.001 
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aggregated proteins. Additionally, previous reports have demonstrated increased disulfide-
bonded HSP90 in the insoluble fraction in response to oxidative stress (Cumming et al., 2004; 
Chen et al., 2008). Enhanced exposure of Western blots for HSP90 in HeLa and U87 revealed 
minimal changes to total levels of HSP90 in both the soluble and insoluble fractions 24 h after 
2.5-5 µM WA. Slower migrating disulfide-bonded HSP90 was not elevated following WA 
exposure. However, slower migrating proteins of heterogeneic molecular weight positive for 
HSP90 were dose-dependently increased by WA in the triton insoluble fraction indicating 
damaged, aggregated, and delocalized HSP90 protein complexes. Pretreatment with NAC 
completely eliminated this protein aggregation (Figure 5-3D). In contrast, reduction in GSH 
through inhibition of γ-glutamylcysteine synthetase by BSO potentiated the total level of WA-
induced HSP90 aggregate in the insoluble fraction, demonstrating the thiol-dependent nature of 
HSP90 disruption (Figure 5-3E). While BSO enhanced WA-induced HSP70 upregulation and 
NAC prevented HSP70 induction, changes in disulfide-bonded or otherwise aggregated HSP70 
was not detected (data not shown). 
 
5.4.4 Withaferin A-mediated protein degradation requires the proteasome 
 
Cellular protein elimination is largely driven through two primary pathways: proteasome- 
and lysosome-mediated degradation. Given the observation that WA drives upregulation of 
HSP70 and ubiquitination of proteins globally and that the latter targets proteins to the 
proteasome, the mechanism of WA-driven protein depletion was evaluated. 
Triton X-100 fractionation under reducing conditions was utilized to evaluate WA-altered 
protein localization and depletion in the presence of proteasome inhibitor MG132 and lysosome 
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inhibitor chloroquine (Figure 5-4A). As previously described, 20 µM MG132 alone, mimicking 
cellular stress and altering normal protein turnover, reduced soluble levels of the proteins 
evaluated (Cdk6, Cdk4, mTOR, c-myc, Akt, and EGFR) and promoted elevated levels in the 
insoluble fraction (Kawahara et al., 2008). Also, consistent with previous reports (Carter and 
Sorkin, 1998), 50 µM chloroquine, an inhibitor of lysosomal protein degradation, blocked 
endogenous EGFR turnover driven in part through endocytosis and lysosomal degradation and 
enhanced the triton insoluble fraction. WA treatment promoted depletion of soluble proteins with 
variable shift to the insoluble fraction. Complete elimination after 24 h WA exposure was 
favored in the more sensitive HeLa cells compared to U87. However, extended treatment 
duration in U87 cells demonstrated diminished levels of insoluble proteins (data not shown). 
Compared to WA alone, the combination of WA and MG132 demonstrated increased retention 
of all evaluated proteins in the insoluble fraction, suggesting that WA-mediate protein depletion 
occurred at least in part through proteasomal degradation. Protein retention with chloroquine 
pretreatment was variable and demonstrated larger effect in the HeLa cells, suggesting a greater 
cellular role of WA-induced lysosomal degradation in addition to proteasomal degradation. 
Combination of MG132 and chloroquine to rescue WA-induced protein depletion was not shown 
to be greater than either compound alone. 
HSP90 client protein c-myc has previously been shown to require amino acid sites T58 
and S62 for phosphorylation-directed ubiquitination and subsequent degradation via the 
proteasome (Gregory and Hann, 2000; Sears et al., 2000; Kamemura et al., 2002). 293T cells 
were stably transfected with T58A/S62A FLAG-tagged c-myc (c-myc
T58A/S62A
-FLAG), a variant 
with mutations to disrupt the normal c-myc proteasomal degradation, and treated with WA. Both 
vector control and mutant transfected cells demonstrated dose-dependent depletion of  
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Figure 5-4. A)  HeLa and U87 cells were pretreated with the proteasome inhibitor MG132 or the 
lysosome inhibitor chloroquine for 1 h followed by WA for 24 h, and cellular proteins were 
fractionated by triton X-100 solubility. Treatment with WA induced a loss of HSP90 client 
proteins (Cdk6, Cdk4, mTOR, c-myc, Akt, EGFR) in the soluble fraction with a shift to either 
the insoluble fraction or a depletion in both fractions. MG132 also acted to shift proteins to the 
insoluble fraction. Combination of WA and MG132 demonstrated increased retention of all 
evaluated proteins in the insoluble fraction. Protein retention with chloroquine pretreatment 
followed by WA was variable and demonstrated greater effect in the HeLa cells. Combination of 
MG132 and chloroquine to rescue WA-induced protein depletion was not shown to be greater 
than either compound alone. B) 293T cells were transfected with c-myc
T58A/S62A
-FLAG, a variant 
with mutations to disrupt the normal c-myc proteasomal degradation, and treated with WA. 
Endogenous wild-type c-myc was depleted by WA in a dose-dependent manner, but the mutant 
failed to decrease after 24 h. 
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endogenous wild-type c-myc by 2.5 µM WA. The c-myc
T58A/S62A
 mutant, however, showed no 
decrease in response to WA treatment, demonstrating the functional requirement for 
proteasomal-targeting in WA-mediated protein degradation (Figure 5-4B). 
 
5.4.5 Proteasomal inhibition potentiates the cytotoxicity of withaferin A 
 
Given the apparent importance of the HSP70 chaperone axis and the proteasome in 
regulating protein degradation following WA treatment, simultaneous inhibition of the 
proteasome with MG132 to prevent degradation of aberrant protein accumulation was evaluated 
to determine the utility of combination therapy. Cell viability was assessed by MTS assay after 
72 h (Figure 5-5A). HeLa and U87 cells displayed no significant decrease in viability with 25-75 
nM and 75-125 nM MG132 alone, respectively. However, 1h sub-cytotoxic MG132 pretreatment 
potentiated the anti-proliferative response to treatment with escalating concentrations of WA. 
62.5 nM WA reduced HeLa cell viability by 15.5% after 72 h but was enhanced to 38.2% with 
25 nM MG132 (p = 0.010) and 42.2% with 75 nM MG132 (p = 0.043). Comparable 
enhancement was observed with 125-250 nM WA. In U87, 750 nM WA decreased cell viability 
by 25.0% but was enhanced to 56.3% with 75 nM MG132 (p = 0.072) and 83.1% with 125 nM 
MG132 (p = 0.016). 
Similarly, evaluation of drug-induced cell death by flow cytometry revealed that 
pretreatment with MG132 potentiated the cytotoxicity of WA (Figures 5-5B and 5-5C). In HeLa, 
combination therapy induced 45.8% cell death (25.3% early apoptosis, 7.7% necrosis, 12.9% late 
apoptosis/necrosis) compared to only 2.4% in control (1.2% early apoptosis, 0.5% necrosis, 0.7% 
late apoptosis/necrosis; p = 0.015), 2.6% with 125 nM MG132 (0.6% early apoptosis, 1.1%  
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Figure 5-5. A) HeLa and U87 cell viability following combination therapy with proteasome 
inhibitor MG132 and WA was evaluated by MTS assay after 72 h. HeLa and U87 cells displayed 
no significant decrease in viability with 25-75 nM and 75-125 nM MG132 alone, respectively. 
However, MG132 pretreatment at these concentrations potentiated the anti-proliferative response 
to treatment with escalating concentrations of WA. B) Efficacy of combination MG132 and WA 
therapy on HeLa and U87 cells after 24 h was further evaluated by flow cytometry with 
propidium iodide and annexin V-FITC doe cell death. Staining revealed that pretreatment with 
125 nM MG132 potentiated the cytotoxicity of 1 µM WA in both lines. MG132 alone had no 
statistically significant effect compared to control, and only WA demonstrated elevated death in 
U87 cells, but combined, the cytotoxic effects were significantly elevated. C) A representative 
example of the flow cytometry results in HeLa cells. D) Flow cytometry data was supported by 
molecular evaluation of apoptotic markers procaspase 3 and PARP cleavage in both HeLa and 
U87 cells. After 24 h, treatment with 125-250 nM MG132 in both lines as well as 0.5-1 µM WA 
in HeLa and 1-2 µM WA in U87 failed to induce significant cleavage of either protein but 
yielded large increases in the cleaved product when combined. E) Combined treatment with 
MG132 and WA for 24 h resulted in the accumulation of ubiquitinated proteins at all 
concentrations evaluated in both HeLa and U87 cells, demonstrating retention of proteins 
targeted for degradation. *p < 0.05, **p < 0.01, ***p < 0.001 
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necrosis, 0.9% late apoptosis/necrosis; p = 0.016), and 3.2% with 1 µM WA (1.2% early 
apoptosis, 1.3% necrosis, 0.7% late apoptosis/necrosis; p = 0.016). WA and WA+RT 
demonstrated no statistically significant difference over control. Similarly, in U87, combination 
therapy induced 50.2% cell death (37.3% early apoptosis, 2.2% necrosis, 10.6% late 
apoptosis/necrosis) compared to only 4.7% in control (2.8% early apoptosis, 0.8% necrosis, 1.1% 
late apoptosis/necrosis; p = 0.013), 8.3% with 125nM MG132 (5.4% early apoptosis, 1.2% 
necrosis, 1.8% late apoptosis/necrosis; p = 0.024), and 20.9% with 1 µM WA (14.6% early 
apoptosis, 3.0% necrosis, 3.3% late apoptosis/necrosis; p = 0.015). WA alone also demonstrated 
a statistically significant cytotoxic advantage over control (p = 0.011). Together, these data 
demonstrate that sub-cytotoxic pre-exposure to MG132 potentiates minimally or non-lethal WA 
concentrations. 
 Flow cytometry data was supported by molecular evaluation of apoptotic markers 
procaspase 3 and PARP cleavage in both HeLa and U87 cells (Figure 5-5D). After 24 h, 
treatment with 125-250 nM MG132 in both lines failed to induce significant cleavage of either 
protein. Similar findings were observed with 0.5-1 µM WA in HeLa and 1-2 µM WA in U87. 
However, combination of these agents at the noted concentrations revealed large increases in the 
cleaved product of both procaspase 3 and PARP, demonstrating the advantage of combination 
therapy. 
Consistent with the expectation that combination therapy would result in enhanced 
cytotoxicity through an accumulation of aberrant proteins generated by WA treatment and unable 
to be properly degraded via the proteasome due to MG132, dual treatment over 24 h resulted in 
the accumulation of ubiquitinated proteins at all concentrations evaluated (Figure 5-5E). 
Potentiation of the effect was particularly notable at modest concentration of each compound that 
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alone produced minimal yet early indications of ubiquitination. By denisometry, 125 nM MG132 
increased ubiquitination 2.2-fold in HeLa and 1.8-fold in U87, while 1 µM and 2 µM WA 
resulted in 3.0- and 3.3-fold elevations in HeLa and U87, respectively. Combination of MG132 
and WA showed further enhanced levels of global protein ubiquination by 11.4-fold in HeLa and 
10.7-fold in U87, demonstrating the value of this approach. 
 
5.5 Discussion 
 
WA is a promising naturally-derived anti-cancer compound that has demonstrated 
efficacy across a spectrum of cancer types both in vitro and in vivo. Underlying WA’s 
antiproliferative, pro-apoptotic, and anti-angiogenic effects is disruption of various signaling 
pathways including those utilizing Akt/mTOR, MAPK, Notch, NFκB, JAK/STAT, and more 
(Vanden Berghe et al., 2012; Vyas and Singh, 2014). However, details of the mechanism driving 
these diverse effects have remained poorly defined to-date. Previous studies have identified a 
pro-oxidant effect (Malik et al., 2007; Widodo et al., 2010; Hahm et al., 2011; Mayola et al., 
2011; Santagata et al., 2012; Grogan et al., 2013) and suggested that alterations in HSP90 
function occurs with WA treatment (Yu et al., 2010; Gu et al., 2014). Here, we further 
characterized these findings and propose each as the two of the dominant mechanisms by which 
WA mediates in anti-cancer effects: Induction of cellular oxidation and disruption of the 
interaction between HSP90 and its co-chaperone Cdc37 independent of direct HSP90 inhibition. 
These proposed mechanisms explain the numerous descriptions of alterations in oncogenic 
proteins and signaling pathways that have come to define the cellular response to WA. 
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 HSP90 functions as a chaperone to promote the folding, refolding, and function of a 
specific set of client proteins (Pearl et al., 2008). This ability is dependent on the association of 
HSP90 with several co-chaperone proteins that promote this function (Taipale et al., 2010). 
Although not yet fully understood mechanistically, Cdc37 is thought to act largely as a kinase-
specific co-chaperone to promote the folding and maturation of these proteins through 
localization with HSP90 with enhanced client loading though modulation of HSP90 ATPase 
activity (Siligardi et al., 2002; Roe et al., 2004). Cdc37 has also demonstrated chaperoning 
functions independent of HSP90 (MacLean and Picard, 2003). Here, we demonstrate that 
pharmacological disruption of this interaction between HSP90 and Cdc37 with WA is associated 
with a failure of HSP90 to associate with Cdc37-dependent protein Cdk6 but not Cdc37-
independent protein GR as well as degradation of multiple HSP90 client proteins. Additionally, 
depletion of HSP90 client proteins known to interact with Cdc37 (Akt, Raf-1, EGFR, Cdk4, 
Cdk6, and Chk1) was observed. Intrinsic HSP90 chaperone function, assessed by supporting GR 
steroid binding, was not impaired at relevant concentrations of WA, although several HSP90 
client proteins not previously described as Cdc37-dependent (BRCA1, c-myc, GR) were also 
depleted suggesting an alternate mechanism of protein modulation and/or a previously 
undescribed requirement for Cdc37. These findings, if not mediated through an alternative 
mechanism, suggest that WA may still maintain a direct role in the inhibition of HSP90’s folding 
mechanism independent of its GR support. Cdc37 has been primarily reported to facilitate 
folding of newly translated proteins (MacLean and Picard, 2003; Karnitz and Felts, 2007), but its 
importance has been demonstrated in the stability of existing proteins (Jinwal et al., 2011). 
Further studies are necessary to determine if either situation represents the predominant 
inhibitory effect of WA. 
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Interestingly, a recent study demonstrated that mutant Cdc37 lacking the C-
terminal/middle HSP90-association domain maintained cellular levels of client proteins and 
augmented the interaction between HSP90 and client Cdk4 despite diminished client protein 
interaction itself (Smith et al., 2013). However, this directly contrasts previous reports about the 
importance of the C-terminal/middle domain for association with HSP90 in maintaining the 
stability of client proteins like Raf-1 (Grammatikakis et al., 1999; Rao et al., 2001). It is possible 
that the client proteins evaluated have different co-chaperone requirements for interacting with 
HSP90 or can be maintained through Cdc37’s inherent chaperone activity given that only 
approximately half of mammalian Cdc37/Cdk4 complexes contain HSP90 (Dai et al., 1996). 
However, the latter is likely not the case here given the  reduced client affinity of the mutant 
Cdc37 despite maintained client levels (Smith et al., 2013). Cdc37 has also been shown to 
interact with other co-chaperone proteins, suggesting another way by which it can still join the 
HSP90 chaperone complex, although its ability to alter HSP90 ATPase activity and otherwise 
function properly through this indirect association is unknown (Abbas-Terki et al., 2002). 
Clearly, further study of this system is required to better understand the variations observed. 
Regardless of the nature of the HSP90/Cdc37 interaction, its disruption and the resulting 
cytotoxicity by exposure to WA and celastrol, as previously studied, demonstrate 
pharmacological proof-of-concept of this target (Zhang et al., 2008; Zhang et al., 2009; He et al., 
2013). 
While computational analysis revealed a potential binding site for WA on Cdc37 to 
disrupt the HSP90/Cdc37 interaction (Grover et al., 2011), IP studies with biotinylated WA 
showed that it actually bound to the C-terminus of HSP90 (Yu et al., 2010). The C-terminus of 
HSP90 is responsible for the association with various co-chaperones (Young et al., 1998; Sidera 
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and Patsavoudi, 2014), however, WA does not decrease HSP90 association with co-chaperones 
Hop or p23 but rather Cdc37 which interacts primarily on the N-terminus of HSP90 (Yu et al., 
2010; Eckl et al., 2013). This unexpected finding requires further study to explain but may be a 
result of WA-mediated direct steric hindrance, conformational alterations in HSP90 structure that 
prevent effective binding of Cdc37 but maintain HSP90 function, or changes in the ability of 
Cdc37 to associate with C-terminal co-chaperones. Interestingly, celastrol also binds to the C-
terminus of HSP90 to disrupt HSP90/Cdc37 interaction but fails to disrupt association with 
HSP70, Hop, or p23 (Zhang et al., 2009). Novobiocin, also known to associate with the C-
terminus, demonstrates completely opposite effects, suggesting specific sites of co-chaperone 
regulation on HSP90 (Yun et al., 2004). 
HSP90 represents an intriguing anti-cancer target given that it is endogenously expressed 
in all cells, typically accounting for 1-3% of the total cellular protein (Welch and Feramisco, 
1982; Workman et al., 2007; Moulick et al., 2011; Barrott and Haystead, 2013). However, most 
cancer cells demonstrate significantly greater sensitivity to HSP90 inhibitors than non-cancerous 
cells with sub-toxic doses resulting in anti-tumor efficacy. This is thought to likely be the result 
of several factors that frequently differ in cancer cells including upregulation of HSP90 protein 
and mRNA, enhanced basal activation of HSP90 through post-translational modifications and/or 
enhanced association with various co-chaperones and client proteins, and altered localization to 
the ectopic portion of the cell (Barrott and Haystead, 2013). These considerations for enhancing 
inhibitory selectivity of HSP90 alone would appear to translate well to the disruption of co-
chaperones such as Cdc37, particularly HSP90 dependency and localization. Further studies are 
necessary to identify whether WA affinity favors disruption of HSP90 and Cdc37 that are 
already associated or prevention of the initiation of the association. Treatment with WA in 
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several murine models demonstrates an appropriate therapeutic window against several cancer 
types with minimal off-target toxicity and shows the translatable promise of this approach (Vyas 
and Singh, 2014). 
WA also demonstrated the ability to induce cellular oxidation. AA was used as a non-
thiol antioxidant to evaluate the oxidative effects of WA independent of concerns that NAC may 
simply sequester WA, preventing the availability of free drug rather than actually directly 
reducing generated oxidation (Santagata et al., 2012; Vyas and Singh, 2014). AA at a previously-
identified effective concentration (100 µM) was capable of reducing total oxidative potential 
within U87 GBM cells but was unable to completely eliminate the effect like NAC. Similarly, 
the cytotoxicity of WA was completely blocked by NAC but not AA. These findings suggest that 
while oxidation does indeed play a part in the mechanism of WA, the generation of free reactive 
oxygen species likely does not have nearly as significant of an impact in the manifestations of 
WA as its thiol reactivity and thiol-mediated redox alterations. The observation that WA depletes 
GSH suggests that the oxidation may be a general effect of an altered redox state. Interestingly, 
overexpression of Cu,Zn-superoxide dismutase demonstrated a partial protective effect against 
WA treatment in breast cancer cells (Hahm et al., 2011). The same study suggested that WA-
mediated ROS generation and subsequent toxicity was a result of mitochondrial respiration 
inhibition, although the impact of the mitochondrial alterations on normal intrinsic/mitochondrial 
apoptotic pathway function, shown to be partially necessary for apoptosis following WA 
exposure (Grogan et al., 2014), was not evaluated. Taken together, these findings support an 
important role for oxidation following WA treatment but suggest it may be more critical for 
cytotoxicity in certain cancer types. 
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We have also previously demonstrated WA-mediated depletion of MGMT, a non-HSP90 
client protein with known susceptibility to oxidation (Fu et al., 2010; Ryu et al., 2012; Grogan et 
al., 2014). Similarly, GR has been shown to be modulated by redox alteration, especially with 
thiol-modifying agents (Carter and Ragsdale, 2014). Despite not requiring Cdc37 for its function 
and stability and maintaining association with HSP90, we demonstrated in the present study that 
GR is eventually depleted with WA treatment, suggesting either an extended role of WA as an 
HSP90 inhibitor beyond Cdc37 effects or oxidation-meditated proteotoxicity. Utilization of 
oxidative therapies to induce proteotoxicity has gained interest as an anti-cancer approach given 
the frequently altered redox states and exposure to increased cellular stress which can be 
exploited in cancer cells (Laurent et al., 2005; Cabello et al., 2007). 
Treatment with WA resulted in the accumulation of aggregated HSP90 of heterogeneic 
molecular weight in the triton insoluble fraction of the cell, often regarded as the biologically 
inactive compartment. Previous studies have suggested that chaperone proteins form disulfide 
bonds in response to oxidative insults (Cumming et al., 2004; Chen et al., 2008), and while the 
described homodimeric complex of HSP90 was not readily observed in this study, significant 
aggregation was noted. Further study will be necessary to determine whether this pattern of 
aggregation was related to dissociation from Cdc37 (showing direct interplay between the two 
proposed mechanisms of WA), a byproduct of oxidative stress, or misfolding and destabilization 
guided by direct WA binding. While Cdc37 plays a role in the appropriate client targeting for 
HSP90 and has been shown to localize in the cell for recruitment of HSP90-mediated refolding 
(Jinwal et al., 2011), it has not been shown necessary to promote HSP90 complex stability or 
intrinsic function. While pretreatment with NAC reduced or eliminated the general cytotoxicity 
of WA, it also prevented this alteration in HSP90 localization. Conversely, depletion of cellular 
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GSH through inhibition of γ-glutamylcysteine synthetase by BSO greatly enhanced this HSP90 
alteration. Together, these findings support an oxidative or thiol-reactive role of WA in 
promoting insoluble complexation of HSP90. Of note, BSO also enhanced general WA 
cytotoxicity in several additional cancer models (data not published). Combined with the 
observation that WA depleted GSH, this suggests that GSH plays a protective role against WA. 
Future studies are necessary to determine how basal cellular oxidation, GSH levels, and 
susceptibility to oxidative stress enhance or resist the cytotoxic sequelae of WA exposure. 
 Several early studies attempting to identify the mechanism of WA suggested that it 
functions through inhibition of the proteasome (Yang et al., 2007; Khan et al., 2012; Yang et al., 
2012). Our data suggests that the proteasome is still functionally intact and necessary for protein 
degradation at cytotoxically-relevant concentrations of WA. While the findings in these reports 
are likely accurate, they have consistently utilized concentrations of WA well-above those 
considered therapeutically relevant – including in cell-free models – to achieve modest 
proteasomal inhibition, suggesting that these findings may simply be off-target effects that 
manifest at high concentrations. Interestingly, our studies demonstrate direct inhibition of the 
HSP90 chaperone heterocomplex independent of Cdc37 in a cell-free system with an IC50 of 
<10µM (data not shown), well above physiologically relevant dosing but still lower than 
observed in the GR-reactivation cell lysate system. Combined, these findings indicate non-
specific targeting by WA at high concentrations and suggest caution is necessary during the 
interpretation of data at these levels.  
While the suggestion that HSP90 promotes protein refolding while HSP70 favors 
degradation oversimplifies the complex mechanism of the protein chaperone machinery, these 
generalizations accurately describe the accepted primary roles that these chaperones play in 
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protein homeostasis (Pratt et al., 2010). In the presence of oxidative stress, proteins are prone to 
misfold with greater frequency. Simultaneous inhibition of the HSP90 axis, as observed with 
WA, would suggest the accumulation of many aberrant proteins requiring proper degradation to 
limit cellular cytotoxicity. Previous studies have identified upregulation of HSP70, as observed 
in the present study, to be a biomarker of HSP90 inhibition and/or oxidative stress (Zhang et al., 
2006; Workman et al., 2007; Ansari et al., 2011; Qiao et al., 2012), acting as a compensatory 
mechanism for protein dysregulation and promoting this necessary degradation. Indeed, 
inhibition of HSP70 or the proteasome in the presence of traditional HSP90 inhibitors promotes a 
synergistic effect (Minnnaugh et al., 2004; Ma et al., 2014). Given the promotion of proteasome-
mediated protein degradation induced by WA, the addition of a proteasome inhibitor was a 
logical progression in the development of a clinical utility for WA. Here, we further demonstrate 
the efficacy of this approach with WA, an oxidizing inhibitor of the HSP90/Cdc37 association. 
This suggests a potential clinical utility for combining a co-chaperone disruptor with already 
established chemotherapeutic agents like the proteasome inhibitor bortezomib. While the value 
of this combination therapy was demonstrated in highly aggressive solid tumor cervical and 
brain cancer cell lines, perhaps the greatest early clinically applicability lies in the treatment of 
multiple myeloma (MM). Proteasome inhibitors have been approved for use as standard agents 
in the treatment of MM (Chauhan et al., 2005), and an early human trial with combination 
bortezomib and the HSP90 inhibitor tanespimycin, a promising formulation of 17-AAG with a 
Cremophor-containing vehicle (Modi et al., 2007; Modi et al., 2011), has shown promise 
(Richardson et al., 2011). Given the enhanced efficacy of many agents in combination with 
traditional HSP90 inhibitors, further exploration of combination therapy with WA in alternative 
models is also warranted (Neckers, 2002). 
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 The studies here provide an important framework for further defining the mechanisms by 
which WA induces significant protein depletion. We demonstrate that WA acts to produce thiol-
mediated oxidation and disrupt the interaction between HSP90 and Cdc37 but fails to inhibit 
intrinsic HSP90 function assessed by HSP90-mediated GR steroid binding. Ultimately, this shifts 
the HSP90/HSP70 balance toward HSP70-domination with associated protein degradation that 
can be cytotoxically potentiated therapeutically with simultaneous inhibition of the proteasome. 
While further pre-clinical studies will be necessary to fully evaluate the therapeutic potential of 
WA alone and in combination with proteasome inhibitors, current findings support the 
translational utility of this approach. 
  
202 
 
Chapter 6 
 
Withaferin A disrupts the cellular DNA-damage response to 
promote radiosensitization 
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6.1 Abstract 
 
Radiation therapy (RT) plays in important role in the treatment of cancer for an estimated 
50% of patients, including as a standard therapy for the brain tumor glioblastoma multiforme 
(GBM). Withaferin A (WA) is a naturally-derived steroidal lactone that has demonstrated 
significant intrinsic anti-cancer activity. Several preliminary reports have identified WA as a 
potential radiosensitizer, but the underlying mechanism has remained largely unexplored. In this 
study, WA potentiated or otherwise enhanced the anti-proliferative activity of RT in both U87 
GBM and HeLa cervical cancer cells. These findings were associated with reduction of cells in 
the DNA-synthesis phase of the cell cycle and increased levels of cell cycle checkpoint inhibitors 
p21 and p27 with combination therapy through 72 h. Combination therapy failed to enhance 
PARP cleavage and LC3B conversion, demonstrating that the effect was not mediated through 
apoptosis or autophagy. Treatment with WA reduced total levels of DNA-damage response 
(DDR) proteins involved in damage recognition (Mre11, p95/NBS1, Rad50), signaling (ATM, 
Chk1), and repair through homologous recombination (BRCA1, BRCA2, Rad51), non-
homologous end-joining (DNA-PKcs, XLF, Ku70, and Ku80), and mismatch repair (MLH1, 
MSH2, MSH6) in both U87 and HeLa. This protein depletion was an expansion of that observed 
with traditional HSP90 inhibitor 17-AAG. WA differentially modulated normal the normal 
recognition response to RT-mediated DNA damage with U87 and HeLa cells showing a 
reduction and an increase of p-H2A.X compared to RT alone, respectively, with WA 
pretreatment. Both lines showed alterations of normal signal transduction through ATM and 
Chk1. WA pretreatment also enhanced the level of RT-induced double strand DNA damage after 
4 h measured by a neutral comet assay and was associated with functional inhibition of 
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homologous recombination through a DR-GFP reporter. These findings demonstrate that WA-
driven radiosensitization is a direct result of an impaired DDR. Given the widespread success of 
WA as a monotherapy in numerous cancer models and the large therapeutic spectrum for RT, 
further translational exploration of WA as an adjuvant agent is warranted. 
  
6.2 Introduction 
 
In recent years, significant effort has been invested in the development of more effective 
therapeutic and diagnostic techniques to better the outcomes of cancer patients. While numerous 
advances have adjusted the treatment paradigms of various malignancies, the management and 
treatment of many cancers depends on the use of radiation therapy (RT), including an indication 
in an estimated 50% of patients (Delaney et al., 2005). Given that survival rates following RT, 
which in many cases represents a component of the base available approved therapeutic regimen, 
remain low for certain cancer types like glioblasoma multiforme (GBM), any means by which to 
elevate RT efficacy would be critical in helping a wide population of patients (Begg et al., 2011). 
With the widespread importance and critical role of RT, efforts have been made to 
maximize its therapeutic potential through adjustments of dose intensity and fractionation as well 
as addition of chemotherapeutics. Such therapies focus on modulating the DNA damage 
response (DDR), signal transduction pathways critical for radioresistance, and oxygen levels 
necessary for generating an effect (Begg et al., 2011). Additionally, several commonly utilized 
DNA-modifying anticancer agents, including 5-fluorouracil (5-FU) and temozolomide (TMZ), 
have shown radiosensitization effects with unclear mechanisms. Similar agents like gemcitabine 
demonstrate off-target inhibition of HR as a mechanism of radiosensitization (Byfield, 1989; 
205 
 
Wachters et al., 2003; Chakravarti et al., 2006; Bobola et al., 2010). Other agents that directly 
target elements of the cellular DDR, including the recognition and repair of the damage, have 
generated significant interest as well (Begg et al., 2011). 
RT utilizes the energy of ionizing radiation (IR) to induce DNA lesions in targeted cells. 
Genomic instability through double-strand DNA (dsDNA) breaks (DSBs) is largely recognized 
as the primary cytotoxic event of IR, but other lesions such as single-strand DNA (ssDNA) 
breaks (SSBs) and damage to individual bases has been reported. DSBs are repaired by two 
primary pathways: homologous recombination (HR) and non-homologous end joining (NHEJ). 
While HR maintains the fidelity of the DNA sequence at the break site, NHEJ simply anneals 
two ends of DNA without respect to sequence homology and is therefore intrinsically mutagenic. 
The cellular response to DNA damage, including that induced by IR, involves an 
immensely complex network of signaling pathways that recognize and repair the damage with 
associated arrest of the cell cycle or induction of death (Lamarche et al., 2010; Baskar et al., 
2012). Very generally, following DSBs, damage is recognized by the MRN complex (Mre11, 
Rad50, p95/NBS1) which functions to coordinate signal transduction through ATM to arrest cell 
growth at specific cell cycle checkpoints. This complex also functions directly and indirectly to 
mediate dsDNA damage repair through HR and NHEJ (Weterings and Chen, 2008; Krejci et al., 
2012). Appropriate coordination of these efforts in normal tissue usually results in either 
effective DNA damage repair and cell survival or failure to appropriately correct the insult 
followed by the controlled induction of cellular senescence or death.  
Several studies have identified the potential utility of withaferin A (WA), a 28-carbon 
steroidal lactone identified from genera of the Solenceae plant family with intrinsic cytotoxicty, 
as a potential radiosensitizer (Vanden Berghe et al., 2012; Vyas and Singh, 2014). One study that 
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utilized a knockout model suggested WA may alter NHEJ (Devi et al., 2008), while another 
group identified enhanced oxidation and modulation of the mitogen-activiated protein kinase 
(MAPK) and Akt pathways as markers of combination therapy efficacy (Yang et al., 2011b; 
Yang et al., 2011a). However, to date, the underlying mechanism behind this effect has not been 
explored. Studies from our group and others have identified two key components of WA 
monotherapy that are hypothesized to lead to the inhibition and modulation of many oncogenic 
proteins that have been observed: oxidation and inhibition of the HSP90 axis through disruption 
of the HSP90/Cdc37 association (Malik et al., 2007; Widodo et al., 2010; Yu et al., 2010; Hahm 
et al., 2011; Mayola et al., 2011; Santagata et al., 2012; Grogan et al., 2013). Indeed, direct 
inhibition of HSP90 has been previously noted to function in a radiosensitizing role (Dote et al., 
2006; Kabakov et al., 2010; Ko et al., 2012; Stecklein et al., 2012), suggesting a potential 
mechanism by which WA may function and a novel role for disruption of Cdc37. 
In this study, we identify WA as a potent radiosensitizer of two highly aggressive cancer 
cell lines, the GBM U87 and the cervical cancer HeLa with the latter being utilized as a known 
model of highly competent HR, through depletion of key DDR proteins that prevent the proper 
recognition and repair of DSBs. 
 
6.3 Materials and methods 
 
6.3.1 Cell culture and reagents 
 
The human GBM cell line U87 was generously provided by Dr. Jann N. Sarkaria (Mayo 
Clinic, Rochester, MN), and the human cervical cancer line HeLa was obtained through the 
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American Type Culture Collection (ATCC; Manassas, VA). These cell lines were chosen given 
their DNA damage repair preferences: HeLa is more competent at HR than GBM cells while the 
latter favor NHEJ after RT (Kachhap et al., 2001; Golding et al., 2004; Ransburgh et al., 2010; 
Quiros et al., 2011; Lim et al., 2012; Stecklein et al., 2012). Both cell lines were grown in 
Dulbecco’s modified Eagle’s medium (DMEM #11995-065; Gibco, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) and 1% 
penicillin/streptomycin (Gibco), at a 37 °C humidified atmosphere of 5% CO2 in air. Medium for 
HeLa cells was further supplemented with 2% L-glutamine (200 mM; Gibco), 1% MEM-vitamin 
(100x; Hyclone, Logan, UT), and 1% MEM nonessential amino acids (Sigma Aldrich). Where 
indicated, cells were irradiated with a Kimtron IC-320 orthovoltage x-ray device (Oxford, CT) at 
a calibrated dose-rate of 452.23 cGy/minute. WA was isolated as previously described (Samadi 
et al., 2010b). Propidium iodide (PI), RNase, and puromycin dihydrochloride were acquired from 
Sigma-Aldrich, and 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) was obtained from 
LC Laboratories (Woburn, MA). 
 
6.3.2 Clonogenic assay 
 
HeLa and U87 cells in exponential growth phase were plated in 6cm dishes at densities 
expected to yield approximately 20-50 colonies per plate following exposure to WA, RT, or 
combination therapy based on preliminary studies. After 6 h, plates were changed to WA- or 
DMSO-containing media and allowed to incubate for 2 h before exposure to 2-4 Gy of radiation. 
24 h post-RT, media was changed on each plate to remove WA. Cells were incubated for 10-14 d 
at which time they were gently washed with 1x phosphate-buffered saline (PBS), stained and 
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fixed with Coomassie brilliant blue, and quantified. Colonies were considered viable if they 
consisted of approximately > 50 cells. 
 
6.3.3 Cell cycle analysis 
 
U87 and HeLa cells were plated to ~20-50% confluency depending on the collection 
timepoint and treated with WA for 2 h followed by 2.5-5 Gy RT. After 24-72 h, cells were 
collected, pelleted, fixed/permeablized in 70% ice-cold ethanol and stored at -20 °C. Cells were 
subsequently stained with PI as previously described (Grogan et al., 2013) and analyzed by flow 
cytometry on a Beckman Coulter CyAn ADP analyzer (Brea, CA). Only living cells without 
DNA fragmentation were gated for analysis. 
 
6.3.4 Immunoblotting 
 
Cells were plated to appropriate confluencies as outlined for cell cycle analysis and 
treated with various concentrations of WA or 17-AAG. Where indicated, cells were irradiated 
with 5-10 Gy 2 h post-WA. After 1-72 h, cells were trypsinized and washed twice with 1x PBS. 
Proteins were isolated in a HEPES-based lysis buffer, quantified, separated by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), and transferred onto a Hybond 
nitrocellulose membrane as previously described (Samadi et al., 2011; Grogan et al., 2014). 25-
50 µg of protein sample was loaded per lane with equal loading and transfer of sample confirmed 
by total actin levels. Studies were repeated for accuracy. 
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Primary antibodies kits were acquired from Cell Signaling Technology (Danvers, MA) 
and used as per the manufacturer’s recommendations: DNA damage (#9947), double stand 
breaks (DSB) repair (#9653), MRN complex (#8344), mismatch repair (#9786), and Rb (#9969). 
Additional primary antibodies obtained from Cell Signaling Technology included ATM (#2873; 
1:1000), Chk1 (#2360; 1:1000), Chk2 (#2662; 1:1000), Ku70 (#4588; 1:1000), BRCA1 (#9010; 
1:500), BRCA2 (#9012; 1:1000), p27 (#2552; 1:1000), cyclin B1 (#4138; 1:1000), cyclin D1 
(#2926; 1:500), cyclin E1 (#4129; 1:1000), poly(ADP-ribose) polymerase (PARP; #9542; 
1:1000), and LC3B (#3868; 1:1000). Rad51antibody (#ab213; 1:1000) was purchased from 
Abcam (Cambridge, England). p-H2A.X antibody (Ser139; #613401; 1:1000) was acquired from 
Biolegend (San Diego, CA). Total actin antibody (#MAB1501; 1:50000) was obtained from 
EMD Millipore (Billerica, MA). The primary antibody for p21 (#sc-6246; 1:200) and the donkey 
anti-rabbit IgG HRP (sc-2313; 1:2500-1:10000) and goat anti-mouse IgG HRP (sc-2005; 1:5000-
1:20000) secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). 
 
6.3.5 Immunocytochemistry (ICC) 
 
U87 and HeLa cells were plated to ~50% confluency in 8-well chamber slides (Nalge 
Nunc International, Penfield, NY) and treated with 2.5 µM WA for 2 h. Slides then received 10 
Gy RT. After 1 h, cells were fixed in 4% PBS-buffered paraformaldehyde at room temperature 
for 30 minutes and washed 3x with 1x PBS. Cell membranes were de-permeablized for 15 
minutes in 1x PBS containing 0.3% triton X-100 and subsequently blocked in 5% goat serum 
(Cell Signaling Technology) in 1x PBS containing 0.15% triton X-100 shaking for 1 h. Cells 
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were exposed to p-H2A.X (Ser139) primary antibody (1:500; Biolegend #613401) in blocking 
solution overnight at 4 °C. After three washes with 1x PBS, secondary antibody (1:1000; anti-
mouse IgG Fab2 Alexa Fluor 488, Cell Signaling #4408) was added to each well for 1h at room 
temperature followed by an additional 3 washes. Coverslips were mounted on each slide with 
ProLong Gold Antifade with DAPI (Cell Signaling Technology), allowed to dry, and visualized 
on a Leica DM IRB microscope (Wetzlar, Germany) with Metamorph Basic software (version 
7.7.3.0.; Molecular Devices; Sunnyvale, CA) 
 
 
6.3.6 Comet assay 
 
U87 cells were assessed for dsDNA damage by a neutral comet assay. Cells were plated 
to 50% confluency and treated with WA. After 12 h, cells were irradiated 5 Gy via the 
orthovoltage device and allowed to incubate for 4 h. Evaluation of DNA damage through 
migration was conducted according to the manufacturer’s instructions (Trevigen, Gaithersburg, 
MD). Briefly, cells were collected, combined with agar, and plated on slides (~500 cells/slide). 
Agar was solidified at 4 °C for 10 minutes, and slides were immersed in a lysis buffer solution 
for 1 h at room temperature. Slides were then washed with neutral electrophoresis buffer and 
underwent electrophoresis for 45 minutes at 4 °C with the recommended voltage. At room 
temperature, slides were then immersed in DNA precipitation buffer for 30 minutes followed by 
70% ethanol for 30 minutes. Samples were dried at 37 °C for 15 minutes, stained with SYBR 
Gold (Molecular Probes, Eugene, OR) as outlined in the instructions, and visualized on the Leica 
DM IRB microscope with Metamorph Basic software. Comets from eight independent visual 
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fields per sample were quantified with ImageJ software (version 1.46r; Bethesda, MD) using the 
automated scoring of the OpenComet software macro (version 1.3) (Gyori et al., 2014). 
 
6.3.7 DR-GFP reporter assay 
 
 The DR-GFP reporter construct, pCAGGS empty vector, and pCBASce I-SceI vector 
were generously provided by Dr. Maria Jasin (Memorial Sloan-Kettering Cancer Center, New 
York, NY). Adenovirus was kindly provided by Dr. Jeffrey Parvin (The Ohio State University, 
Columbus, OH). The production and titering of HA-tagged I-SceI or empty vector adenovirus 
was described previously (Stecklein et al., 2012). U87 and HeLa cells were transfected with the 
DR-GFP and selected with 2-5 µg/mL puromycin. Surviving colonies were collected and 
expanded under puromycin selection. The empty control vector or HA-I-SceI construct (~1 
µg/1x10
5
 cells) were introduced into the U87-DR-GFP stable transfectants via electroporation 
using the Amaxa Cell Line Nucleaofector Kit V according to the manufacturer’s instructions 
(Lonza, Bazel, Switzerland). The vectors were introduced into the HeLa-DR-GFP cells via the 
adenovirus. Both cells were immediately plated and treated with DMSO or various 
concentrations of WA. After 72 h, cells were collected, and HR was evaluated visually by 
microscopy and by determining the number of GFP+ cells on the Beckman Coulter CyAn ADP 
analyzer. Western blotting for HA was used to confirm that WA had no effect on the expression 
level of the HA-tagged I-SceI. 
 
6.3.8 Data and statistical analysis 
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Comparisons of differences between two or more means/values were determined by 
Student’s unpaired t-test via the statistical functions of GraphPad Prism 6 (version 6.02; 
GraphPad Inc., San Diego, CA) or Microsoft Excel 2010 software (version 14.0.6129.5000; 
Microsoft Corporation Redmond, WA). Densitometry, where indicated, was completed using 
ImageJ software (version 1.46r; Bethesda, MD). Data are presented as mean values with error 
bars denoting standard deviation or standard error of the mean where appropriate. The levels of 
significance were set at *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
6.4 Results 
 
6.4.1 WA potentiates the cytotoxicity of radiation therapy 
 
Combinational efficacy of WA and RT was evaluated by the clonogenicity survival assay 
for single cell colony formation (Figure 6-1). Plated cells of appropriate number were pretreated 
with WA for 2 h followed by RT at various doses, washed after 24 h, and quantified after a 
growth period of 10-14 days. WA demonstrated the ability to potentiate or otherwise enhance the 
anti-proliferative effects of RT in both U87 and HeLa cells at concentrations as low as 125 nM. 
U87 cells showed no significant changes in cell survival between control and 2 Gy alone groups 
with a colony growth efficiency reduction of only 1.4% (p = 0.947). The addition of 125 nM and 
250 nM WA reduced colony formation efficiency by 10.8% (p = 0.538) and 74.5% (p = 0.003) in 
U87 cells not treated with RT and 57.3% (p = 0.010 compared to RT only; p < 0.001 compared 
to WA only) and 84.8% (p = 0.002 compared to RT only; p = 0.026 compared to WA only) in 2 
Gy treated cells, respectively. 4 Gy RT reduced colony formation efficiency to 29.1%, however,  
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Figure 6-1.  
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Figure 6-1. U87 and HeLa cells were treated with WA and irradiated 2 h later. After 10-14 d, 
surviving cells demonstrating growth clonogenicity through the formation of a colony were 
scored. WA potentiated or otherwise enhanced the anti-proliferative effects of RT in both U87 
and HeLa cells at concentrations as low as 125 nM. Notably, no significant decrease in cell 
survival was observed with 2 Gy RT in U87 and 125 nM WA in HeLa. Addition of the other 
agent in each line significantly potentiated the anti-proliferative effect. *p < 0.05, **p < 0.01, 
***p < 0.001 (Statistics indicate significant difference from the WA alone treatment.) 
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the relative enhancement of treatment efficacy mediated by WA was comparable to that of the 2 
Gy treated cells. HeLa cells showed a similar pattern of WA-mediated radiosensitization. 2 Gy 
and 4 Gy RT reduced colony formation by 13.2% (p = 0.002) and 26.7% (p < 0.001) compared 
to control, respectively, while 125 nM WA reduced this efficacy by 7.7% (p = 0.126). The 
combination of 125nM WA with 2 Gy RT reduced colony formation by 35.0% (p < 0.001 
compared to control and WA only) and 25.2% relative to 2 Gy alone (p < 0.001). Similarly, The 
combination of 125 nM WA with 4 Gy RT showed additional efficacy, reducing colony 
formation efficiency by 67.7% (p < 0.001 compared to control and WA only) and 56.0% relative 
to 4 Gy alone (p < 0.001). Further extension of these WA sensitizing effects were observed at 
higher WA concentrations with enhanced combinational efficacy compared both to control and 
when normalized to individual RT groups. 
 
6.4.2 Combination WA and RT favors reduced cell cycling but not enhanced apoptosis or 
autophagy 
 
To determine the nature of the reduced clonogenicity following combination WA and RT 
treatment for 24-72 h, cell cycle evaluation was conducted by PI staining and subsequent flow 
cytometry to quantify levels of DNA. As demonstrated previously, WA treatment resulted in an 
increased percentage of cells in the G2/M-phase of the cell cycle with minimal changes in S-
phase percentage (Supplemental Figure 6-1) (Grogan et al., 2013).  RT-treated U87 and HeLa 
cells both demonstrated small reductions in S-phase percentage, maximally at 24 h or 48 h, but 
showed variable shifts with cell predominantly moving to G0/G1 (2N DNA) in U87 and G2/M 
(4N DNA) in HeLa. Combination of WA and RT produced enhanced depletion of S-phase cells 
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at 24 h and maintained the depletion at 72 h despite normalizing levels in the RT-only groups in 
both U87 and HeLa cells (Figure 6-2A). Depletion of S-phase cells was primarily associated 
with maintained or minimally decreased levels of G0/G1-phase cells compared to WA-only with 
displacement to G2/M after 24 h. U87 cells demonstrated maintained elevation of G0/G1-phase 
cells at 24 h only with combination therapy, consistent with a predominant response to RT. 
At 24 h, control HeLa cells displayed 22.3% of cells in S-phase. Treatment with 250 nM 
WA maintained the S-phase fraction at 21.8% (p = 0.205), while 5Gy RT reduced S-phase to 
19.5% (p = 0.010). Combined, the treatment yielded 16.1% of cells in S-phase (p = 0.006 vs. 
control; p = 0.002 vs. WA; p = 0.005 vs. RT). This efficacy was even more pronounced after 72 
h in HeLa cells with respective depletion of the S-phase fraction of WA, RT, and WA+RT to be 
1.7% (p = 0.075), 4.5% (p = 0.036), and 10.6% (p = 0.019 vs. control; p = 0.022 vs. WA; p = 
0.002 vs. RT) (Figure 6-2A). Comparable findings were observed in U87 cells, notably at 24 h 
when the percentage of S-phase cells increased by 0.5% following 500 nM WA (p = 0.648 vs. 
control) but was decreased by 3.5% with 2.5 Gy RT (p = 0.064 vs. control) and 6.8% with 
combination therapy (p = 0.045 vs. control; p = 0.019 vs. WA; p = 0.025 vs. RT) (Figure 6-2A). 
Reduction in S-phase percentage was maintained at 72 h post-treatment. Complete changes in 
G0/G1 and G2/M levels are presented in Supplemental Figure 6-1. 
Shifts in the cell cycle at different levels were then evaluated molecularly through 
Western blotting for cyclins B1 (G2/M transition), D1 (G1/S transition), E1 (G1/S transition) and 
cyclin-dependent kinase inhibitors p21/cip1 (G1/S transition) and p27/kip1 (G1/S transition) 
(Sgambato et al., 2000; Cazzalini et al., 2010) (Figure 6-2B). Consistent with the induction of 
G2/M cell cycle arrest, WA treatment in U87 increased levels of cyclin B1, but this was not 
observed in HeLa at the moderate concentrations tested. Cyclin B1 was also mildly induced with  
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Figure 6-2. A) Cell cycle analysis was conducted by propidium iodide staining and subsequent 
flow cytometry following combination WA and RT treatment for 24-72 h. RT-treated U87 and 
HeLa cells both demonstrated small reductions in S-phase percentage, maximally at 24 h or 48 h, 
but combination of WA and RT produced enhanced depletion of S-phase cells at 24 h and 
maintained the depletion after 72 h despite normalizing levels in the RT-only groups in both 
cells. B) Shifts in the cell cycle at different levels were then evaluated molecularly through 
Western blotting for cyclins B1 (G2/M transition), D1 (G1/S transition), E1 (G1/S transition) and 
cyclin-dependent kinase inhibitors p21/cip1 (G1/S transition) and p27/kip1 (G1/S transition). 
Consistent with G2/M arrest, WA alone induced elevated cyclin B1 in U87 cells but was 
abrogated with RT. While Cyclin E1 was largely unchanged, cyclin D1 was elevated in a WA 
dose-dependent manner at 24-48 h in both cell lines. At 24 h in both lines, small increases in 
cyclin D1 were noted with the addition of RT after WA pretreatment. Negative regulators of the 
G1/S transition, p21 and p27, demonstrated notable induction with combination WA and RT 
compared to either agent alone in a time-dependent manner. C) Treatment with RT diminished 
total levels of total Rb protein and phosphorylation at Ser780, Ser795, and Ser807/811 after 6-24 
h. Pretreatment with WA further enhanced this decreased Rb phorphorylation with observable 
depletion of Ser780 and Ser795 at 6h and Ser807/811 at 24h. D) Combination of WA with RT 
failed to enhance apoptotic PARP cleavage or the autophagy-mediated conversion of LC3B 
compared to either agent alone, suggesting the cytotoxic effect of combination therapy was not 
through these mechanisms. *p < 0.05, **p < 0.01, ***p < 0.001 
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5 Gy RT in U87 through 24h and in HeLa through 6 h. WA-mediated induction of cyclin B1 in 
U87 cells was repressed with RT co-treatment. Cyclin E1 was largely unchanged with small RT-
induced elevation at 6 h and 1 µM WA-induced cell-dependent increases at 24-48 h. Cyclin D1 
was elevated in a WA dose-dependent manner at 24-48 h in both cell lines. At 24 h in both lines, 
small increases in cyclin D1 were noted with the addition of RT to WA, suggesting a potential 
block in the G1/S transition and an enhanced attempt to enter S-phase, consistent with the 
reduced S-phase fraction noted by flow cytometry findings. 
Levels of p21 and p27, negative regulators of the G1/S transition which function to block 
cyclin-Cdk1/2/4/6 activity (Sgambato et al., 2000; Cazzalini et al., 2010), supported this claim, 
demonstrating notable induction with combination WA and RT compared to either agent alone 
(Figure 6-2B). p21 was significantly induced by RT in U87 after only 6 h as previously reported 
(Lee et al., 2011) and mildly increased in HeLa. Induction of p21 by WA alone was not observed 
until 24 h in HeLa and 48h in U87, and the enhanced combinational effect, particularly 
distinguishable at 0.5 µM WA, was consistent with these timepoints. p27 induction was driven 
by WA in a dose-dependent manner in both U87 and HeLa cells. Combination with radiation 
enhanced this induction at 6 h but failed to show notable benefit at later timepoints except with 1 
µM WA in HeLa at 48 h as total induced levels were nearing depletion, suggesting that 
predominant early combinational effects are mediated by p27 while long-term responses are p21-
driven. 
 The retinoblastoma protein (Rb) prevents progression from G1- to S-phase through 
inactivation of the transcription factor E2F (Cazzalini et al., 2010). Because cyclin-Cdk1/2/4/6 
promotes inactivation of Rb through hyperphosphorylaton and is inhibited by p21 and p27, both 
of which were elevated with WA+RT therapy, the downstream status of Rb was evaluated in 
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U87 (Figure 6-2C). Consistent with a previous report demonstrating the activated status of Rb 
(Orr et al., 1997), treatment with RT paradoxically diminished total levels of the protein. RT also 
decreased inhibitory phosphorylation of Rb at Ser780, Ser795, and Ser807/811 after 6-24 h. 
Pretreatment with WA further decreased Rb phorphorylation with observable depletion of 
Ser780 and Ser795 at 6 h and Ser807/811 at 24 h. Phosphorylation of Ser795 was nearly 
completely eliminated in all RT treatment groups at 24 h. Notably, 1 µM WA alone increased 
phosphorylation at all measured sites after 24 h, suggesting a single agent-mediated inverse 
effect when not used in combination with RT. 
 To evaluate whether enhanced apoptosis and/or autophagy also played a role in the 
cytotoxicity of combination therapy, cleavage of PARP (apoptosis marker) and conversion of 
LC3B-I to LC3B-II (autophagy marker) were examined by Western blotting from 24-72 h 
(Figure 6-2D). PARP cleavage was noted with increasing concentrations of WA in both cell lines 
but only in HeLa with RT as previously reported (Eriksson et al., 2009; Lee et al., 2011; Grogan 
et al., 2013). WA+RT failed to increase PARP cleavage above RT alone in HeLa cells and 
decreased WA-mediated PARP cleavage in U87 cells. Despite dose-dependent increases with 
WA alone, conversion of LC3B-I to LC3B-II did not demonstrate a consistent pattern of 
enhancement with combination therapy. In U87 cells at 48-72 h, 1 µM WA with RT 
demonstrated reduced levels of LC3B-II compared to WA alone, and by 72 h in HeLa cells, 
LC3B-II levels were consistently depleted compared to control. These findings suggest that 
combination of WA and RT favors a mechanism of diminished cellular replication over 
apoptosis or autophagy in U87 and HeLa cells.  
 
6.4.3 WA induces depletion of key proteins in HR, NHEJ, and MMR 
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The recognition and repair of DNA damage, particularly double-stranded breaks, 
involves the coordination of numerous proteins in multiple pathways with known overlap. For 
the purposes of this study, several well-defined proteins necessary for the DSB response were 
broadly categorized: damage recognition and signal transduction (Mre11, p95/NBS1, Rad50, 
ATM, Chk1, Chk2), homologous recombination repair (Rad51, Rad52, BRCA1, BRCA2), and 
non-homologous end-joining (DNA-PKcs, Ku70, Ku80, and XLF). WA demonstrated the ability 
to deplete key proteins involved in all dsDNA damage response categories as well as mismatch 
repair (MMR) in HeLa and U87 cells (Figure 6-3). 17-AAG was used as a control HSP90 
inhibitor at both timepoints to demonstrate the potential direct or indirect role of HSP90 in the 
stability of each protein. While most proteins depleted by 17-AAG demonstrated a similar 
pattern with WA, the reverse was not explicitly observed. HeLa cells expressed basally lower 
levels of NHEJ proteins DNA-PKcs and XLF while U87 cells exhibited lower expression of the 
HR protein Rad52, consistent with previous reports that HeLa is more competent at HR than 
glioma cells while the latter favor NHEJ after RT (Kachhap et al., 2001; Golding et al., 2004; 
Ransburgh et al., 2010; Quiros et al., 2011; Lim et al., 2012; Stecklein et al., 2012). Each line has 
demonstrated the ability to complete both HR and NHEJ. 
At 24-48 h, dose-dependent decreases in the expression of recognition and transduction 
proteins Mre11, p95/NBS1, Rad50, ATM, and Chk1 were observed in both cell lines evaluated 
with depletion of Chk2 in only U87 cells. Similarly, total levels of HR proteins BRCA1, 
BRCA2, and Rad51 were also decreased following escalated exposure to WA but depletion of 
Rad52 was limited to HeLa.  Notably, reductions of ATM, Chk1, and BRCA1 in both lines 
occurred at the lower WA concentrations evaluated (1-2.5 µM) after 24 h, suggesting enhanced  
222 
 
Figure 6-3.  
  
223 
 
Figure 6-3. Treatment with increasing concentrations of WA for 24-48 h reduced total levels of 
DNA-damage response (DDR) proteins involved in damage recognition (Mre11, p95/NBS1, 
Rad50), signaling (ATM, Chk1), and repair through homologous recombination (BRCA1, 
BRCA2, Rad51), non-homologous end-joining (DNA-PK, XLF, Ku70, and Ku80), and 
mismatch repair (MLH1, MSH2, MSH6) in both U87 and HeLa. This protein depletion was an 
expansion of that observed with 1 µM of the traditional HSP90 inhibitor 17-AAG. 
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and consistent selectivity for these targets. Reduced expression of these three proteins was also 
observed with 17-AAG. NHEJ proteins XLF, Ku70, Ku80 were depleted with WA dose 
escalation in both cells lines after 24-48 h, however, the effect in Ku70/80 was observed at 2.5 
µM WA in HeLa (lower baseline expression) compared 10µM WA in U87 (higher expression). 
Higher DNA-PKcs expression was detected in U87 cells and was decreased at 1 µM WA. WA-
mediated decreases in NHEJ protein levels corresponded with the effects of 17-AAG treatment. 
MMR proteins MLH1, MSH2, and MSH6 showed reduction in expression at 2.5 µM WA at 24 h 
with complete protein ablation by 5-10 µM in both HeLa and U87 cells. Treatment with 17-AAG 
induced minimal MMR protein reduction after 24 h, however, this effect was more pronounced 
in HeLa cells after 48 h. Overall, most proteins evaluated demonstrated reduced or absent 
expression at 10 µM WA, suggesting limited selectivity of effect at high concentrations. HeLa 
cells also demonstrated enhanced response to 1µM 17-AAG compared to U87 cells which was 
confirmed by a cell viability assay (data not shown). 
 
6.4.4 WA alters radiation-induced DNA damage recognition 
 
 Following the induction of dsDNA damage and recognition by the MRN complex, ATM 
is recruited to the site of the break where it is phosphorylated and can then phosphorylate 
Chk1/Chk2 for cell cycle checkpoint activation and H2A.X at the site of damage for recruitment 
of repair proteins (Lamarche et al., 2010). Normalized phosphorylation of ATM at Ser1981 was 
measured to evaluate the response to RT-mediated DNA damage following WA pretreatment. 
Compared to control 1 h post-RT (5 Gy in U87; 10 Gy in HeLa), p-ATM was induced 15.4-fold 
in U87 and 8.8-fold in HeLa. The presence of 1 µM WA reduced this activation 56.3% and 
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14.9% in the two lines, respectively (Figure 6-4A). By 6 h, reduction of ATM activation by WA 
was no longer observed in U87 cells, showing a delayed enhancement of this phosphorylation 
with combination therapy. In HeLa cells, despite diminished total activation of ATM after 6h 
(2.2-fold above control) and 24 h (1.89-fold above control), WA 1 µM WA reduced this 
activation 66.2% and 74.6%, respectively, showing a delayed response to 2 h WA pretreatment. 
U87 cells demonstrated increased p-ATM with WA exposure after 24 h, but this still 
demonstrated a 33.6% and 16.9% reduction in the residual p-ATM induced by RT (5.09-fold 
above control) with 0.5 µM and 1 µM WA, respectively, by despite the increase induced by 
combination therapy at 6 h. 
 To further evaluate the downstream effects of altered ATM signaling, normalized 
phosphorylation of Chk1 at Ser296, an autophosphorylation site requiring previous ATM-
mediated signaling, was measured (Okita et al., 2012) (Figure 6-4A). Minimal changes were 
observed in U87 cells 1 h post-RT with slight elevation of p-Chk1. After 6 h, however, total RT-
mediated induction was 2.82-fold compared to control and was reduced by 58.5% with 1µM WA 
pretreatment, demonstrating a delayed response compared to p-ATM. Despite relative WA-
mediated reductions in p-ATM largely manifesting at 6 h in HeLa cells, induction of p-Chk1 by 
RT at 1 h (2.46-fold above control) was reduced by 40.2% with 1 µM WA pretreatment, 
suggesting WA-mediated inhibition of signal transduction. Overall, high induction of p-Chk1 at 
1 h corresponded with the largest levels of p-ATM 1h post-RT. Induction by RT at 6 h was 
reduced to 1.74-fold above control and only slightly diminished with WA pretreatment. 
 Phosphorylation of H2A.X (Ser139) is regarded as a marker of DNA damage for 
recruitment of repair machinery and is mediated, at least in part, by the activity of ATM 
(Lamarche et al., 2010). Recognition of DNA damage was evaluated by immunocytochemistry  
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Figure 6-4. A) WA pretreatment disrupted the normal signal transduction response following 
RT. RT (5 Gy in U87; 10 Gy in HeLa) initiated phosphorylation of ATM (Ser1981) and 
downstream Chk1 (Ser296) at 1-6 h post-irradiation. Pretreatment with WA altered the normal 
signaling response with reduction in ATM and Chk1 phosphorylation in a dose- and time-
dependent manner. Total levels of ATM and Chk1 remained largely unchanged at 1-6 h post-RT. 
Bar graphs represent quantified densitometry of the Western blots. B) Recognition of DNA 
damage was evaluated by ICC for p-H2A.X (Ser139) and quantified by intensity of the nuclear 
staining. Both HeLa and U87 demonstrated significant induction of p-H2A.X 1 h post-10 Gy RT, 
but 2.5 µM WA yielded no effect. WA differentially modulated normal the normal recognition 
response to RT-mediated DNA damage with combination therapy showing enhanced p-H2A.X 
in HeLa but reduction in U87. C) These immunocytochemistry findings were supported by 
Western blotting for p-H2A.X which demonstrated comparable patterns of treatment-mediated 
modulation. *p < 0.05, **p < 0.01, ***p < 0.001 
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for p-H2A.X and quantified by intensity of the nuclear staining (Figure 6-4B). HeLa and U87 
cells displayed 8.1-fold (p = 0.017) and 11.1-fold (p = 0.021) increases in p-H2A.X 1 h post-10 
Gy RT compared to controls, respectively. Pretreatment with 2.5 µM WA for 2 h, which alone 
produced no deviation from control in either line, resulted in diverging effects when followed by 
RT. In HeLa cells, combination therapy further induced expression of p-H2A.X 3.0-fold greater 
than RT alone (p = 0.006) and 24.7-fold above control (p = 0.007). In contrast, the addition of 
WA to RT in U87 cells resulted in a 62.5% decrease in the phosphorylation of H2A.X compare 
to RT alone (p = 0.049) but was still significantly greater than control (p = 0.048). These results 
were supported by Western blotting for p-H2A.X which demonstrated comparable patterns of 
treatment-mediated modulation (Figure 6-4C). Modulation of H2A.X phosphorylation was 
consistent with the large early impairment of ATM activation in U87 but not HeLa, suggesting 
that the effects of WA are manifest at different signaling levels in various cells, such that 
diminished ability to recognize DNA damage is observed in U87 whereas a failure to response to 
and repair the damage is observed and in HeLa despite enhanced phosphorylation of H2A.X.  
 
6.4.5 WA blocks dsDNA damage repair  
 
Direct measurement of dsDNA damage was evaluated through the neural comet assay, 
measuring the movement of the DNA content of single cells through electrophoresis (Figure 6-
5A and 5B). U87 cells were pretreated with WA for 12 h, irradiated, and collected after a 4 h 
incubation. Enhanced DNA damage was associated with a higher percentage of total DNA 
shifted and a greater distance traveled, quantified as the tail moment. Control cells displayed a 
baseline tail moment of 1.1 which was increased 2.3-fold to 2.6 with 0.5 µM WA (p = 0.028),  
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Figure 6-5.  
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Figure 6-5. A) Direct measurement of dsDNA damage was evaluated through the neural comet 
assay, measuring the movement of the DNA content of single cells through electrophoresis 
followed by nucleic acid staining with SYBR Gold. U87 cells were pretreated with WA for 12 h, 
irradiated with 5 Gy, and collected after a 4 h incubation. Mildly increased DNA damage was 
observed with treatment of either WA or RT, but combination of the agents significantly 
enhanced the average comet tail moment, demonstrating enhanced DNA damage. B) 
Representative examples of comets from each treatment group. SYBR Gold = green. C) HeLa 
and U87 cells stably expressing the DR-GFP reporter were transfected with an empty vector 
control or an I-SceI construct, plated, and treated immediately with multiple concentrations of 
WA for 72 h before analysis of GFP expression, a marker of successful HR, by flow cytometry. 
WA demonstrated significant dose-dependent reduction in HR function through decreases in 
GFP+ cells in both lines. Cells transfected with the control empty vector demonstrated no or 
minimal GFP at all concentrations. D) Representative examples of the flow cytometry results for 
HeLa and U87. *p < 0.05, **p < 0.01, ***p < 0.001 
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likely a result of minor DNA fragmentation characteristic of intrinsically cytotoxic compounds, 
and 2.6-fold to 2.9 with 5Gy RT (p = 0.023). Combination of these two agents resulted in a tail 
moment of 6.9, a 6.1-fold increase over baseline (p < 0.001) and statistically greater than either 
agent alone (p < 0.001). These findings demonstrate that reduced phosphorylation of H2A.X 
resulting from WA+RT compared to RT alone in U87 cells is the result of reduced DDR 
signaling rather than enhanced repair. 
These findings were supported functionally by the WA-mediated inhibition of HR as 
evaluated through the DR-GFP reporter assay (Figure 6-5C and 6-5D; Supplemental Figure 6-2). 
U87 and HeLa cells stably expressing the reporter following clonal selection were transfected 
with a vector for the restriction enzyme I-SceI or a control vector. Expression of I-SceI in the cell 
functioned to cut the reporter assay at a specific site, mimicking a dsDNA break with functional 
HR repair that could be monitored through ultimate expression of GFP by flow cytometry and 
microscopy. HR-mediated repair was shown to occur in 1.10% of U87 and 1.12% of HeLa 
control cells after 72 h. This was significantly reduced by treatment with WA. At 0.5 µM, U87 
and HeLa cell repair of the break through HR was reduced to 0.07% (p = 0.017) and 0.59% (p = 
0.003), respectively which was further reduced by 1 µM WA to 0.02% (p = 0.018) and 0.20% (p 
< 0.001), respectively. Cells transfected with the control empty vector demonstrated no GFP+ 
cells at all concentrations in U87 and 0.03% at all concentrations in HeLa. Preliminary data in 
the murine GBM cell line GL26 demonstrated the same pattern of HR reduction with WA 
treatment. These findings support the results demonstrating enhanced dsDNA damage with 
combination of WA and RT as well as reductions in DNA damage repair proteins following WA 
treatment. This suggests that WA-mediated radiosensitization functions in-part through 
inhibition of these repair pathways. 
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6.5 Discussion 
 
WA is a promising novel anti-cancer therapeutic agent that has shown both in vitro and in 
vivo promise in a variety of models by targeting a multitude of proliferation, survival, and 
growth progression pathways (Vanden Berghe et al., 2012; Vyas and Singh, 2014). While 
monotherapy with WA in animal models has yielded impressive results, single agent therapy in 
the treatment of human cancer often demonstrates disappointing outcomes and the rapid 
development of resistance. Treatment of many cancers now relies on the utilization of several 
adjuvant therapies to target multiple cellular susceptibilities simultaneously, often through 
production of DNA damage or alterations of DNA/cellular  replication (Kamal and Burrows, 
2004). Here, we demonstrated that WA inhibits normal pathways of DSB repair through 
depletion of total proteins involved in HR and NHEJ as well as alterations and delays in DDR 
signaling in two highly aggressive cancer cell lines, HeLa and U87. Combining WA and RT 
potentiated the efficacy of both agents leading to enhanced DNA damage and diminished 
viability through failure of cells to synthesize DNA and progress through the cell cycle. 
Several early studies on WA identified it as a possible radiosensitizer, including its 
potential in vivo utility as such (Devi et al., 1995; Devi et al., 1996; Devi et al., 2000; Devi and 
Kamath, 2003; Devi et al., 2008). This research group then demonstrated that knockout of 
Rad54, but not Ku70 or both Ku70 and Rad54, could sensitize cells to radiation and concluded 
that WA may alter normal homologous recombination repair (Devi et al., 2008). Since then, 
several additional studies further evaluated the merit of combination therapy and suggested that 
it increases efficacy through enhanced oxidation and modulation of the MAPK and Akt 
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pathways (Yang et al., 2011b; Yang et al., 2011a). A lack of adequate controls and data 
quantification limits the overall interpretation of the data in these studies, but each demonstrated 
the promise of co-treatment with both agents. 
 Ionizing RT is a frequently utilized treatment modality against many primary cancer 
types and some metastatic disease. While certain cancers are quite responsive to the DNA 
damaging effects of RT, others show only modest sensitivity or even radio-resistance (Begg et 
al., 2011). Given the widespread importance of RT for cancer patients, efforts have been made to 
identify means by which to enhance its effect, frequently through the additional of specific 
adjuvant chemotherapies. For example, the addition of TMZ to RT in the treatment of GBM 
patients extended average post-diagnosis survival by approximately two months, although the 
specific mechanism for this radiosensitization is unclear (Chakravarti et al., 2006; Stupp et al., 
2009; Bobola et al., 2010). Other agents have been developed to specifically target mechanisms 
of the DDR such as direct inhibitors of ATM and Chk1 (Dent et al., 2011; Nadkarni et al., 2012). 
In the present study, WA demonstrated the ability to reduce expression of multiple 
proteins in the HR, NHEJ, and MMR DDR pathways. Such findings suggest that WA may 
sensitize cancer cells to radiotherapy and/or other DNA-altering chemotherapeutic agents 
through induction of instability and promotion of degradation of proteins critical in the 
recognition and response to such an insult. WA has previously shown the ability to disrupt the 
interaction between HSP90 and Cdc37 with direct binding to the C-terminus of HSP90, a 
chaperone protein that functions to fold, refold, and stabilize a specific set of client proteins (Yu 
et al., 2010). This disruption corresponds with subsequent degradation of various client proteins 
despite no direct inhibition of HSP90 function through its mediation of GR steroid binding 
(unpublished data). However, total GR and levels of proteins not previously described to be 
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associated with Cdc37 were depleted, suggesting that WA may also directly inhibit HSP90 
activity through a separate mechanism or induce protein depletion through an alternative means. 
While Cdc37 is thought to have minor intrinsic protein chaperone properties, it has traditionally 
been considered a co-chaperone of HSP90 that promotes localization of the HSP90 chaperone 
complex to various protein targets, largely kinases. Such a binding effect of WA to HSP90 
appears to be specific to a small subset of proteins such as HSP90 and vimentin (Bargagna-
Mohan et al., 2007), demonstrating the specificity of WA targeting. We hypothesize that the 
depletion of a large number proteins globally, including those involved in the DDR, is not due to 
direct interaction with the compound but rather the secondary effect of HSP90 axis modulation. 
Indeed, WA-mediated depletion of DDR proteins patterned HSP90 inhibition with 
enhanced decreases in known HSP90 clients BRCA1 (Stecklein et al., 2012), Chk1 (Arlander et 
al., 2003), and DNA-PK (Solier et al., 2012) compared to other proteins at 1-2.5 µM after 24 h. 
Other HSP90 client or interacting proteins such as BRCA2 (Noguchi et al., 2006), members of 
the MRN complex (Dote et al., 2006), and Rad51 (Ko et al., 2012) demonstrated enhanced 
depletion upon WA exposure or responded in a cell line-dependent manner. This suggests either 
diminished cellular importance on the HSP90 axis for stability as frequently confirmed with 17-
AAG treatment such as for BRCA2, Cdc37-independent protein targeting, or alternate WA-
induced effects. The importance of the roles of HSP90 and Cdc37 for the stability and function 
of proteins involved in the DNA damage recognition and repair pathway is incompletely defined, 
and these findings suggest that it may be more significant than currently understood. Consistent 
with these findings, direct inhibition of HSP90 has been shown to result in radiosensitization 
with inhibition or depletion of proteins in the DDR such as Akt, BRCA1, and Rad51 (Dote et al., 
2006; Kabakov et al., 2010; Ko et al., 2012; Stecklein et al., 2012). To date, no studies have been 
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completed to identify a role for Cdc37 in the interaction with the altered DDR proteins either 
directly or indirectly. Further study is also necessary to identify why ATM is significantly 
depleted with both WA and 17-AAG treatment but has previously been shown to not interact 
with HSP90 (Dote et al., 2006). Importantly, WA modulates proteins from all pathways of the 
DDR, including both HR and NHEJ, demonstrating its potential broad-spectrum effectiveness as 
a radiosensitizer against various malignancies regardless of the favored repair pathway(s). 
Additionally, our group has demonstrated the ability of WA to elevate the oxidative 
potential in cancer cells which suggests an alternative mechanism by which DDR proteins can be 
degraded (Grogan et al., 2013; Grogan et al., 2014). O
6
-methylguanine-DNA methyltransferase 
(MGMT), a protein involved in the removal of TMZ-mediated DNA alkylation, was depleted by 
WA in a dose-dependent manner. While MGMT has not been described as a client of HSP90 or 
Cdc37 and was not significantly decreased with 17-AAG exposure, it had previously shown 
sensitivity to compounds inducing oxidative stress such as valproic acid (Fu et al., 2010; Ryu et 
al., 2012). Further studies are necessary to identify whether the pro-oxidant capacity of WA 
results in protein misfolding and/or depletion and if it is a direct consequence of reactive oxygen 
species (ROS) production through its epoxide group or an indirect shift in background potential 
resulting from thiol sequestering of the compound. Regardless, such a dual mechanism of 
oxidation and HSP90 axis inhibition provides great potential for enhanced efficacy while 
minimizing the development of resistance. In addition, oxygen is a known radiosensitizer 
(Teicher, 1995; Okunieff et al., 1996), and the known oxidizing effects of WA may play an 
indirect role in further enhancing the efficacy of RT through increased formation of DNA-
damaging free radicals, although it is unclear if introduction of oxygen in this form will indeed 
be beneficial. While WA elevates cellular oxidative potential and increases p-H2A.X at high 
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concentrations after 24 h (Grogan et al., 2014), this p-H2A.X induction could be completely 
eliminated with pretreatment of a global caspase inhibitor in a breast cancer model, suggesting 
the effect was an apoptosis-related phenomenon rather than direct damage to the DNA (data not 
published). 
Interestingly, the results of this study suggest that WA not only functions to deplete total 
levels of proteins critical to the DDR but can also alter normal signaling at concentrations below 
those that alter protein levels. In the evaluation of ATM and Chk1 activation and signaling, total 
levels of each protein at low-dose WA remain largely unchanged while phosphorylation is 
altered. If these findings are related to inhibition of the HSP90 chaperone axis induced by WA, 
this may suggest general mild destabilization of some fraction of ATM and its upstream kinases 
that alters function but remains detectable in total level analysis. Consistent with this 
observation, disruption of Cdc37 has previously been demonstrated in prostate cancer to inhibit 
cellular kinase activity without significantly depleting certain HSP90 client proteins (Gray et al., 
2007). 
Despite the WA-mediated modulation of ATM and Chk1 signaling following RT, each 
cell line showed an enhanced the ability to undergo cell cycle arrest at 24-72 h with a notably 
reduced fraction of DNA synthesis phase cells. Diminished phosphorylation of Chk1 after 
combination therapy was observed between 1-6 h post-RT but not after 24 h, suggesting delayed 
but not eliminated cell cycle checkpoint signaling which may perpetuate error generation or lack 
of timely repair early post-RT as the cell continues to cycle. Further, additional signaling 
proteins such as ataxia telangiectasia and Rad3-related protein (ATR) and Chk2 may compensate 
for this effect, and it is unclear if the mild reduction in p-Chk1 was functionally significant. It is 
hypothesized that the maintained low dose WA-mediated reduction of p-ATM after RT favors 
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reduction in DNA damage recognition and ultimately repair, both effects demonstrated in this 
study, compared to inhibited checkpoint modulation and may eventually overcome any 
diminished regulation of the checkpoints. Higher dose WA, which leads to significant direct 
depletion of Chk1 and/or Chk2 but manifests notable cytotoxicity independent of RT, may 
eventually limit the functional execution of these checkpoints. 
Interestingly, the data suggest that combination of WA and RT results in a reduction of 
cells entering the DNA synthesis phase of the cell cycle with cells existing in the S-phase 
shifting to a non-mitotic population containing 4N DNA. The notable accumulation of cyclin B1 
in U87 cells treated with WA for 24-48 h is nearly completely reduced to baseline when 
simultaneously treated with RT. This suggests that the 4N DNA cells are not appropriately 
progressing in the G2/M phase as has previously been demonstrated with the flavoprotein-
specific inhibitor diphenyl eneiodonium (Scaife, 2004). While p21, which is increased in this 
study with WA treatment and further with combination therapy, has traditionally been regarded 
as a regulator of the G1/S transition, it has also been demonstrated to play a role during the 
G2/M phase (Sherr and Roberts, 1995; Dulic et al., 1998; Cazzalini et al., 2010). Indeed, 
knockout of p21 prevented cells from appropriately arresting at the G2/M checkpoint following 
the induction of DNA damage. This was similarly identified in p27 which has also been 
traditionally regarded as an inhibitor of the G1/S transition and is increased in the present study 
(Sgambato et al., 2000; Payne et al., 2008). Further, this induction of p21 and repression of 
cyclin B1 to maintain G2 arrest has been demonstrated to be a p53-mediated effect (Levesque et 
al., 2008), a protein that of wild-type status in both U87 and HeLa albeit of low expression in the 
latter. In addition to functioning as a transient inhibitor of the cell cycle, p21 elevation is also a 
marker of cellular senescence. While further studies are necessary to address this, the enhanced 
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retention of cell cycle arrest and elevated p21 with combination WA and RT supports this idea. 
A previous study has demonstrated that WA alone is capable of inducing senescence with 
induction of marker β-galactosidase (Vaishnavi et al., 2012). 
Previous reports from Yang, et al. showed that combination of WA and RT in U937 and 
Caki cells resulted in enhanced markers of apoptosis without cell cycle radiosensitization 
contributions from p21 (Yang et al., 2011b). In contrast, we demonstrated in HeLa and U87 cells 
that cleavage of PARP as an apoptotic marker was either not enhanced or otherwise reduced with 
combination therapy compared to either agent alone in favor of increased expression of p21 and 
p27 and diminished progression of the cell cycle. These differences may represent intrinsic 
difference among cells or variability in dosing timepoints and concentration as analysis was only 
completed up to 24 h in the previous evaluation, however, both studies demonstrate the 
therapeutic value of combining WA and RT. Of note, U937 cell are a known p53-mutant cell line 
(Sugimoto et al., 1992), suggesting one potential intrinsic explanation for the difference. Caki 
cells contain wild-type p53 comparable to the cells used in the present study which was indeed 
shown to be activated through phosphorylation in the Yang, et al. study, indicating the potential 
role of an alternative mechanism not yet identified (Warburton et al., 2005). The Caki study did 
not evaluate changes in cell cycle distribution resulting from combination therapy, so it is 
possible that p53/p21 may still demonstrate comparable effects at later timepoints. 
Future studies will be necessary to further define the dosing schedule that will yield 
optimal potentiation or synergy in the combination of WA and RT, particularly in vivo. Our in 
vitro studies determined that 2 h pretreatment was sufficient to all for this enhanced efficacy. 
Depending on the tissue levels achieved and the time necessary to manifest effects in the DDR 
pathways, a build-up period may be necessary in translational studies. WA dosing prior to rounds 
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of RT appear to be necessary to fully take advantage of the blockage of DNA damage repair. 
Studies are also necessary to identify the ability of WA to penetrate the blood-brain barrier 
(BBB) to evaluate its potential utility against brain tumors such as GBM which is indicated 
based on these studies, although tumors such as these are frequently described to disrupt the 
normal architecture of the BBB (Zhang et al., 1992). One preliminary study of WA in a murine 
orthotopic GBM model demonstrated a survival advantage with treatment, indicating that WA 
was reaching its target (Santagata et al., 2012). Further, evaluation of WA against the Lipinski 
Rule of Five, typically utilized for predicting favorability of drug absorption oral but often 
applied to the BBB, demonstrates that it does not violate any rule (Banks, 2009; Vaishnavi et al., 
2012). 
In this study, WA was determined for the first time to be a highly effective radiosensitizer 
through modulation of the normal DDR. Following WA treatment, proteins involved in DNA 
damage recognition and repair through HR and NHEJ were depleted, resulting in altered 
recognition and functionally inhibited repair of RT-induced DNA damage. Our previous findings 
show that WA acts as a potent cytotoxic monotherapy against GBM and re-sensitizes resistant 
cells to TMZ, the standard chemotherapeutic along with RT against GBM (Grogan et al., 2013; 
Grogan et al., 2014). Other groups have demonstrated WA efficacy other non-central nervous 
system (CNS) cancers and identified that WA enhances the efficacy of the broad-spectrum agent 
cisplatin, an agent often used against cervical cancer (Kakar et al., 2012; Vanden Berghe et al., 
2012; Vyas and Singh, 2014). Taken together with WA-mediated enhancement of RT, these 
findings suggest the great clinical potential of WA as an adjuvant agent for brain tumors and 
non-CNS solid tumors like cervical cancer that warrant further translational exploration. 
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Supplemental Figure 6-1.  
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Supplemental Figure 6-1. Complete cell cycle analysis of the percentages of cells in the G0/G1 
(2N DNA), S, and G2/M (4N DNA) phases with WA and RT treatment. WA treatment results in 
an increased percentage of cells in the G2/M-phase of the cell cycle with minimal changes in S-
phase percentage. RT-treated U87 and HeLa cells both demonstrated small reductions in S-phase 
percentage, maximally at 24 h or 48 h, but showed variable shifts with cell predominantly 
moving to G0/G1 in U87 and G2/M in HeLa. Combination of WA and RT produced enhanced 
depletion of S-phase cells at 24 h and maintained the depletion at 72 h despite normalizing levels 
in the RT-only groups in both U87 and HeLa cells. Depletion of S-phase cells was primarily 
associated with maintained or minimally decreased levels of G0/G1-phase cells compared to 
WA-only with displacement to G2/M after 24 h. U87 cells demonstrated maintained elevation of 
G0/G1-phase cells at 24 h only with combination therapy. 
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Supplemental Figure 6-2.  
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Supplemental Figure 6-2. HeLa cells stably expressing the DR-GFP reporter were transfected 
with an empty vector control or an I-SceI construct, plated, and treated immediately with 1 µM 
WA for 72 h before analysis of GFP expression, a marker of successful HR. WA demonstrated 
significant reduction in HR function with undetectable GFP+ cells as assessed by microscopy. 
Cells transfected with the control empty vector demonstrated no detected GFP by microscopy. 
GFP = green.  
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7.1 Summary and significance 
 
7.1.1 Introduction 
 
The treatment of brain tumors, particularly high grade malignancies like glioblastoma 
multiforme (GBM) and medulloblastoma (MB), continues to remain a tremendous clinical 
challenge. While surgical resection followed by radiation therapy (RT) and temozolomide 
(TMZ) in GBM patients limits disease progression, the average post-diagnosis survival time is 
still only approximately 14 months with rapid and frequent development of TMZ resistance 
(Stupp et al., 2002; DeAngelis, 2005; Stupp et al., 2005; Taphoorn et al., 2005; Chamberlain et 
al., 2007). TMZ was approved for use in GBM patients in 2004, but little therapeutic progress 
has been achieved since that time. Avastin® (bevacizumab), an angiogenesis inhibitor, was 
approved after TMZ but is largely utilized to reduce disease progression during the management 
phase rather than to provide a long-term disease response (Friedman et al., 2009; Zhang et al., 
2012a). MB, largely but not exclusively a pediatric disease, demonstrates a greater response to 
currently available chemotherapies and RT, but patients are shown to frequently develop short-
term and chronic quality of life issues that manifest from the off-target effects of the treatment in 
a young patient population (Khatua et al., 2012; Smoll, 2012). The research of the present study 
demonstrates the potent in vitro utility of WA as a therapeutic agent against the high-grade 
malignant brain tumors GBM and MB. The following briefly summarizes relevant finds in each 
of the chapters and identifies key significance and utility of the data. Further detailed 
interpretation and discussion can be found in each chapter. 
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7.1.2 Chapter 2: Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative 
stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways 
 
Given the promising efficacy of WA in several non-brain tumor models and the identified 
need for novel therapeutic approaches in these cancers, the effects of WA were evaluated in a 
GBM model. The aim of this chapter was to determine if these previously observed cytotoxic 
effects could be translated to GBM with subsequent analysis of the nature of these effects. In this 
study, WA was indeed described to have an anti-proliferative effect on GBM cells with induction 
of G2/M cell cycle arrest at correspondingly low-to-moderate concentrations with a transition to 
cell death through apoptotic mechanisms at moderate-to-high doses. These findings were 
associated with changes in expression of Akt/mTOR and MAPK pathway proteins and upstream 
tyrosine kinase receptors. Notably, WA reduced activation of oncoproteins in the Akt/mTOR 
pathway but enhanced phosphorylation in MAPK proteins despite a reduction of total Raf-1. 
Simultaneously, WA produced significant cellular oxidation with induction of biomarkers 
HSP27, HSP32, and HSP70. All effects could be completely abrogated with N-acetyl-L-cysteine 
(NAC) pretreatment. 
These findings demonstrated the in vitro utility of WA against GBM and provided a 
broad and general evaluation of its utility. Notably it also expanded on the limited data available 
addressing the effects of WA on the Akt/mTOR pathway. Here, WA not only decreased total and 
phosphorylated Akt as previously described but also diminished activation of downstream 
mTOR and p70 S6K. The α-subunit of the stress-response protein AMPK and its downstream 
tumor suppressor TSC2 that ultimately signal to mTOR were also activated via phosphorylation. 
This demonstrates that WA functions, in part, to inhibit the the Akt/mTOR pathway in the 
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manifestation of its effects. This study also showed the potential utility of thiol-reactive oxidative 
agents against GBM, further enhancing the altered redox state that has been described in cancer 
cells. 
 
7.1.3 Chapter 3: Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant 
glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway 
inhibitory modulation 
 
Intrinsic or acquired therapeutic resistance to TMZ has been shown to represent a major 
problem in the treatment of GBM patients (Hansen et al., 2007; Kitange et al., 2009). With a 
poor system of pre-therapy tumor screening methods currently in place, patients frequently 
receive TMZ when it would be contraindicated either early in the treatment process or after 
multiple cycles of chemotherapy (Chamberlain, 2010; Quick et al., 2010; Zhang et al., 2012c). 
Given the in vitro success of WA in known TMZ-sensitive GBM cell lines, the aim of this 
chapter was to evaluate the potential use of WA in developed TMZ-resistant GBM as a 
monotherapy and as a potential re-sensitizer to TMZ. As a monotherapy, WA demonstrated the 
same pattern of efficacy in resistant cells as was seen in the sensitive lines but with enhanced 
potency. This was expanded to demonstrate that phosphorylation of components of the MAPK 
cascade was a compensatory activation of the pathway in response to the cytotoxicity of WA, 
identifying a potentially effective target for the use of WA in synergistic combination therapy. 
Additionally, inhibition of both the intrinsic and extrinsic apoptotic pathways resulted in reduced 
downstream cleavage of PARP and effector caspases, demonstrating the role of both pathways in 
WA-mediated apoptosis. 
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Most importantly, WA demonstrated the ability to deplete cells of O
6
-methylguanine-
DNA-methyltransferase (MGMT) which confers resistance to TMZ. This effect was associated 
with re-sensitization to TMZ and was potentiated with TMZ combination therapy. Re-
sensitization was not observed in a TMZ-resistant line with resistance through mismatch repair 
(MMR) alterations, and TMZ-sensitive lines were inconsistently further sensitized to TMZ by 
WA but never desensitized. These results demonstrate that WA, in addition to functioning as an 
effective monotherapy in a model of TMZ resistance, can be utilized to enhance the utility of 
WA in a setting where it would otherwise be contraindicated. Given that around 50% of patients 
are thought to display intrinsic characteristics for poor response to TMZ but receive TMZ 
regardless (Chamberlain, 2010; Quick et al., 2010; Zhang et al., 2012c), addition of WA to GBM 
treatment has the potential to function as 1) a cytotoxic therapeutic addition in a system that 
would otherwise be using an ineffective chemotherapeutic agent, and 2) as an agent to establish 
value with for the inclusion of TMZ. Of note, while MMR-driven resistance may not be re-
sensitized to TMZ with WA, the presence of WA potentially provides a valuable cytotoxic 
component in a system with otherwise limited efficacy beyond RT. In cases where tumors 
display TMZ sensitivity, despite the inconsistent synergistic benefit of combination therapy, the 
additive presence of two agents may still be beneficial. Overall, the addition of WA, if tolerated, 
would appear to be universally beneficial. 
 
7.1.4 Chapter 4: Withaferin A is a novel inhibitor of the Wnt/β-catenin signaling pathway in 
medulloblasoma through proteasome-mediated degradation of TCF/LEF 
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 With the effective in vitro utilization of WA against GBM and its observed inhibition of 
Akt/mTOR pathway signaling, the use of WA was expanded to a model of MB. The aim of this 
chapter was to confirm the known cytotoxicity of WA in MB and evaluate the effects of WA in 
the Wnt/β-catenin signaling pathway. Indeed, WA demonstrated the anti-proliferative, pro-
apoptotic, G2/M cell cycle arresting, and oxidative effects identified previously in GBM. Given 
the well-described cross-talk between the Akt/mTOR and Wnt/β-catenin pathways through GSK-
3β and the overactivation of Wnt signaling in a subgroup of MBs (Baryawno et al., 2010; 
Northcott et al., 2012), inhibition of Akt as previously described in GBM was expected to result 
in inhibition of Wnt signaling through diminished phosphorylation of GSK-3β and subsequent 
degradation of β-catenin. WA did in fact reduce Wnt signaling through a reporter assay. 
However, in contrast to this original expectation, WA induced significant phosphorylation of 
GSK-3β and failed to significantly alter β-catenin levels or nuclear translocation in the cells. 
Rather, WA promoted proteasomal degradation of the TCF/LEF transcription factors that 
associate with β-catenin for the transcription of Wnt target genes. 
These findings not only demonstrate the general efficacy of WA against MB but also 
identify it as a novel inhibitor of the Wnt/β-catenin signaling pathway through a unique 
mechanism. Further, WA was shown to disrupt the interaction between HSP90 and co-chaperone 
Cdc37 in MB, and inhibition of HSP90 with the established small molecule 17-AAG resulted in 
depletion of TCF/LEF proteins. Previous studies have identified the interaction of HSP90 with 
upstream components of the pathway like β-catenin and GSK-3β but have failed to conclusively 
demonstrate the role of HSP90 in their stability (inhibition of HSP90 did not consistently reduce 
levels of these proteins) (Cooper et al., 2011; Liu et al., 2012). Despite our inability to co-IP 
TCF/LEF members with HSP90 or Cdc37, these findings demonstrate a previous undescribed 
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role for HSP90 in the function of the Wnt signaling pathway which will require further 
exploration but suggests a novel role for HSP90 inhibitors against Wnt-driven malignancies like 
MB and colorectal cancer (Polakis, 2012). While WA targets this important signaling pathway 
overactivated in a subset of MB, it is also intrinsically cytotoxic through alternative pathways 
suggesting that it can be utilized against all MB subgroups without pathological pre-
identification of subgroup. Its known selectivity for cancer cells with minimal off-target toxicity 
in murine models, as currently described, could reduce quality of life issues plaguing pediatric 
MB patients with current treatments while maintaining efficacy, although more studies are 
required in regard to translational toxicity and efficacy. 
 
7.1.5 Chapter 5: Withaferin A promotes global proteasome-mediated protein degradation 
through oxidation and inhibition of the HSP90 chaperone axis and is cytotoxically potentiated by 
inhibition of the proteasome 
 
 WA has demonstrated the ability to yield diverse effects throughout the cell, frequently 
with protein depletion and modulation of multiple oncogenic signaling pathways (Vanden 
Berghe et al., 2012; Vyas and Singh, 2014). Several studies have suggested that WA alters the 
HSP90 chaperone axis and promotes cellular oxidation to promote the broad effects that are 
observed (Samadi et al., 2009; Yu et al., 2010; Wang et al., 2012). The aim of this chapter was to 
identify and explore the role of WA on cellular proteotoxicity through these mechanisms in 
GBM and the well-established HeLa cervical cancer line. WA favored a shift to HSP70 in the 
HSP90/HSP70 balance, promoting enhanced global protein ubiquitination. This was associated 
with degradation of HSP90 client proteins via the proteasome with inhibition of the HSP90 axis 
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through disruption of the HSP90/Cdc37 interaction but not direct reduction in intrinsic HSP90 
function. Cytotoxicity and oxidation events following WA exposure could be completely 
abrogated with thiol antioxidant NAC pretreatment and enhanced with reduction in cellular 
glutathione. Non-thiol antioxidant ascorbic acid reduced oxidation but failed to alter cytotoxicity. 
These findings further define the novel mechanism by which WA manifests its cytotoxic 
effects and provide details regarding both the oxidative and HSP90 inhibitory components which 
are likely not mutually exclusive. Such an effect on the HSP90 axis may predict WA utility in 
altering additional proteins and pathways critical to cancer progression subsequently revealing 
appropriate clinical uses. Future studies identifying other HSP90 inhibitory aspects given the 
depletion of non-Cdc37 proteins will be necessary. Additional experiments were completed to 
evaluate WA in combination with a proteasome inhibitor. Given that WA promotes widespread 
protein degradation via the proteasome, simultaneous inhibition of the proteasome promoted 
accumulation of ubiquitinated aberrant proteins, induced cytotoxicity with reduced cell viability, 
and ultimately potentiated the induction of apoptosis compared to either agent as a monotherapy. 
Proteasome inhibitors are currently approved for clinical use in some cancer types including 
multiple myeloma (Chauhan et al., 2005), identifying an opportunity for rapid WA translation to 
human use and establishment of proof-of-concept. This enhanced efficacy of combination with a 
proteasome inhibitor has been supported with the use of traditional HSP90 inhibitors 
(Minnnaugh et al., 2004). These data support translational utility derived from the identified 
mechanisms of WA. 
 
7.1.6 Chapter 6: Withaferin A disrupts the cellular DNA-damage response to promote 
radiosensitization 
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 RT represents a key therapeutic component in the treatment of a significant percentage of 
primary tumors including GBM and MB (Delaney et al., 2005). Therefore, efforts to enhance 
RT-induced DNA damage and limit the repair of this damage by cancer cells has been seen as 
means by which to effectively enhance cytotoxicity and efficacy of clinical RT in patients (Begg 
et al., 2011). Given that inhibition of HSP90, among other targets, can radiosensitize (Dote et al., 
2006; Kabakov et al., 2010; Ko et al., 2012; Stecklein et al., 2012), the aim of this chapter was to 
evaluate the radiosensitization properties of WA against GBM cells and the homologous 
recombination (HR)-competent HeLa cervical cancer line. Indeed, low-dose WA potentiated the 
efficacy of RT in both lines. This was associated with a reduction in cells synthesizing new DNA 
and elevation of the checkpoint inhibitors p21 and p27. Functionally, WA reduced total levels of 
key proteins involved in the recognition and repair of DNA damage through HR and non-
homologous end-joining (NHEJ) and modulated normal signaling in response to RT. This lead to 
altered recognition of the damage assessed by p-H2A.X, enhanced and sustained DNA damage 
with combination therapy, and a functional block of HR. 
 These findings further demonstrate the potential clinical application of WA. Given that 
RT is used in the treatment of an estimated 50% of cancer patients (Delaney et al., 2005), 
enhancing the efficacy of this therapeutic modality is an extremely important translational 
prospect and has been a consideration in the selection of adjuvant chemotherapy previously, 
including the addition of TMZ to RT (Chakravarti et al., 2006). The data suggests that WA is 
likely to enhance DNA damage induced by other agents and repaired through a range of 
modalities including HR, NHEJ, and MMR which identifies a potential for broad spectrum 
combination use clinically alone with the intrinsic cytotoxicity of WA as a monotherapy. 
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Because augmented DNA damage response mechanisms are known to play a key role in chemo- 
and radio-resistance, we believe that modulation and depletion of these pathways with WA may 
provide enhanced efficacy of therapeutics in refractory or resistant GBM or other cancer types. 
Indeed, we demonstrated WA’s ability to re-sensitize resistant GBM cells to TMZ through 
depletion of MGMT, showing proof-of-concept (Grogan et al., 2014). 
 
7.2 Future directions 
 
The conducted research identified, defined, and utilized the cytotoxic anti-cancer 
properties of WA in a model of high-grade brain tumors. Among the results, WA induced 
inhibitory modulation of the PI3K/Akt/mTOR and Wnt/β-catenin oncogenic signaling pathways. 
These are the first studies to thoroughly evaluate the influence of WA on both pathways in any 
cancer model and potentially define several therapeutic roles for the compound. Given the broad 
effects of WA on multiple oncogenic or otherwise cancer-promoting pathways in our studies and 
those published by others (Vanden Berghe et al., 2012; Vyas and Singh, 2014), particularly with 
noted activity against the HSP90 chaperone axis with over 400 known client or interacting 
proteins, future experiments are necessary to further expand on the effects of WA against other 
proteins that have yet to be explored and the resulting changes in signal transduction efficiency. 
Notably, there are currently no published reports on the effect of WA on the SHH pathway, 
important in a subgroup of MB. Similarly, the inhibition of the pathways identified with this 
research can be expanded to other relevant cancer models. For example, the Wnt/β-catenin 
pathway is overactivated in a significant percentage of colorectal cancers (Polakis, 2012). 
Targeting this pathway with WA along with the general cytotoxicity of the compound through 
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additional mechanisms would be thought to have great therapeutic benefits clinically by blocking 
a key driving oncogenic pathway and inducing additional anti-cancer manifestations. 
The efficacy of WA was also demonstrated to be enhanced in combination with both RT 
and a proteasome inhibitor and functioned to re-sensitize resistant GBM cells to TMZ. Previous 
studies have identified that WA synergizes with other chemotherapeutic agents such as sorafenib 
and cisplatin (Cohen et al., 2012; Kakar et al., 2012). HSP90 inhibition, a described function of 
WA, has also been shown to potentiate, enhance, or re-sensitize the activity of numerous agents 
(Lu et al., 2012). These observations suggest that WA may function well in combination with 
other therapeutic agents, particularly those inducing DNA damage, generating a large expansion 
in the potential for studying and ultimately using this compound. Additionally, because WA was 
demonstrated to promote activation of the MAPK pathway through phosphorylation of Raf-1 and 
ERK1/2, relevant inhibitors of these proteins would be expected to yield favorable efficacy in 
combination with WA. Given the apparent protective effect of GSH against WA, selective 
depletion of GSH in redox susceptible cancer cells, perhaps through inhibition of γ-
glutamylcysteine synthetase, could serve to enhance the cellular cytotoxicity to WA, although 
the potential for off-target toxicity would need to be evaluated if similar reduction in GSH was 
observed in normal tissue. These combinations also establish greater therapeutic relevance for 
WA given the problems of ineffectiveness and resistance frequently associated with 
monotherapy. Interestingly, however, our in vitro attempts to develop cell line resistance to WA 
have been largely unsuccessful and warrant further exploration. 
These findings open some additional questions regarding the role of WA in the inhibition 
of the HSP90 axis. While these results clearly indicate that WA eliminates the interaction 
between HSP90 and the co-chaperone Cdc37 at high enough concentrations and does not appear 
255 
 
to alter the intrinsic activity of HSP90 at least in regard to steroid receptor association, protein 
depletion mirrors total inhibition of HSP90 (and perhaps more) rather than a prevention of Cdc37 
function. Cdc37 primarily functions as a kinase-specific co-chaperone to promote the folding and 
maturation of these proteins through localization with HSP90 with enhanced client loading 
though modulation of HSP90 ATPase activity (Siligardi et al., 2002; Roe et al., 2004). However, 
proteins not previously known to associate with Cdc37 and non-kinase proteins such as c-myc 
and the glucocorticoid receptor were dose-dependently degraded with WA exposure. Such 
findings suggest that while the disruption of the HSP90/Cdc37 interaction was real, the effects of 
WA extend beyond that observation or the role of Cdc37 is greater than currently thought. Cdc37 
has also been shown to interact with other co-chaperone proteins, suggesting another way by 
which it can still join the HSP90 chaperone complex (Abbas-Terki et al., 2002). Given that WA 
interacts with the C-terminus of HSP90 in the location that other co-chaperones are known to 
associate, this represents a potential explanation of these expanded findings (Yu et al., 2010). 
Interestingly p23 and Hop were not dissociated from HSP90 in the presence of WA (Yu et al., 
2010), but their maintained functionality directly with HSP90 was not addressed. Clearly, further 
study of this system is required to better understand the variations observed whether due to 
additional modulation of the HSP90 axis or indirect effect from associated observations like 
cellular oxidation. 
Additionally, while alterations in the HSP90 chaperone axis have been clearly 
demonstrated to play a role in the cytotoxicity of WA, there have been arguments regarding the 
specificity of this effect. In order to determine whether the cytotoxic manifestations are primarily 
driven by its association with HSP90, it is proposed that future studies be conducted with cells in 
which endogenous HSP90 has been replaced or supplemented with HSP90 mutants retaining 
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function but lacking the appropriate WA binding site, likely through mutation of an existing C-
terminal cysteine. As such, the HSP90-independent effects of WA could be studied. Further, 
enrichment or depletion of GSH in the context of non-thiol antioxidants could further help define 
the nature of the effect as it relates to general oxidation and redox alterations. To date, few 
proteins have been shown to directly associate with WA, including via a broad spectrum analysis 
of biotinylated-WA binding, suggesting some specificity of is binding (Bargagna-Mohan et al., 
2007; Yu et al., 2010). Such studies could further demonstrate the importance of the HSP90 
target with WA treatment. 
 Studies from our group and others have evaluated novel natural and semi-synthetic 
withanolides beyond WA (Zhang et al., 2011a; Santagata et al., 2012; Zhang et al., 2012b; 
Wijeratne et al., 2014). Notably, significant cytotoxicity is lost with the elimination of the A-ring 
enone and/or the epoxide group. Our preliminary studies in triple negative breast cancer and 
several other models demonstrate that acetylation of one or more of the hydroxide groups 
enhance cytotoxic activity and anti-tumor efficacy in vivo. A recent study also identified that 
synthetic acetylation or other modifications of functional groups on WA or the withanolide 
structure can differentially alter biological cytotoxicity and/or heat shock-inducing activity 
(Wijeratne et al., 2014). It is unclear if this heat shock response is a function of HSP90 
inhibition, general oxidation, or perhaps more likely, both. Such structure-activity relationship 
(SAR) studies will be necessary going forward to identify improved therapeutic withanolides 
with better anti-cancer efficacy, more favorable pharmacokinetics for a particular malignancy 
[especially for crossing the blood-brain-barrier (BBB)], and diminished off-target toxicity. To 
date, SAR studies with withanolides have primarily been assessed in vitro. While these studies 
have yield valuable information, they have failed to address the pharmacokinetic aspect for 
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translational use. Withanolides, primarily WA, have demonstrated in vivo efficacy against a 
number of murine cancer models (Vyas and Singh, 2014) but drug absorption, distribution, and 
elimination have remained largely unexplored. 
Pharmacokinetic studies, particularly those involving the metabolism of WA and these 
other novel withanolides, will shed light on the body’s ability to activate and/or detoxify these 
compounds, thereby suggesting potential benefits or limitations to various dosing schemes. To 
date, very few studies have evaluated the metabolism of WA with the last studies emerging from 
the 1980s. Those studies, conducted in Cunninghamella elegans and Arthrobacter simplex, 
revealed that WA can be metabolized via hydroxylation, hydrogenation, and hydrolysis (Rosazza 
et al., 1978; Fuska et al., 1982; Proksa et al., 1986; Fuska et al., 1987). Because WA shares many 
structural similarities with endogenous steroids given its steroidal lactone classification, the 
study of its metabolism remains a critical element necessary for its potential use in the clinic as 
steroids are often metabolized in oxidative reactions by cytochrome P450 (CYP450) enzymes 
(Gonzalez, 1990). On top of that, an estimated minimum of 75-90% of the reactions in the 
metabolism of pharmaceutical drugs are by CYP450s, demonstrating an integral role for their 
study in the development of any compound (Guengerich, 2008; Sun and Scott, 2010). An overlap 
in the metabolic processes serving WA with other chemotherapeutic agents whose metabolism 
has been previously well-characterized could suggest successful pairing schemes on the basis of 
toxicokinetics or generating more favorable pharmacokinetic parameters (Cheng et al., 2010). 
Additionally, studies on the distribution of WA and its metabolites, particularly to the 
brain and more specifically during the diseased state of a brain tumor, have remained largely 
unpublished, although one preliminary study utilizing a murine orthotopic glioma model 
demonstrated a survival benefit with WA (Santagata et al., 2012). Given this survival benefit, it 
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is evident that the compound or an active metabolite likely reaches the site of the tumor lesion 
regardless of whether the BBB lacks integrity. What is less clear is whether WA is capable of 
crossing an intact BBB peritumorally where tumor invasion has occurred or in healthy brain 
tissue with relatively normal and maintained architecture. A recent bioinformatics study 
suggested that WA’s structure fails to violate Lipinski’s Rule of Five and has a favorable 
blood/brain partition coefficient (Vaishnavi et al., 2012), but translation to a biological system 
still needs to be examined. Other active withanolides in which polar functional groups are 
masked or simply absence may yield more favorable results if not ultimately achieved with WA, 
and indeed, preliminary studies in several non-brain tumor murine models show this. 
Encouragingly, multiple additional non-brain tumor murine models have demonstrated 
promising responses to WA treatment with multiple dosing schedules and levels (Vyas and 
Singh, 2014). One report identified a maximum plasma concentration of WA following a single 
intraperitoneal injection of the moderate dose of 4 mg/kg to be 1.8 µM, well-above typical in 
vitro IC50 values for cancer cells, with a plasma half-life of 1.3 h. Tissue distribution has not yet 
been reported. Overall, further translational studies with WA and other withanolides, particularly 
in an orthotopic brain tumor model, are necessary to evaluate both the pharmacokinetics and 
pharmacodynamics of the compound and establish maximally effective and minimally toxic 
dosing levels and schedules. Such studies can be followed up with efficacy and toxicity studies 
for combination therapy as previously discussed and utilization of NAC as a rescue agent in 
cases of toxicity or attempted high-dose regimens. 
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